e10vqza
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-Q/A
|
|
|
(Mark One)
|
|
|
|
þ
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
For the quarterly period ended
March 31, 2006
|
or
|
|
|
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
For the transition period
from to
|
Commission file number: 1-11397
Valeant Pharmaceuticals
International
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
|
|
33-0628076
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
One Enterprise,
Aliso Viejo, California
(Address of principal
executive offices)
|
|
92656
(Zip Code)
|
|
|
|
(949) 461-6000
(Registrants telephone
number, including area code)
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past
90 days. Yes o No þ
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated
filer. See definition of accelerated filer and large
accelerated filer in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated
filer þ Accelerated
filer o Non-accelerated
filer o
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange
Act). Yes o No þ
The number of outstanding shares of the registrants Common
Stock, $0.01 par value, as of January 16, 2007
was 94,414,465.
VALEANT
PHARMACEUTICALS INTERNATIONAL
INDEX
1
Explanatory
Note
We are amending our quarterly report on
Form 10-Q
for the quarter ended March 31, 2006 filed on May 9,
2006 (the Original Filing) to restate our condensed
consolidated financial statements for the three-month periods
ended March 31, 2006 and 2005 and the related disclosures.
See Note 2, Restatement of Consolidated Financial
Statements of the Notes to Consolidated Condensed
Financial Statements for a detailed discussion of the effect of
the restatement. On January 22, 2007 we filed an amended
Annual Report on
Form 10-K/A
for the year ended December 31, 2005.
The restatement of the Original Filing reflected in this amended
quarterly report on
Form 10-Q/A
includes adjustments arising from the determinations of a
Special Committee, consisting of independent members of the
Board of Directors, which was formed in September 2006 to
conduct a comprehensive review into the Companys past
stock option practices, as well as our internal review relating
to our historical financial statements.
In July 2006, we were contacted by the Securities and Exchange
Commission, or SEC, with respect to an informal inquiry
regarding events and circumstances surrounding trading in our
common stock and the public release of data from our first
pivotal Phase 3 trial for
Viramidine®
(taribavirin). In addition, on August 22, 2006, the SEC
requested data regarding our stock option grants and exercises
since January 1, 2000. The SEC has also requested
information about our pursuit in the Delaware Chancery Court of
the return of certain bonuses paid to Milan Panic, the former
chairman and chief executive officer, and others, in connection
with the Ribapharm initial public offering. We commenced an
internal review by our finance department of stock option grants
from 1982 to July 2006. In September 2006, our board of
directors appointed a special committee of the board composed
solely of independent directors (the Special
Committee) to conduct a review of our historic stock
option practices and related accounting. The Special Committee,
with the assistance of outside legal counsel, undertook a
comprehensive review of the stock option grants to our officers,
directors and employees from 1982 to July 2006 under our various
stock option plans in effect during this period. The Special
Committee has concluded its investigation and has reported its
findings to our board of directors.
On October 20, 2006, our board of directors concluded that
certain of our consolidated financial statements should be
restated to record the additional non-cash stock-based
compensation expense items that had been incorrectly accounted
for under accounting principles generally accepted in the United
States, or GAAP. In addition, we have restated our financial
statements to correct certain accounting errors which were
previously identified but not considered to be material. These
corrections related to accounting for employee tax withholding
on certain compensation transactions, elimination of an
intercompany difference, accounting for product exchanges
(resulting in a revenue adjustment), and certain income tax
adjustments.
For more information on these matters, please refer to
Item 2, Managements Discussion and Analysis of
Financial Condition and Results of Operations
Restatement of Consolidated Financial Statements, Note 2 of
the Notes to the Condensed Consolidated Financial Statements,
and Item 4, Controls and Procedures.
As a result of the findings of the Special Committee as well as
our internal review, we concluded that it was necessary to amend
our annual report on
Form 10-K
for the year ended December 31, 2005, originally filed on
March 16, 2006, to restate our consolidated financial
statements for the years ended December 31, 2005, 2004 and
2003 and the related disclosures as well as
Managements Report on Internal Control Over
Financial Reporting as of December 31, 2005. The
annual report on
Form 10-K/A,
filed on January 22, 2007, also includes the restatement of
selected consolidated financial data as of and for the years
ended December 31, 2005, 2004, 2003, 2002 and 2001, and the
unaudited quarterly financial data for each of the quarters in
the years ended December 31, 2005 and 2004. We also
concluded that we needed to amend the quarterly reports on
Form 10-Q
for the quarters ended March 31, 2006 and June 30,
2006, originally filed on May 9, 2006 and August 8,
2006, respectively, to restate our condensed consolidated
financial statements for those periods. We also restated the
September 30, 2005 financial statements with the filing of
our September 30, 2006
Form 10-Q
on January 22, 2007. We have not amended and we do not
intend to amend any of our other previously filed annual reports
on
Form 10-K
or quarterly reports on
Form 10-Q
for the periods affected by the restatement or adjustments other
than (i) this amended quarterly report on
Form 10-Q/A
for the quarter ended March 31, 2006, (ii) the amended
quarterly report on
Form 10-Q/A
for the quarter ended June 30, 2006 being filed on the same
date as this filing, and (iii) the amended annual report on
Form 10-K/A
for the year ended December 31, 2005, filed
January 22, 2007.
2
All of the information in this amended quarterly report on
Form 10-Q/A
is as of March 31, 2006 and does not reflect events
occurring after the date of the Original Filing, other than the
restatement, or modify or update disclosures (including, the
exhibits to the Original Filing, except for the updated
Exhibits 31.1, 31.2, and 32.1 described below) affected by
subsequent events. For the convenience of the reader, this
amended quarterly report on
Form 10-Q/A
sets forth the Original Filing in its entirety, as amended by,
and to reflect, the restatement. The following sections of this
Form 10-Q/A
were adjusted to reflect the findings of the Special Committee
as well as our internal review:
Part I Item 1 Unaudited
Financial Statements;
Part I Item 2
Managements Discussion and Analysis of Financial Condition
and Results of Operations;
Part I Item 4 Controls and
Procedures;
Part II Item 1A Risk Factors;
and
Part II Item 6 Exhibits
This amended quarterly report on
Form 10-Q/A
should be read in conjunction with our amended Annual Report on
Form 10-K/A
for the year ended December 31, 2005, our periodic filings
made with the SEC subsequent to the date of the Original Filing
and any Current Reports filed on
Form 8-K
subsequent to the date of the Original Filing. In addition, in
accordance with applicable SEC rules, this amended quarterly
report on
Form 10-Q/A
includes updated certifications from our Chief Executive Officer
and Chief Financial Officer as Exhibits 31.1, 31.2, and
32.1.
3
PART I
FINANCIAL INFORMATION
|
|
Item 1.
|
Financial
Statements
|
VALEANT
PHARMACEUTICALS INTERNATIONAL
CONSOLIDATED CONDENSED BALANCE SHEETS
As of March 31, 2006 and December 31, 2005
(In thousands, except par value data)
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(Restated)(1)
|
|
|
(Restated)(1)
|
|
|
|
(Unaudited)
|
|
|
|
|
|
ASSETS
|
Current Assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
244,362
|
|
|
$
|
224,856
|
|
Marketable securities
|
|
|
11,121
|
|
|
|
10,210
|
|
Accounts receivable, net
|
|
|
174,433
|
|
|
|
187,987
|
|
Inventories, net
|
|
|
137,729
|
|
|
|
136,034
|
|
Prepaid expenses and other current
assets
|
|
|
38,862
|
|
|
|
40,354
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
606,507
|
|
|
|
599,441
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
217,813
|
|
|
|
230,126
|
|
Deferred tax assets, net
|
|
|
21,510
|
|
|
|
25,342
|
|
Goodwill
|
|
|
79,767
|
|
|
|
79,486
|
|
Intangible assets, net
|
|
|
519,614
|
|
|
|
536,319
|
|
Other assets
|
|
|
45,284
|
|
|
|
43,176
|
|
Assets of discontinued operations
|
|
|
105
|
|
|
|
127
|
|
|
|
|
|
|
|
|
|
|
Total non-current assets
|
|
|
884,093
|
|
|
|
914,576
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,490,600
|
|
|
$
|
1,514,017
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS EQUITY
|
Current Liabilities:
|
|
|
|
|
|
|
|
|
Trade payables
|
|
$
|
48,708
|
|
|
$
|
55,279
|
|
Accrued liabilities
|
|
|
138,551
|
|
|
|
140,838
|
|
Notes payable and current portion
of long-term debt
|
|
|
346
|
|
|
|
495
|
|
Income taxes
|
|
|
39,465
|
|
|
|
47,324
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
227,070
|
|
|
|
243,936
|
|
|
|
|
|
|
|
|
|
|
Long-term debt, less current
portion
|
|
|
785,850
|
|
|
|
788,439
|
|
Deferred tax liabilities, net
|
|
|
5,126
|
|
|
|
8,208
|
|
Other liabilities
|
|
|
19,918
|
|
|
|
16,372
|
|
Liabilities of discontinued
operations
|
|
|
23,024
|
|
|
|
23,118
|
|
|
|
|
|
|
|
|
|
|
Total non-current liabilities
|
|
|
833,918
|
|
|
|
836,137
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Stockholders Equity:
|
|
|
|
|
|
|
|
|
Common stock, $0.01 par
value; 200,000 shares authorized; 92,793 (March 31,
2006) and 92,760 (December 31, 2005) shares
outstanding (after deducting shares in treasury of 1,094 as of
March 31, 2006 and December 31, 2005)
|
|
|
928
|
|
|
|
928
|
|
Additional capital
|
|
|
1,230,955
|
|
|
|
1,224,907
|
|
Accumulated deficit
|
|
|
(783,487
|
)
|
|
|
(770,350
|
)
|
Accumulated other comprehensive
income (loss)
|
|
|
(18,784
|
)
|
|
|
(21,541
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
429,612
|
|
|
|
433,944
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,490,600
|
|
|
$
|
1,514,017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 2, Restatement of Consolidated Financial
Statements. |
The accompanying notes are an integral part of these
consolidated condensed financial statements.
4
VALEANT
PHARMACEUTICALS INTERNATIONAL
For the three months ended March 31, 2006 and 2005
(Unaudited, in thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(Restated)(1)
|
|
|
(Restated)(1)
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
Product sales
|
|
$
|
181,401
|
|
|
$
|
161,782
|
|
Ribavirin royalties
|
|
|
18,091
|
|
|
|
19,335
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
199,492
|
|
|
|
181,117
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
Cost of goods sold (excluding
amortization)
|
|
|
58,601
|
|
|
|
48,783
|
|
Selling expenses
|
|
|
64,276
|
|
|
|
52,850
|
|
General and administrative expenses
|
|
|
28,446
|
|
|
|
24,705
|
|
Research and development costs
|
|
|
29,553
|
|
|
|
25,831
|
|
Acquired in-process research and
development
|
|
|
|
|
|
|
126,399
|
|
Gain on settlement of litigation
|
|
|
(34,000
|
)
|
|
|
|
|
Restructuring charges
|
|
|
26,466
|
|
|
|
1,695
|
|
Amortization expense
|
|
|
17,523
|
|
|
|
13,968
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
190,865
|
|
|
|
294,231
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations
|
|
|
8,627
|
|
|
|
(113,114
|
)
|
Other income (loss), net,
including translation and exchange
|
|
|
937
|
|
|
|
(1,791
|
)
|
Interest income
|
|
|
2,657
|
|
|
|
3,015
|
|
Interest expense
|
|
|
(10,437
|
)
|
|
|
(9,681
|
)
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing
operations before income taxes and minority interest
|
|
|
1,784
|
|
|
|
(121,571
|
)
|
Provision for income taxes
|
|
|
7,542
|
|
|
|
16,514
|
|
Minority interest, net
|
|
|
1
|
|
|
|
171
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(5,759
|
)
|
|
|
(138,256
|
)
|
Loss from discontinued operations
|
|
|
(212
|
)
|
|
|
(1,503
|
)
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(5,971
|
)
|
|
$
|
(139,759
|
)
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share:
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(0.06
|
)
|
|
$
|
(1.55
|
)
|
Loss from discontinued operations
|
|
|
|
|
|
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per
share
|
|
$
|
(0.06
|
)
|
|
$
|
(1.57
|
)
|
|
|
|
|
|
|
|
|
|
Basic and diluted shares used in
per share computation
|
|
|
92,770
|
|
|
|
88,836
|
|
|
|
|
|
|
|
|
|
|
Dividends paid per share of common
stock
|
|
$
|
0.08
|
|
|
$
|
0.08
|
|
|
|
|
|
|
|
|
|
|
Dividends declared per share of
common stock
|
|
$
|
0.08
|
|
|
$
|
0.08
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 2, Restatement of Consolidated Financial
Statements. |
The accompanying notes are an integral part of these
consolidated condensed financial statements.
5
VALEANT
PHARMACEUTICALS INTERNATIONAL
For the three months ended March 31, 2006 and 2005
(Unaudited, in thousands)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(Restated)(1)
|
|
|
(Restated)(1)
|
|
|
Net loss
|
|
$
|
(5,971
|
)
|
|
$
|
(139,759
|
)
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
Foreign currency translation
adjustments
|
|
|
2,346
|
|
|
|
(15,363
|
)
|
Unrealized gain (loss) on
marketable equity securities and other
|
|
|
411
|
|
|
|
3,258
|
|
Reclassification adjustment for
loss realized included in net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income (loss)
|
|
$
|
(3,214
|
)
|
|
$
|
(151,864
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 2, Restatement of Consolidated Financial
Statements. |
The accompanying notes are an integral part of these
consolidated condensed financial statements.
6
VALEANT
PHARMACEUTICALS INTERNATIONAL
For the three months ended March 31, 2006 and 2005
(Unaudited, in thousands)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(Restated)(1)
|
|
|
(Restated)(1)
|
|
|
Cash flows from operating
activities:
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$
|
(5,971
|
)
|
|
$
|
(139,759
|
)
|
Loss from discontinued operations
|
|
|
(212
|
)
|
|
|
(1,503
|
)
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(5,759
|
)
|
|
|
(138,256
|
)
|
Adjustments to reconcile net loss
to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
23,482
|
|
|
|
21,038
|
|
Provision for losses on accounts
receivable and inventory
|
|
|
3,597
|
|
|
|
1,594
|
|
Stock compensation expense
|
|
|
5,618
|
|
|
|
863
|
|
Translation and exchange (gains)
losses, net
|
|
|
(937
|
)
|
|
|
1,791
|
|
Impairment charges and other
non-cash items
|
|
|
20,426
|
|
|
|
1,461
|
|
Acquired in-process research and
development
|
|
|
|
|
|
|
126,399
|
|
Deferred income taxes
|
|
|
1,910
|
|
|
|
(13,879
|
)
|
Change in assets and liabilities,
net of effects of acquisitions:
|
|
|
|
|
|
|
|
|
Accounts Receivable
|
|
|
13,779
|
|
|
|
6,482
|
|
Inventories
|
|
|
(3,736
|
)
|
|
|
(10,951
|
)
|
Prepaid expenses and other assets
|
|
|
4,918
|
|
|
|
(129
|
)
|
Trade payables and accrued
liabilities
|
|
|
(9,886
|
)
|
|
|
(7,706
|
)
|
Income taxes
|
|
|
(13,116
|
)
|
|
|
15,960
|
|
Other liabilities
|
|
|
842
|
|
|
|
3,995
|
|
|
|
|
|
|
|
|
|
|
Cash flow from operating
activities in continuing operations
|
|
|
41,138
|
|
|
|
8,662
|
|
Cash flow from operating
activities in discontinued operations
|
|
|
(281
|
)
|
|
|
(471
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating
activities
|
|
|
40,857
|
|
|
|
8,191
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing
activities:
|
|
|
|
|
|
|
|
|
Capital expenditures
|
|
|
(13,351
|
)
|
|
|
(4,848
|
)
|
Proceeds from sale of assets
|
|
|
135
|
|
|
|
762
|
|
Proceeds from investments
|
|
|
2,000
|
|
|
|
498,600
|
|
Purchase of investments
|
|
|
(3,940
|
)
|
|
|
(296,213
|
)
|
Acquisition of businesses, license
rights and product lines
|
|
|
|
|
|
|
(281,778
|
)
|
|
|
|
|
|
|
|
|
|
Cash flow from investing
activities in continuing operations
|
|
|
(15,156
|
)
|
|
|
(83,477
|
)
|
Cash flow from investing
activities in discontinued operations
|
|
|
(1
|
)
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing
activities
|
|
|
(15,157
|
)
|
|
|
(83,476
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing
activities:
|
|
|
|
|
|
|
|
|
Payments on long-term debt and
notes payable
|
|
|
(157
|
)
|
|
|
(593
|
)
|
Proceeds from issuance of stock
|
|
|
430
|
|
|
|
640
|
|
Proceeds from stock offering
|
|
|
|
|
|
|
189,393
|
|
Dividends paid
|
|
|
(7,173
|
)
|
|
|
(6,502
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in)
financing activities
|
|
|
(6,900
|
)
|
|
|
182,938
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on
cash and cash equivalents
|
|
|
728
|
|
|
|
(4,794
|
)
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash
and cash equivalents
|
|
|
19,528
|
|
|
|
102,859
|
|
Cash and cash equivalents at
beginning of period
|
|
|
224,903
|
|
|
|
222,719
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end
of period
|
|
|
244,431
|
|
|
|
325,578
|
|
Cash and cash equivalents of
discontinued operations
|
|
|
(69
|
)
|
|
|
(132
|
)
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents of
continuing operations
|
|
$
|
244,362
|
|
|
$
|
325,446
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 2, Restatement of Consolidated Financial
Statements. |
The accompanying notes are an integral part of these
consolidated condensed financial statements.
7
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
March 31, 2006
(Unaudited)
In the consolidated condensed financial statements included
herein, we, us, our,
Valeant and the Company refer to Valeant
Pharmaceuticals International and its subsidiaries. The
condensed consolidated financial statements have been prepared
by the Company, without audit, pursuant to the rules and
regulations of the Securities and Exchange Commission. Certain
information and footnote disclosures normally included in
financial statements prepared on the basis of accounting
principles generally accepted in the United States of America
have been condensed or omitted pursuant to such rules and
regulations. The results of operations presented herein are not
necessarily indicative of the results to be expected for a full
year. Although we believe that all adjustments (consisting only
of normal, recurring adjustments) necessary for a fair
presentation of the interim periods presented are included and
that the disclosures are adequate to make the information
presented not misleading, these consolidated condensed financial
statements should be read in conjunction with the consolidated
financial statements and notes thereto included in our annual
report on
Form 10-K/A
for the year ended December 31, 2005.
|
|
1.
|
Organization
and Summary of Significant Accounting Policies
|
Organization: We are a global, science-based,
specialty pharmaceutical company that develops, manufactures and
markets a broad range of pharmaceutical products. In addition,
we generate royalty revenues from the sale of ribavirin by
Schering-Plough Ltd. (Schering-Plough) and F.
Hoffman-LaRoche (Roche).
Principles of Consolidation: The accompanying
consolidated condensed financial statements include the accounts
of Valeant, its wholly owned subsidiaries and all of its
majority-owned subsidiaries. Minority interest in results of
operations of consolidated subsidiaries represents the minority
stockholders share of the income or loss of these
consolidated subsidiaries. All significant intercompany account
balances and transactions have been eliminated.
Marketable Securities: We invest in investment
grade securities and classify these securities as
available-for-sale
as they typically have maturities of one year or less and are
highly liquid. As of March 31, 2006 and December 31,
2005, the fair market value of these securities approximated
cost.
Acquired In-Process Research and
Development: We incurred an expense of
$126,399,000 associated with acquired in-process research and
development (IPR&D) related to the acquisition
of Xcel Pharmaceuticals, Inc. (Xcel) in the three
months ended March 31, 2005. Amounts expensed as IPR&D
represent an estimate of the fair value of purchased in-process
technology for projects that, as of the acquisition date, had
not yet reached technological feasibility and had no alternative
future use. The data used to determine fair value requires
significant judgment. Differences in those judgments would have
the impact of changing the allocation of purchase price to
goodwill, which is an intangible asset that is not amortized.
The estimated fair value of these projects was based on the use
of a discounted cash flow model (based on an estimate of future
sales and an average gross margin of 80%). For each project, the
estimated after-tax cash flows (using a tax rate of 35%) were
probability weighted to take account of the stage of completion
and the risks surrounding the successful development and
commercialization. The assumed tax rates are our estimate of the
effective tax rate for acquisitions of similar type of assets.
These cash flows were then discounted to a present value using a
discount rate of 18% which is our estimated, after tax, adjusted
weighted average cost of capital.
The major risks and uncertainties associated with the timely and
successful completion of these projects consist of the ability
to confirm the safety and efficacy of the technology based on
the data from clinical trials and obtaining necessary regulatory
approvals. In addition, no assurance can be given that the
underlying assumptions used to forecast the cash flows or the
timely and successful completion of such projects will
materialize, as estimated. For these reasons, among others,
actual results may vary significantly from the estimated results.
8
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
Derivative Financial Instruments: Our
accounting policies for derivative instruments are based on
whether they meet our criteria for designation as hedging
transactions, either as cash flow or fair value hedges. Our
derivative instruments are recorded at fair value and are
included in other current assets, other assets, accrued
liabilities or debt. Depending on the nature of the hedge,
changes in the fair value of the hedged item are either offset
against the change in the fair value of the hedged item through
earnings or recognized in other comprehensive income until the
hedged item is recognized in earnings.
Comprehensive Income: We have adopted the
provisions of Statement of Financial Accounting Standards
(SFAS) No. 130, Reporting Comprehensive
Income. Accumulated other comprehensive loss consists of
accumulated foreign currency translation adjustments, unrealized
losses on marketable equity securities, minimum pension
liability and changes in the fair value of derivative financial
instruments.
Per Share Information: Basic earnings per
share are computed by dividing income available to common
stockholders by the weighted-average number of common shares
outstanding. In computing diluted earnings per share, the
weighted-average number of common shares outstanding is adjusted
to reflect the effect of potentially dilutive securities
including options, warrants, and convertible debt; income
available to common stockholders is adjusted to reflect any
changes in income or loss that would result from the issuance of
the dilutive common shares.
Stock-Based Compensation Expense: On
January 1, 2006, we adopted Statement of Financial
Accounting Standards No. 123 (revised 2004),
Share-Based Payment, (SFAS 123(R))
which requires the measurement and recognition of compensation
expense for all share-based payment awards made to employees and
directors including employee stock options and employee stock
purchases under our Employee Stock Purchase Plan based on
estimated fair values. SFAS 123(R) supersedes our previous
accounting under Accounting Principles Board Opinion
No. 25, Accounting for Stock Issued to
Employees (APB 25). In March 2005, the
Securities and Exchange Commission issued Staff Accounting
Bulletin No. 107 (SAB 107) relating
to SFAS 123(R). We have applied the provisions of
SAB 107 in its adoption of SFAS 123(R).
We adopted SFAS 123(R) using the modified prospective
transition method, which requires the application of the
accounting standard as of January 1, 2006. Our consolidated
condensed financial statements as of and for the three months
ended March 31, 2006 reflect the impact of
SFAS 123(R). In accordance with the modified prospective
transition method, the financial statements for prior periods
have not been restated to reflect, and do not include, the
impact of SFAS 123(R).
SFAS 123(R) requires companies to estimate the fair value
of share-based payment awards on the date of grant using an
option-pricing model. The value of the portion of the award that
is ultimately expected to vest is recognized as expense over the
requisite service periods in the consolidated condensed
statement of operations. Prior to the adoption of
SFAS 123(R), we accounted for stock-based awards to
employees and directors using the intrinsic value method in
accordance with APB 25 as allowed under Statement of
Financial Accounting Standards No. 123, Accounting
for Stock-Based Compensation (SFAS 123).
Under the intrinsic value method, stock-based compensation
expense is recognized in the financial statements for the
amounts related to restricted stock unit grants and stock
options granted to employees at exercise prices which are less
than the market price of our stock on the dates that the stock
option is awarded. (See Note 2 regarding restatement of our
financial statements for stock-based compensation expense.)
We have determined the fair value of stock option grants using
the Black-Scholes option-pricing model (Black-Scholes
model). Our determination of fair value of share-based
payment awards on the date of grant using an option-pricing
model is affected by the Companys stock price as well as
assumptions regarding a number of highly complex and subjective
variables. These variables include, but are not limited to, the
Companys expected stock price volatility over the term of
the awards, and actual and projected employee stock option
exercise behaviors (See Note 8). The value of stock options
that are expected to vest is amortized to expense using the
straight line, graded vesting method over the vesting period of
each stock option granted. Previously, for purposes of the
disclosure only calculations under SFAS 123, the aggregate
value of stock option grants was amortized to expense on a
straight line basis.
9
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
Stock-based compensation expense included in the accompanying
financial statements for the three months was $5,618,000 and
$862,000 in the three months ended March 31, 2006 and 2005,
respectively.
The following table provides the pro forma results if we had
recognized stock compensation expense under the provisions of
SFAS 123(R) in 2005:
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31, 2005
|
|
|
|
(In thousands, except
|
|
|
|
per share amounts)
|
|
|
|
(Restated)
|
|
|
Net loss as reported
|
|
$
|
(139,759
|
)
|
Stock compensation expense
recorded at intrinsic value for stock incentive plans
|
|
|
862
|
|
Stock compensation expense
determined under fair value method for stock incentive plans
|
|
|
(5,560
|
)
|
|
|
|
|
|
Pro forma net loss
|
|
$
|
(144,457
|
)
|
|
|
|
|
|
Net loss per share:
|
|
|
|
|
Basic and diluted as
reported
|
|
$
|
(1.57
|
)
|
|
|
|
|
|
Basic and diluted pro
forma
|
|
$
|
(1.63
|
)
|
|
|
|
|
|
Prior to the restatement discussed in Note 2, we reported
that the pro forma net loss and net loss per share resulting
from the application of SFAS 123R would have been
$144,309,000 and $1.62 per share, respectively, for the
three month period ended March 31, 2005.
Income tax benefits in the United States that are associated
with the our stock option programs and stock compensation
expense have been recorded net of a completely offsetting
valuation allowance because, at this time, there is insufficient
objective evidence to assure that the Company will have
sufficient US taxable income to realize such benefits.
Assets Held for Sale: Valeant has entered into
a preliminary agreement of sale for a manufacturing facility in
Warsaw, Poland. At March 31, 2006 the net book value of
this facility ($7,421,000) is classified as assets held for sale
and included in prepaid expenses and other current assets in the
accompanying consolidated condensed financial statements.
Use of Estimates: The preparation of financial
statements in conformity with accounting principles generally
accepted in the United States of America requires us to make
estimates and assumptions that affect the reported amount of
assets and liabilities, the disclosure of contingent assets and
liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting
periods. Actual results could differ materially from those
estimates.
Reclassifications: Certain prior year items
have been reclassified to conform to the current year
presentation, with no effect on previously reported net income
or stockholders equity.
|
|
2.
|
Restatement
of Consolidated Financial Statements
|
We are amending our quarterly report on
Form 10-Q
for the quarter ended March 31, 2006 to restate our
condensed consolidated financial statements for the three month
periods ended March 31, 2006 and 2005 and the related
disclosures. On January 22, 2007 we filed an amended Annual
Report on
Form 10-K
for the year ended December 31, 2005.
In July 2006, we were contacted by the Securities and Exchange
Commission, or SEC, with respect to an informal inquiry
regarding events and circumstances surrounding trading in our
common stock and the public
10
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
release of data from our first pivotal Phase 3 trial for
Viramidine®
(taribavirin). In addition, on August 22, 2006, the SEC
requested data regarding our stock option grants and exercises
since January 1, 2000. The SEC has also requested
information about our pursuit in the Delaware Chancery Court of
the return of certain bonuses paid to Milan Panic, the former
chairman and chief executive officer, and others, in connection
with the Ribapharm initial public offering. We commenced an
internal review by our finance department of stock option grants
from 1982 to July 2006. In September 2006, our board of
directors appointed a special committee of the board composed
solely of independent directors (the Special
Committee) to conduct a review of our historic stock
option practices and related accounting. The Special Committee,
with the assistance of outside legal counsel, undertook a
comprehensive review of the stock option grants to our officers,
directors and employees from 1982 to July 2006 under our various
stock option plans in effect during this period. The Special
Committee has concluded its investigation and has reported its
findings to our board of directors.
On October 20, 2006, our board of directors concluded that
certain of our consolidated financial statements should be
restated to record the additional non-cash stock-based
compensation expense items and certain other items that had been
incorrectly accounted for under accounting principles generally
accepted in the United States, or GAAP.
Continuing the work done in September, the Special Committee
analyzed in detail stock option grants awarded between November
1994 and July 2006 and analyzed supporting documentation for
awards granted between 1982 and 1994. For the period between
November 1994 and July 2006, the Special Committees
analysis included an extensive review of paper and electronic
documents supporting or related to our stock option grants, the
accounting for those grants, compensation-related financial and
securities disclosures and
e-mail
communications as well as interviews with numerous current and
former employees and current and former members of our board of
directors. While the Special Committee concluded that there were
some errors as late as January 2006, the majority of errors in
accounting for options pertain to those options granted prior to
the change in our board of directors and management in mid-2002
(the Change in Control). None of the errors
occurring in periods after the Change in Control related to
options granted to the chief executive officer, chief financial
officer or members of our board of directors.
The Special Committee made a determination, based on the
available evidence, of measurement dates for each affected
grant. If the grants were approved at a meeting of the
compensation committee of the board of directors and there was
no actual evidence of a change in the approved list of
individual awards, the measurement date selected was the date of
the compensation committee meeting. If there was actual evidence
of a change in the list of individual awards and evidence of
when the list became final, the measurement date selected was
the date when the list became final. If there was actual
evidence of a change in the list but evidence of when the list
became final was not definitive, the measurement date was
reconstructed using the best available evidence to ensure that
an adequate amount of compensation expense was recorded in the
restatement.
In total we recorded $31,049,000 of additional pre-tax,
non-cash, stock-based compensation expense in the restatement to
correct errors for awards granted from 1982 to date. Of this,
$28,651,000 related to awards granted prior to the Change in
Control and $2,398,000 to awards granted after the Change in
Control. None of these changes affected our previously reported
revenues, cash, or cash equivalents. As explained below,
however, we also reported corrections for certain other items
which impact our reported revenues and cash flow presentations.
Options
Granted Prior to the Change in Control
The Special Committee found that the recorded grant dates for
the majority of stock options awarded prior to the Change in
Control differed from the actual grant dates for those
transactions. In connection with that finding, the Special
Committee concluded that, with respect to many broad-based
grants of stock options prior to the Change in Control, prior
management used a methodology of selecting a recorded grant date
based on the lowest closing price during some time period (e.g.,
quarter, ten trading days) preceding the actual grant date.
While the Special Committee did not reach a conclusion as to how
prior management selected other recorded grant dates for broad-
based or individual grants that did not use the lowest closing
price methodology, there is some evidence that dates were
selected based on the occurrence of an event or when the former
chief executive officer, Milan Panic, agreed in
11
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
principle to the grant. While these and similar practices
resulted in the grant of
in-the-money
options, and the Special Committee identified evidence that two
pre-Change in Control directors may have been aware of these
backdating practices, it does not appear that prior management
pre-Change in Control attempted to conceal that the stock option
grants were discounted using the backdating methodology.
Between November 1994 and the June 2002 Change in Control, eight
broad-based grants were made. All of the 908 individual awards
of options to purchase 6.9 million shares comprising those
grants had recorded grant dates that differed from the actual
grant dates for those transactions and each resulted in
additional compensation charges that are reflected in our
restated financial statements. Of those eight broad-based
grants, six appear to have been annual grants that used the
lowest closing price methodology and two appear to have been
event-related (in those instances, there are lower prices
between the recorded grant date and actual grant date). These
eight broad-based option grants accounted for $11,488,000 of the
$31,049,000 in pre-tax compensation charges.
During this period, options to directors to purchase a total of
334,000 shares were also found to have recorded grant dates
earlier than the dates when the board of directors acted to
approve the grants. The grants were dated in accordance with the
1994 Stock Option Plan which provided expressly that the grants
were to be dated as of November 11, 1994. The board of
directors, however, did not approve that stock option plan until
January 1995. Accordingly, we are taking additional non-cash
compensation charges equal to the difference between the closing
stock price on the date of approval and November 11, 1994.
These option grants to directors accounted for $148,000 of the
$31,049,000 in pre-tax compensation charges.
Also during this period, there were 114 other individual grants
of options to purchase a total of 2.0 million shares with
stipulated grant dates earlier than the dates the compensation
committee acted to approve these awards. The Special Committee
could not determine whether the date of those grants were based
on an event or when the former chief executive officer, Milan
Panic, agreed in principle to the award. These individual option
grants accounted for $4,538,000 of the $31,049,000 in additional
compensation charges.
The restatement also includes a pre-tax charge of $997,000
related to a stock option grant to a former chief financial
officer, who left in 2002. This grant of options to purchase
100,000 shares was granted to him with a recorded grant
date a few days before he joined the Company in May 1998. The
Special Committee concluded that this award of options was
effectively amended in December 1998 to lower its exercise
price. There is evidence which suggests that certain members of
former management knew or should have known that this
transaction and one other transaction (resulting in a pre-tax
charge of $450,000) had accounting, tax, and disclosure
consequences and that they failed to take appropriate action.
These options have been accounted for as variable awards in
accordance with FASB Interpretation No. 44, Accounting
for Certain Transactions involving Stock Compensation
(FIN 44) in the restated financial
statements. Variable accounting ceased in 2002 when these
options were surrendered.
We also recorded $1,375,000 of additional pre-tax, non-cash,
stock-based compensation expense in the restatement for awards
granted between 1982 and 1994.
In total 1,038 individual awards of options to purchase a total
of 9.2 million shares granted before the Change in Control
were found to have been granted
in-the-money,
representing 71% of total awards granted in the period November
1994 through June 11, 2002. This included 87 awards of
options to purchase 4.5 million shares awarded to ten
executive officers, including the former chief executive
officer, Milan Panic. These
in-the-money
awards to executive officers accounted for $10,507,000, or 34%
of the total pre-tax accounting charge of additional stock-based
compensation expense in the restatement.
Cash
Surrender of Options at Change in Control in 2002
The election of certain persons as directors at the annual
meeting of our stockholders on May 29, 2002 caused a Change
in Control under our stock option plans. Our 1998 Stock Option
Plan (the 1998 Plan) provided that all outstanding
options vested immediately upon the Change in Control and that
an option holder had 60 days following the Change in
Control to surrender his or her non-incentive stock options for
a cash payment equal to the excess of
12
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
the highest closing price of the stock during the 90 days
preceding the Change in Control, which was $32.50 per
share, or the closing price on the day preceding the date of
surrender, whichever was higher, over the exercise price for the
surrendered options.
During the year ended December 31, 2002, we recorded a
pre-tax charge of $61,400,000 related to our cash payment
obligation under the 1998 Plan. The findings of the Special
Committee relating to
in-the-money
options that were affected by the Change in Control require that
we recognize the remaining grant date intrinsic value resulting
from the acceleration of vesting for a number of these options
and the value that certain other options could have been
surrendered for cash under APB 25 and FIN 44. As a
result, an additional compensation charge of $10,105,000 has
been recorded in fiscal year 2002.
Options
Granted After the Change in Control
The Special Committee also found that, due to flaws in the
processes relied on to make our annual broad-based grants after
the Change in Control, we did not correctly apply the
requirements of APB 25 through December 2005. These option
accounting errors, however, differ significantly from those made
prior to the Change in Control. Unlike the broad-based grants
made prior to the Change in Control, for which the recorded
grant dates were selected from a period prior to the approval
dates, the broad-based grants after the Change in Control were
approved at either regularly scheduled meetings of the
compensation committee or at meetings of the board of directors,
and the exercise price for each of these grants was the closing
price on the date of such meetings.
The stock option accounting errors after the Change in Control
resulted from allocation adjustments to the list of grants to
individual non-executives after the compensation committee or
the board of directors had approved the allocation of an
aggregate number of shares to be available to non-executive
employees. In no event did the adjustments result in shares
being granted in excess of the aggregate number of shares
approved by the compensation committee or the board of
directors. Further, none of those adjustments related to the
chief executive officer, chief financial officer, or any member
of the board of directors. The Special Committee concluded that
there was no evidence that management operating since the Change
in Control were aware that the processes used to grant and
account for broad-based grants were flawed or that the process
employed was for the purpose of granting
in-the-money
stock options. In reaching this conclusion, the Special
Committee took note that that process had been consistently
employed even for the November 2005 grants in which the process
resulted in stock option grants at higher exercise prices than
the closing price of our common stock on the date of
finalization of the allocation list for non-executives. The
Special Committee also concluded that there was no evidence that
current management was aware of any financial statement impact,
tax consequences or disclosure implications of its flawed
processes.
Between May 2003 and November 2005, we made four broad-based
grants (May 2003, November 2003, November 2004 and November
2005). The May 2003 grants were made to non-executive employees.
The November 2003, 2004 and 2005 grants were made to a broad
base of employees, including senior executives (the
November Grants). With respect to each of the
November Grants, the granting authority (either the compensation
committee or the board of directors) made specific grants to
specific members of executive management, including, among
others, the chief executive officer, the chief operating
officer, and the chief financial officer. Additionally, the
broad-based grants made after the Change in Control were
approved either at regularly scheduled meetings of the
compensation committee or at meetings of the board of directors.
The stock option accounting errors that affected 164 individual
grants of options to purchase 1.5 million shares resulted
from slight adjustments to the non-executive grant lists after
the relevant compensation committee or board meetings. In no
event did the adjustments result in shares being granted in
excess of the number of options approved by the compensation
committee or the board of directors. As a result of its work,
the Special Committee made a determination of new measurement
dates for each affected grant. With respect to three of the four
broad-based grants (May 2003, November 2003 and November 2005),
the measurement date selected was the date on which the rank and
file list became final. With respect to the remaining
broad-based grant (November 2004), there was actual evidence of
a change in the rank and file list but inconclusive evidence
when the list became final. The measurement date for that grant
was reconstructed using the best available evidence to ensure
that an
13
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
adequate amount of compensation expense was recorded in the
restatement. A total of 14 other individual awards
(0.1 million shares) made to
rank-and-file
employees since the change of control were also found to contain
administrative stock option accounting errors.
To correct these errors, we recorded $2,398,000 of additional
pre-tax, non-cash, stock-based compensation expense in the
restatement for the period July 1, 2002 through
March 31, 2006. These non-cash charges have no impact on
previously reported revenues, cash or cash equivalents. As
explained below, however, we also reported corrections for
certain other items which do have an impact on reported revenues
and cash flow presentations.
New
Hire Grant Practices
The Special Committee investigated our new hire stock option
grant practices and concluded that the new hire grants were
appropriately accounted for under the applicable accounting
principles. Until January 2004, our practice was to set forth,
in a prospective employees offer letter a specific number
of options, specifying that the strike price would be equal to
the closing price on the new employees first date of
employment pending approval of the compensation committee.
Beginning in January 2004, the offer letters set the strike
price equal to the closing price of our stock on the later of
compensation committee approval or the employees start
date.
With respect to our new hire grant practices prior to January
2004, the Special Committee reviewed each offer letter and
related grant during the period June 2002 to January 2004 and a
sample of offer letters and related grants prior to June 2002.
The Special Committee also questioned relevant individuals about
the option-related new hire practices and procedures. This
intensive review confirmed that in each instance reviewed, the
number of options approved was equal to the number of options
set forth in the applicable offer letter, and that no material
terms of the options were changed by the compensation committee
in its approval process. Accordingly, the Special Committee
concluded that, with respect to new hire grants prior to January
2004, compensation committee approval was a mere formality and
that there had been finality with respect to the new hire grants
upon the first day of employment, which had been used as the
measurement date. Based upon the investigation, the Special
Committee concluded that new hire grants were accounted for
appropriately.
Income
Tax Effects
Incremental, stock-based, pre-tax compensation charges resulted
in tax benefits of $7,920,000. These tax benefits through 2000
were $1,940,000, recorded as an increase in the deferred tax
assets with a corresponding increase in retained earnings. For
2001 through 2003, deferred tax assets increased by $5,980,000
and income tax expense decreased by the same amount. In 2004,
the deferred tax asset was fully reserved with a valuation
allowance.
As a result of the review of our stock option granting
practices, management determined that the limitation of tax
benefits for executive compensation imposed by
Section 162(m) of the Internal Revenue Code (the
IRC) was not considered in the income tax returns or
financial statements prior to the Change in Control. The amount
of this limitation has been impacted by the determination that
many of the stock options were granted at prices below fair
market value on the date of grant. As a result of correctly
applying the Section 162(m) limitations, retained earnings
have been decreased by $1,896,000 as of December 31, 2000
and income tax expense has been increased by $702,000, $518,000
and $748,000 in 2001, 2002 and 2003, respectively. Adjustments
of ($205,000) and $122,000 for 2004 and 2005 respectively, did
not affect tax expense due to the valuation allowance. Also, the
cumulative impact on income tax of $3,864,000 was reversed in
2004. This occurred because the valuation allowance for the
deferred tax assets decreased with the Section 162(m)
reductions to the net operating loss.
As a result of our determination that the exercise prices of
certain option grants were below the closing price of our common
stock on the actual grant date, we evaluated whether the
affected employees would have any adverse tax consequences under
Section 409A of the IRC. It was determined that certain of
these options were unvested as of December 31, 2004, and
may be subject to Section 409A unless further action is
taken. None of these options belong to persons who, as of the
date of grant, were subject to the disclosure requirements of
Section 16(a) of the Securities
14
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
Exchange Act of 1934. Therefore, transition relief is available
with respect to these options through December 31, 2007.
Additional guidance may be available before that time that will
allow us to determine whether Section 409A will apply to
the circumstances under which these options were granted.
Depending upon the determination about the correct treatment of
these options for Section 409A purposes, the recipients of
these options may make an election to exercise the options in a
way that excludes them from Section 409A treatment. This
election is available through December 31, 2007.
Summary
and Other Items
In addition, we have restated the aforementioned financial
statements to correct certain accounting errors which were
previously identified but not considered to be material through
December 31, 2005. These corrections related to accounting
for employee tax withholding on certain compensation
transactions, elimination of an intercompany difference,
accounting for product exchanges (resulting in a revenue
adjustment), and certain income tax adjustments. The cumulative
effect of these errors on retained earnings as of
December 31, 2005 was $4,714,000. The restatement impact
through March 31, 2006 of these other corrections and of
the non-cash charges for stock-based compensation that have
resulted from the review of the Special Committee are summarized
in the table below (amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
Three Months
|
|
|
|
|
|
|
|
|
|
|
|
Cumulative
|
|
|
Additional
|
|
|
|
Ended March 31,
|
|
|
Year Ended December 31,
|
|
|
Effect
|
|
|
Expense
|
|
|
|
2006
|
|
|
2005
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
1982 -2002
|
|
|
(Income)
|
|
|
|
(In thousands)
|
|
|
Stock option grants prior to 2002
Change in Control:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Broad-based option grants with
improper measurement dates
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
11,488
|
|
|
$
|
11,488
|
|
Option grants to directors with
improper measurement dates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
148
|
|
|
|
148
|
|
Other option grants with improper
measurement dates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,538
|
|
|
|
4,538
|
|
Re-priced option grant
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
997
|
|
|
|
997
|
|
Improper measurement dates for
option grants
1982-1994
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,375
|
|
|
|
1,375
|
|
Incremental charge in connection
with Change in Control
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,105
|
|
|
|
10,105
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sub total pre Change in Control
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28,651
|
|
|
|
28,651
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock option grants after 2002
Change in Control:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company-wide option grants with
improper measurement dates
|
|
|
(64
|
)
|
|
|
312
|
|
|
|
1,171
|
|
|
|
1,085
|
|
|
|
172
|
|
|
|
|
|
|
|
2,364
|
|
Other stock option matters after
June 2002
|
|
|
|
|
|
|
6
|
|
|
|
21
|
|
|
|
(7
|
)
|
|
|
20
|
|
|
|
|
|
|
|
34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sub total post Change in Control
|
|
|
(64
|
)
|
|
|
318
|
|
|
|
1,192
|
|
|
|
1,078
|
|
|
|
192
|
|
|
|
|
|
|
|
2,398
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total impact of additional stock
compensation on operating income
|
|
|
(64
|
)
|
|
|
318
|
|
|
|
1,192
|
|
|
|
1,078
|
|
|
|
192
|
|
|
|
28,651
|
|
|
|
31,049
|
|
Other items corrected in
connection with restatement
|
|
|
(629
|
)
|
|
|
35
|
|
|
|
(2,273
|
)
|
|
|
(1,265
|
)
|
|
|
(90
|
)
|
|
|
7,766
|
|
|
|
3,509
|
|
Tax effects of above and other tax
items
|
|
|
300
|
|
|
|
147
|
|
|
|
964
|
|
|
|
(14,957
|
)
|
|
|
1,785
|
|
|
|
3,357
|
|
|
|
(8,551
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income decrease (increase)
resulting from all restatement items
|
|
$
|
(393
|
)
|
|
$
|
500
|
|
|
$
|
(117
|
)
|
|
$
|
(15,144
|
)
|
|
$
|
1,887
|
|
|
$
|
39,774
|
|
|
$
|
26,007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
The cumulative effect of the errors in 2002 and prior years of
$39,774,000 was recorded as a reduction of retained earnings at
December 31, 2002.
The pre-tax effect of the correction for stock-based
compensation was $157,000, $206,000, $792,000, $2,503,000,
$2,690,000, $3,491,000, $4,492,000 and $12,945,000 for 1995,
1996, 1997, 1998, 1999, 2000, 2001 and 2002, respectively. The
cumulative pre-tax effect of the correction for stock-based
compensation between 1982 and 1994 was $1,375,000.
The following table summarizes the specific income statement
accounts as reported and as affected by the restatement for the
three month periods ended March 31, 2006 and 2005.
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(In thousands)
|
|
|
Revenues
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
198,848
|
|
|
$
|
181,138
|
|
Adjustment
|
|
|
644
|
|
|
|
(21
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
199,492
|
|
|
$
|
181,117
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
58,580
|
|
|
$
|
48,721
|
|
Adjustment
|
|
|
21
|
|
|
|
62
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
58,601
|
|
|
$
|
48,783
|
|
|
|
|
|
|
|
|
|
|
Selling expenses
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
64,270
|
|
|
$
|
52,815
|
|
Adjustment
|
|
|
6
|
|
|
|
35
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
64,276
|
|
|
$
|
52,850
|
|
|
|
|
|
|
|
|
|
|
Research and development costs
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
29,535
|
|
|
$
|
25,724
|
|
Adjustment
|
|
|
18
|
|
|
|
107
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
29,553
|
|
|
$
|
25,831
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
28,540
|
|
|
$
|
24,577
|
|
Adjustment
|
|
|
(94
|
)
|
|
|
128
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
28,446
|
|
|
$
|
24,705
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations,
before interest, taxes and other items
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
7,934
|
|
|
$
|
(112,761
|
)
|
Adjustment
|
|
|
693
|
|
|
|
(353
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
8,627
|
|
|
$
|
(113,114
|
)
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing
operations before income taxes income taxes and minority interest
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
1,091
|
|
|
$
|
(121,218
|
)
|
Adjustment
|
|
|
693
|
|
|
|
(353
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
1,784
|
|
|
$
|
(121,571
|
)
|
|
|
|
|
|
|
|
|
|
16
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(In thousands)
|
|
|
Provision for income taxes
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
7,242
|
|
|
$
|
16,367
|
|
Adjustment
|
|
|
300
|
|
|
|
147
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
7,542
|
|
|
$
|
16,514
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing
operations
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
(6,152
|
)
|
|
$
|
(137,756
|
)
|
Adjustment
|
|
|
393
|
|
|
|
(500
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
(5,759
|
)
|
|
$
|
(138,256
|
)
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
(6,364
|
)
|
|
$
|
(139,259
|
)
|
Adjustment
|
|
|
393
|
|
|
|
(500
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
(5,971
|
)
|
|
$
|
(139,759
|
)
|
|
|
|
|
|
|
|
|
|
Basic and diluted earnings per
share from continuing operations
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
(0.07
|
)
|
|
$
|
(1.55
|
)
|
Adjustment
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
(0.06
|
)
|
|
$
|
(1.55
|
)
|
|
|
|
|
|
|
|
|
|
Basic and diluted earnings per
share
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
(0.07
|
)
|
|
$
|
(1.57
|
)
|
Adjustment
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
(0.06
|
)
|
|
$
|
(1.57
|
)
|
|
|
|
|
|
|
|
|
|
The following table summarizes the specific balance sheet
accounts as reported and as affected by the restatement as of
March 31, 2006 and December 31, 2005.
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(In thousands)
|
|
|
Other current assets (deferred
taxes)
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
38,862
|
|
|
$
|
36,652
|
|
Adjustment
|
|
|
|
|
|
|
3,702
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
38,862
|
|
|
$
|
40,354
|
|
|
|
|
|
|
|
|
|
|
Deferred tax assets, Net
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
21,510
|
|
|
$
|
45,904
|
|
Adjustment
|
|
|
|
|
|
|
(20,562
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
21,510
|
|
|
$
|
25,342
|
|
|
|
|
|
|
|
|
|
|
Accrued liabilities (reserve for
product returns)
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
135,043
|
|
|
$
|
136,701
|
|
Adjustment
|
|
|
3,508
|
|
|
|
4,137
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
138,551
|
|
|
$
|
140,838
|
|
|
|
|
|
|
|
|
|
|
17
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(In thousands)
|
|
|
Income taxes current
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
37,995
|
|
|
$
|
42,452
|
|
Adjustment
|
|
|
1,470
|
|
|
|
4,872
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
39,465
|
|
|
$
|
47,324
|
|
|
|
|
|
|
|
|
|
|
Deferred taxes
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
5,126
|
|
|
$
|
28,770
|
|
Adjustment
|
|
|
|
|
|
|
(20,562
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
5,126
|
|
|
$
|
8,208
|
|
|
|
|
|
|
|
|
|
|
Additional capital
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
1,209,926
|
|
|
$
|
1,203,814
|
|
Adjustment
|
|
|
21,029
|
|
|
|
21,093
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
1,230,955
|
|
|
$
|
1,224,907
|
|
|
|
|
|
|
|
|
|
|
Accumulated deficit
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
(757,480
|
)
|
|
$
|
(743,950
|
)
|
Adjustment
|
|
|
(26,007
|
)
|
|
|
(26,400
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
(783,487
|
)
|
|
$
|
(770,350
|
)
|
|
|
|
|
|
|
|
|
|
Stockholders equity
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
434,590
|
|
|
$
|
439,251
|
|
Adjustment
|
|
|
(4,978
|
)
|
|
|
(5,307
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
429,612
|
|
|
$
|
433,944
|
|
|
|
|
|
|
|
|
|
|
18
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
The following table sets forth the impact of the restatement on
our consolidated statements of cash flows from operating
activities three months ended March 31, 2006 and 2005 (in
thousands).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
|
March 31, 2006
|
|
|
March 31, 2005
|
|
|
|
As Previously
|
|
|
|
|
|
|
|
|
As Previously
|
|
|
|
|
|
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
As Restated
|
|
|
Reported
|
|
|
Adjustments
|
|
|
As Restated
|
|
|
Cash flows from operating
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$
|
(6,364
|
)
|
|
$
|
393
|
|
|
$
|
(5,971
|
)
|
|
$
|
(139,259
|
)
|
|
$
|
(500
|
)
|
|
$
|
(139,759
|
)
|
Loss from discontinued operations
|
|
|
(212
|
)
|
|
|
|
|
|
|
(212
|
)
|
|
|
(1,503
|
)
|
|
|
|
|
|
|
(1,503
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(6,152
|
)
|
|
|
393
|
|
|
|
(5,759
|
)
|
|
|
(137,756
|
)
|
|
|
(500
|
)
|
|
|
(138,256
|
)
|
Adjustments to reconcile net loss
to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
23,482
|
|
|
|
|
|
|
|
23,482
|
|
|
|
21,038
|
|
|
|
|
|
|
|
21,038
|
|
Provision for losses on accounts
receivable and inventory
|
|
|
3,597
|
|
|
|
|
|
|
|
3,597
|
|
|
|
1,594
|
|
|
|
|
|
|
|
1,594
|
|
Stock compensation expense
|
|
|
5,682
|
|
|
|
(64
|
)
|
|
|
5,618
|
|
|
|
544
|
|
|
|
319
|
|
|
|
863
|
|
Translation and exchange (gains)
losses, net
|
|
|
(937
|
)
|
|
|
|
|
|
|
(937
|
)
|
|
|
1,791
|
|
|
|
|
|
|
|
1,791
|
|
Impairment charges and other
non-cash items
|
|
|
20,426
|
|
|
|
|
|
|
|
20,426
|
|
|
|
1,461
|
|
|
|
|
|
|
|
1,461
|
|
Acquired in-process research and
development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
126,399
|
|
|
|
|
|
|
|
126,399
|
|
Deferred income taxes
|
|
|
1,910
|
|
|
|
|
|
|
|
1,910
|
|
|
|
(14,026
|
)
|
|
|
147
|
|
|
|
(13,879
|
)
|
Change in assets and liabilities,
net of effects of acquisitions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts Receivable
|
|
|
13,779
|
|
|
|
|
|
|
|
13,779
|
|
|
|
6,482
|
|
|
|
|
|
|
|
6,482
|
|
Inventories
|
|
|
(3,736
|
)
|
|
|
|
|
|
|
(3,736
|
)
|
|
|
(10,951
|
)
|
|
|
|
|
|
|
(10,951
|
)
|
Prepaid expenses and other assets
|
|
|
1,216
|
|
|
|
3,702
|
|
|
|
4,918
|
|
|
|
(129
|
)
|
|
|
|
|
|
|
(129
|
)
|
Trade payables and accrued
liabilities
|
|
|
(9,886
|
)
|
|
|
|
|
|
|
(9,886
|
)
|
|
|
(7,740
|
)
|
|
|
34
|
|
|
|
(7,706
|
)
|
Income taxes
|
|
|
(9,085
|
)
|
|
|
(4,031
|
)
|
|
|
(13,116
|
)
|
|
|
15,960
|
|
|
|
|
|
|
|
15,960
|
|
Other liabilities
|
|
|
842
|
|
|
|
|
|
|
|
842
|
|
|
|
3,995
|
|
|
|
|
|
|
|
3,995
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow from operating activities
in continuing operations
|
|
|
41,138
|
|
|
|
|
|
|
|
41,138
|
|
|
|
8,662
|
|
|
|
|
|
|
|
8,662
|
|
Cash flow from operating activities
in discontinued operations
|
|
|
(281
|
)
|
|
|
|
|
|
|
(281
|
)
|
|
|
(471
|
)
|
|
|
|
|
|
|
(471
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating
activities
|
|
$
|
40,857
|
|
|
$
|
|
|
|
$
|
40,857
|
|
|
$
|
8,191
|
|
|
$
|
|
|
|
$
|
8,191
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On April 3, 2006 Valeant announced a restructuring program
to reduce costs and accelerate earnings growth.
19
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
The program is primarily focused on our research and development
and manufacturing operations. The objective of the restructuring
program as it relates to research and development activities is
to focus our efforts and expenditures on three late stage
projects (Viramidine and Infergen, both of which are potential
treatments of patients with hepatitis C, and retigabine, a
potential treatment for partial onset seizures of patients with
epilepsy) currently in development. The restructuring program is
designed to rationalize our investments in research and
development efforts in line with our financial resources. We
intend to sell rights to, out-license or secure partners to
share the costs of other major clinical projects and discovery
programs that the research and development division has
underway. The objective of the restructuring program as it
relates to manufacturing is to further rationalize our
manufacturing operations to reflect the regional nature of our
existing products and further reduce our excess capacity after
considering the likely delay in the launch of Viramidine.
The restructuring program is also expected to reduce selling,
general and administrative expenses primarily through
consolidation of the management functions in fewer
administrative groups to achieve greater economies of scale.
Management and administrative responsibilities for our regional
operations in Australia, Africa and Asia (AAA), which have been
managed as a separate business unit, will be combined with those
of other regions.
We anticipate that the total restructuring program will result
in charges that will range between $90,000,000 and $115,000,000.
Although no impairments currently exist for any of our
long-lived asset groups under the assets held and used model of
FAS 144, Accounting for the Impairment or Disposal of
Long-Lived Assets these anticipated charges include
potential future losses that may occur upon the disposition of
specific assets related to our manufacturing operations in
Switzerland and Puerto Rico, as well as assets of other
operations that may be sold or abandoned. The anticipated
charges also include employee severance costs resulting from a
reduction of approximately 750 employees, the majority of whom
work in the manufacturing facilities anticipated to be disposed.
We recorded a provision of $26,466,000 in the three months ended
March 31, 2006 in connection with our decision to implement
the restructuring program. This charge, which was reported in
the Corporate operating segment, consists of the write off of
the costs of assets to be abandoned in the restructuring process
of $19,822,000 and an accrual for a portion of the severance
costs of employees who will be terminated in the program of
$6,644,000. The severance charges recorded in the three months
ended March 31, 2006 relate to 103 employees in
administrative and research positions whose positions were
eliminated in the restructuring. The amount of the accrual for
severance in the three months ended March 31, 2006 was
determined in accordance with Financial Accounting Standard
No. 112 Employers Accounting for Postemployment
Benefits.
In compliance with Financial Accounting Standard No. 146
Accounting for Costs Associated with Exit or Disposal
Activities certain costs relating to the termination of
employees in the restructuring program were not recorded in the
three months ended March 31, 2006 but will be recorded when
communicated to the affected employees (in the second quarter of
2006). Other costs associated with the restructuring and the
associated termination of employees in connection therewith will
be expensed as incurred. Additionally, losses from assets
expected to be sold will be recorded upon disposal, or earlier
if an impairment of the carrying value of the assets is
identified under FAS 144.
Restructuring charges in the three month period ended
March 31, 2005 relate to the decision to dispose of the
Companys manufacturing facility in China offset in part by
the gain on the sale of a manufacturing plant in Argentina.
Infergen: On December 30, 2005, we
acquired the United States and Canadian rights to the Infergen
business of InterMune, Inc. Infergen is indicated for the
treatment of hepatitis C in patients who have not responded
to other treatments or have relapsed after such treatment. In
connection with this transaction we acquired the rights to the
Infergen product as currently approved by the FDA and rights to
a clinical trial underway to expand the clinical
20
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
applications of Infergen. We also employed InterMunes
marketing and research staffs who were dedicated to the Infergen
product and projects and acquired third party contracts for the
manufacture of Infergen. We paid InterMune consideration of
$120,000,000 in cash at the closing. Additionally, we have
agreed to pay up to an additional $22,400,000 of which
$20,000,000 is contingent on certain milestones being reached.
Xcel Pharmaceuticals, Inc.: On March 1,
2005, we acquired Xcel Pharmaceuticals, Inc. (Xcel),
a specialty pharmaceutical company focused on the treatment of
disorders of the central nervous system for $280,000,000 in
cash. Under the terms of the purchase agreement, we paid an
additional $7,470,000 for a working capital adjustment.
Xcels portfolio consisted of four products that are sold
within the United States, and retigabine, a late-stage clinical
product candidate that is an adjunctive treatment for
partial-onset seizures in patients with epilepsy. Approximately
$44,000,000 of the cash consideration was used to retire
Xcels outstanding long-term debt.
In connection with the Xcel acquisition, we completed an
offering of 8,280,000 shares of our common stock in
February 2005. After underwriting discounts and commissions, we
received net proceeds of $189,393,000, which was used to
partially fund the Xcel acquisition. The remainder of the funds
required for the Infergen and Xcel acquisitions was provided by
available cash on hand.
A portion of the purchase price for the Xcel acquisition was
placed in an escrow account to cover potential claims under the
purchase agreement that would arise within one year of the
acquisition date. Prior to such date, we filed a claim for
indemnification from the former Xcel stockholders with respect
to certain breaches of representation and warranties made by
Xcel under the Xcel purchase agreement relating to Medicaid
rebates on preacquisition sales and certain third-party claims.
As of March 31, 2006, approximately $5 million of the
Xcel purchase price was in an escrow fund to pay indemnification
claims.
The following unaudited pro forma financial information presents
the combined results of operations of Valeant, Infergen and Xcel
for the three month period ended March, 31 2005 as if the
acquisitions had occurred as of January 1, 2005. The
unaudited pro forma financial information is not intended to
represent or be indicative of the Companys consolidated
results of operations or financial condition that would have
been reported had the acquisitions been completed as of the date
presented, and should not be taken as representative of our
future consolidated results of operations or financial condition.
|
|
|
|
|
|
|
March 31, 2005
|
|
|
|
(in thousands, except
|
|
|
|
per share amounts)
|
|
|
|
(Restated)
|
|
|
Net revenues
|
|
$
|
200,471
|
|
Loss from continuing operations
|
|
|
(196,021
|
)
|
Net loss
|
|
|
(197,524
|
)
|
Basic and diluted net loss per
share:
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(2.12
|
)
|
Net loss
|
|
$
|
(2.13
|
)
|
The above pro forma financial information includes charges for
acquired in-process research and development of $126,399,000
with respect to Xcel and $47,200,000 with respect to Infergen
and adjustments for amortization of identifiable intangible
assets acquired and interest expense as a result of the
retirement of Xcels long-term debt. The effect of the
IPR&D charges of Xcel and Infergen on the pro forma loss per
share is $1.89.
|
|
5.
|
Discontinued
Operations
|
In the second half of 2002, we made a strategic decision to
divest our Russian Pharmaceuticals segment, biomedicals segment,
Photonics business, raw materials businesses and manufacturing
facilities in Central Europe and Circe unit. During 2003, we
disposed of the Russian Pharmaceuticals segment, biomedicals
segment, Photonics
21
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
business and Circe unit. During 2004, we disposed of one of the
raw materials businesses and manufacturing facilities in Central
Europe. During 2005 we completed the sale of the remaining raw
materials business and manufacturing facility in Central Europe.
In 2006 losses from discontinued operations consist of disposal
of remaining real estate facilities and the wind down of
administrative activities associated with these operations.
Summarized selected financial information for discontinued
operations for the three months ended March 31, 2006 and
2005 is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
Revenues
|
|
$
|
|
|
|
$
|
2,092
|
|
|
|
|
|
|
|
|
|
|
Loss before income taxes
|
|
$
|
(212
|
)
|
|
$
|
(1,285
|
)
|
Loss on disposal of discontinued
operations
|
|
|
|
|
|
|
(218
|
)
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued
operations
|
|
$
|
(212
|
)
|
|
$
|
(1,503
|
)
|
|
|
|
|
|
|
|
|
|
The assets and liabilities of discontinued operations are stated
separately as of March 31, 2006 and December 31, 2005
on the accompanying consolidated condensed balance sheets. The
major assets and liabilities categories are as follows (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
Cash
|
|
$
|
69
|
|
|
$
|
47
|
|
Accounts receivable, net
|
|
|
29
|
|
|
|
45
|
|
Property, plant and equipment, net
|
|
|
|
|
|
|
18
|
|
Other assets
|
|
|
7
|
|
|
|
17
|
|
|
|
|
|
|
|
|
|
|
Assets of discontinued operations
|
|
$
|
105
|
|
|
$
|
127
|
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
7
|
|
|
$
|
13
|
|
Accrued liabilities
|
|
|
19,018
|
|
|
|
19,118
|
|
Other liabilities
|
|
|
3,999
|
|
|
|
3,987
|
|
|
|
|
|
|
|
|
|
|
Liabilities of discontinued
operations
|
|
$
|
23,024
|
|
|
$
|
23,118
|
|
|
|
|
|
|
|
|
|
|
Environmental contamination has been identified in the soil
under a facility built by the Company which housed operations of
the discontinued biomedicals segment and is currently vacant.
Remediation of the site will involve excavation and disposal of
the waste at appropriately licensed sites some distance from the
facility. Environmental reserves have been provided for
remediation and related costs that we can reasonably estimate.
Remediation costs are applied against these environmental
reserves as they are incurred. As assessments and remediation
progress, these liabilities will be reviewed and adjusted to
reflect additional information that becomes available. Total
environmental reserves for this site were $18,923,000 and
$19,023,000 as of March 31, 2006 and December 31,
2005, respectively, and are included in the liabilities of
discontinued operations. Although we believe that the reserves
are adequate, there can be no assurance that the amount of
expenditures and other expenses, which will be required relating
to remediation actions and compliance with applicable
environmental laws will not exceed the amounts reflected in
reserves or will not have a material adverse effect on our
consolidated financial condition, results of operations or cash
flows. Any possible loss that may be incurred in excess of
amounts provided for as of March 31, 2006 cannot be
reasonably estimated.
22
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
The following table sets forth the computation of basic and
diluted earnings per share (in thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
Income (loss):
|
|
|
|
|
|
|
|
|
Numerator for basic and dilutive
earnings per share loss attributable to stockholders
|
|
$
|
(5,971
|
)
|
|
$
|
(139,759
|
)
|
|
|
|
|
|
|
|
|
|
Shares:
|
|
|
|
|
|
|
|
|
Denominator for basic and dilutive
earnings per share adjusted weighted-average shares
outstanding
|
|
|
92,770
|
|
|
|
88,836
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share:
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(0.06
|
)
|
|
$
|
(1.55
|
)
|
Loss from discontinued operations
|
|
|
|
|
|
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per
share
|
|
$
|
(0.06
|
)
|
|
$
|
(1.57
|
)
|
|
|
|
|
|
|
|
|
|
For the three months ended March 31, 2006 and 2005, options
to purchase 1,746,000 and 2,868,000 weighted average shares of
common stock, respectively, were not included in the computation
of earnings per share because we incurred a loss and the effect
would have been anti-dilutive.
For the three months ended March 31, 2006 and 2005, options
to purchase 9,324,000 and 1,901,000 weighted average shares of
common stock, respectively, were also not included in the
computation of earnings per share because the option exercise
prices were greater than the average market price of the
Companys common stock and, therefore, the effect would
have been anti-dilutive.
23
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
|
|
7.
|
Detail of
Certain Accounts
|
The following tables present the details of certain amounts
included in the consolidated balance sheet at March 31,
2006 and December 31, 2005 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
Accounts receivable,
net:
|
|
|
|
|
|
|
|
|
Trade accounts receivable
|
|
$
|
134,912
|
|
|
$
|
153,497
|
|
Royalties receivable
|
|
|
18,111
|
|
|
|
27,306
|
|
Other receivables
|
|
|
27,222
|
|
|
|
12,669
|
|
|
|
|
|
|
|
|
|
|
|
|
|
180,245
|
|
|
|
193,472
|
|
Allowance for doubtful accounts
|
|
|
(5,812
|
)
|
|
|
(5,485
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
174,433
|
|
|
$
|
187,987
|
|
|
|
|
|
|
|
|
|
|
Inventories, net:
|
|
|
|
|
|
|
|
|
Raw materials and supplies
|
|
$
|
34,448
|
|
|
$
|
34,931
|
|
Work-in-process
|
|
|
27,520
|
|
|
|
28,726
|
|
Finished goods
|
|
|
89,604
|
|
|
|
85,152
|
|
|
|
|
|
|
|
|
|
|
|
|
|
151,572
|
|
|
|
148,809
|
|
Allowance for inventory
obsolescence
|
|
|
(13,843
|
)
|
|
|
(12,775
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
137,729
|
|
|
$
|
136,034
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment,
net:
|
|
|
|
|
|
|
|
|
Property, plant and equipment, at
cost
|
|
$
|
393,408
|
|
|
$
|
401,613
|
|
Accumulated depreciation and
amortization
|
|
|
(175,595
|
)
|
|
|
(171,487
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
217,813
|
|
|
$
|
230,126
|
|
|
|
|
|
|
|
|
|
|
Intangible assets: As of March 31, 2006 and
December 31, 2005, intangible assets were as follows
(in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2006
|
|
|
December 31, 2005
|
|
|
|
Gross
|
|
|
Accumulated
|
|
|
Gross
|
|
|
Accumulated
|
|
|
|
Amount
|
|
|
Amortization
|
|
|
Amount
|
|
|
Amortization
|
|
|
Intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product rights
|
|
$
|
764,471
|
|
|
$
|
(271,743
|
)
|
|
$
|
763,653
|
|
|
$
|
(257,380
|
)
|
License agreements
|
|
|
67,376
|
|
|
|
(40,490
|
)
|
|
|
67,376
|
|
|
|
(37,330
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total intangible assets
|
|
$
|
831,847
|
|
|
$
|
(312,233
|
)
|
|
$
|
831,029
|
|
|
$
|
(294,710
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense for the three months ended March 31,
2006 and 2005 was $17,523,000 and $13,968,000, respectively, of
which $14,364,000 and $10,709,000, respectively, related to
amortization of acquired product rights.
24
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
We experience losses in the United States tax jurisdiction,
where our research and development activities are conducted and
our corporate offices are located. We anticipate that we will
realize the tax benefits associated with these losses from
reductions of future taxable income resulting from products in
our development pipeline, further growth in US product sales and
other measures. However, at this time, there is insufficient
objective evidence of the timing and amounts of such future
U.S. taxable income to assure realization of the tax
benefits, and valuation allowances have been established to
reserve those benefits. The valuation allowance for the three
months ended March 31, 2006 was approximately $6,500,000
resulting in a provision for income taxes of $7,542,000 which
primarily represents the taxes payable on earnings in tax
jurisdictions outside the United States and for state and local
taxes payable within the U.S.
Our effective tax rate for the three months ended March 31,
2005 was affected by pre-tax losses resulting from a
restructuring charge of $1,695,000 and the write-off of acquired
IPR&D expenses in connection with the Xcel acquisition of
$126,399,000. These charges are not deductible for income tax
purposes. The tax provision in the three months ended
March 31, 2005 relates to the expected taxes on earnings in
tax jurisdictions outside the United States.
|
|
9.
|
Common
Stock and Share Compensation
|
Stock Incentive Plan: In April 2003, we
implemented the Companys 2003 Equity Incentive Plan
(the Incentive Plan), which is an amendment and
restatement of our 1998 Option Plan. The Incentive Plan
increased the number of shares of common stock available for
issuance from 11,604,000 to 18,104,000 in the aggregate. The
Incentive Plan provides for the grant of incentive stock
options, nonqualified stock options, stock appreciation rights,
restricted stock awards, phantom stock and stock bonuses
(collectively, awards) to our key employees,
officers, directors, consultants and advisors. Options granted
under the Incentive Plan must have an exercise price that is not
less than 85% of the fair market value of the common stock on
the date of grant and a term not exceeding 10 years. Under
the Incentive Plan, 500,000 shares may be issued as phantom
stock awards or restricted stock awards for which a participant
pays less than the fair market value of the common stock on the
date of grant. Generally, options vest ratably over a four year
period from the date of grant.
Stock Options Issued Under the Incentive
Plan: The following table sets forth information
relating to stock options issued under the Incentive Plan (in
thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Average
|
|
|
|
Number of
|
|
|
Exercise
|
|
|
|
Shares
|
|
|
Price
|
|
|
Shares under option,
December 31, 2004
|
|
|
13,336
|
|
|
$
|
17.93
|
|
Granted
|
|
|
2,192
|
|
|
$
|
18.16
|
|
Exercised
|
|
|
(160
|
)
|
|
$
|
20.10
|
|
Canceled
|
|
|
(736
|
)
|
|
$
|
22.28
|
|
|
|
|
|
|
|
|
|
|
Shares under option,
December 31, 2005
|
|
|
14,632
|
|
|
$
|
17.80
|
|
Granted
|
|
|
130
|
|
|
$
|
17.22
|
|
Exercised
|
|
|
(33
|
)
|
|
$
|
13.07
|
|
Canceled
|
|
|
(257
|
)
|
|
$
|
27.64
|
|
|
|
|
|
|
|
|
|
|
Shares Under Option,
March 31, 2006
|
|
|
14,472
|
|
|
$
|
17.63
|
|
|
|
|
|
|
|
|
|
|
Exercisable at December 31,
2005
|
|
|
7,197
|
|
|
$
|
17.82
|
|
|
|
|
|
|
|
|
|
|
Exercisable at March 31, 2006
|
|
|
7,387
|
|
|
$
|
17.39
|
|
|
|
|
|
|
|
|
|
|
Options available for grant at
December 31, 2005
|
|
|
513
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options available for grant at
March 31, 2006
|
|
|
635
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
The schedule below reflects the number of outstanding and
exercisable options as of March 31, 2006 segregated by
price range (in thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
|
|
|
Exercisable
|
|
|
Weighted
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
Weighted
|
|
|
Average
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
Average
|
|
|
Remaining
|
|
|
|
Number
|
|
|
Exercise
|
|
|
Number
|
|
|
Exercise
|
|
|
Contractual
|
|
Range of Exercise Prices
|
|
of Shares
|
|
|
Price
|
|
|
of Shares
|
|
|
Price
|
|
|
Term (Years)
|
|
|
$8.10 to $13.08
|
|
|
4,845
|
|
|
$
|
10.29
|
|
|
|
3,308
|
|
|
$
|
10.07
|
|
|
|
6.71
|
|
$13.67 to $18.55
|
|
|
5,250
|
|
|
$
|
17.87
|
|
|
|
1,657
|
|
|
$
|
17.90
|
|
|
|
8.34
|
|
18.70 to 46.25
|
|
|
4,377
|
|
|
$
|
25.46
|
|
|
|
2,422
|
|
|
$
|
27.05
|
|
|
|
7.17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,472
|
|
|
|
|
|
|
|
7,387
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The fair value of options granted in 2006 and 2005 were
estimated at the date of grant using the Black-Scholes
option-pricing model with the following assumptions:
|
|
|
|
|
|
|
|
|
|
|
2006
|
|
|
2005
|
|
|
Weighted-average life (years)
|
|
|
4.1
|
|
|
|
4.1
|
|
Volatility
|
|
|
39
|
%
|
|
|
41
|
%
|
Expected dividend per share
|
|
$
|
0.31
|
|
|
$
|
0.31
|
|
Risk-free interest rate
|
|
|
4.80
|
%
|
|
|
4.33
|
%
|
Weighted-average fair value of
options
|
|
$
|
5.48
|
|
|
$
|
6.10
|
|
The aggregate intrinsic value of the stock options outstanding
at March 31, 2006 was $27,391,000. The aggregate intrinsic
value of the stock options that are both outstanding and
exercisable at March 31, 2006 was $19,454,000. Intrinsic
value is the in the money valuation of the options
or the difference between market and exercise prices. The fair
value of options vesting in the three months ended
March 31, 2006 was $2,609,000.
Restricted Stock Units Issued Under the Incentive
Plan: During 2005, 2004 and 2003, pursuant to our
approved director compensation plan, we granted its non-employee
directors 147,465, 51,476 and 69,653 shares of restricted
stock units, respectively. Additionally in 2005 we granted
certain officers of the Company, in the aggregate, 90,000
restricted stock units. The restricted stock units issued had a
fair value (equal to the market price of the Companys
stock on the grant date) of $2,752,000, $971,000 and $840,000,
in the years ended December 31, 2005, 2004 and 2003,
respectively. Each restricted stock unit granted to non-employee
directors vests over one year, is entitled to dividend
equivalent shares and is exchanged for a share of the
Companys common stock one year after the director ceases
to serve as a member of the Companys Board. Each
restricted stock unit granted to certain officers of the company
vests 50 percent three years after grant with the balance
vesting equally in years four and five after grant, is entitled
to dividend equivalent shares and is exchanged for a share of
the Companys common stock upon vesting. As of
March 31, 2006 and December 31, 2005, there were
242,442 restricted stock units outstanding During the three
months ended March 31, 2006 and 2005, the Company recorded
non-cash charges related to the vesting of restricted stock
units of $637,000 and $544,000 respectively.
2003 Employee Stock Purchase Plan: In May
2003, our stockholders approved the Valeant Pharmaceuticals
International 2003 Employee Stock Purchase Plan (the
ESPP). The ESPP provides employees with an
opportunity to purchase common stock at a 15% discount to market
price. Additionally, the market prices under the ESPP program
are the lower of the Companys stock price at the beginning
or end of each six month ESPP enrollment period. There are
7,000,000 shares of common stock reserved for issuance
under the Purchase Plan, plus an annual increase on the first
day of our fiscal year for a period of ten years, ending on
January 1, 2015, equal to the lower of (i) 1.5% of the
shares of common stock outstanding on each calculation date,
(ii) 1,500,000 shares of common stock, or (iii) a
number of shares that may be determined by the Compensation
Committee. In the year ending 2005, we issued
100,000 shares of common stock for proceeds of $1,644,000.
No shares were issued in the three month period
26
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
ended March 31, 2006 (under the terms of the ESPP shares
are issued twice each year in May and November). Under
SFAS 123(R) we recorded $120,000 as compensation expense in
the three month period ended March 31, 2006 for shares
expected to be purchased under this plan. This amount consists
of the 15% discount to market price offered to participating
employees under the ESPP plus the additional value, determined
under the Black-Scholes model, of the plan feature allowing
purchased share price to be based on the lower of the
Companys share price at the beginning or end of each ESPP
enrollment period.
The components of stock compensation expense and the amounts of
future expense that relate to outstanding but unvested stock
options and phantom stock awards is set forth in the table below
(amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
Recorded as Expense
|
|
|
To be Recorded as
|
|
|
|
Through
|
|
|
Expense in
|
|
|
|
March 31, 2006
|
|
|
Future Periods
|
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
Employee stock options
|
|
$
|
4,861
|
|
|
$
|
23,838
|
|
Phantom and Restrictred stock units
|
|
|
637
|
|
|
|
1,872
|
|
Employee Stock Pruchase Plan
|
|
|
120
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock based compensation
expense
|
|
$
|
5,618
|
|
|
$
|
25,710
|
|
|
|
|
|
|
|
|
|
|
Stock compensation expense was recorded in the following expense
classifications (in thousands).
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
Cost of goods sold
|
|
$
|
434
|
|
|
$
|
62
|
|
Selling expenses
|
|
|
854
|
|
|
|
35
|
|
General and administrative expenses
|
|
|
3,532
|
|
|
|
525
|
|
Research and development costs
|
|
|
798
|
|
|
|
240
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
5,618
|
|
|
$
|
862
|
|
|
|
|
|
|
|
|
|
|
The amounts of future stock compensation expense associated with
outstanding stock options and restricted stock units outstanding
at March 31, 2006 is scheduled to be charged to expense as
follows (amounts are as restated):
|
|
|
|
|
|
|
(In Thousands)
|
|
|
Remainder of 2006
|
|
$
|
13,580
|
|
2007
|
|
|
8,255
|
|
2008
|
|
|
3,108
|
|
2009 and thereafter
|
|
|
767
|
|
|
|
|
|
|
|
|
$
|
25,710
|
|
|
|
|
|
|
Dividends: We have paid quarterly cash
dividends of $0.0775 per share for each quarter in 2005 and
the first quarter of 2006. However, we cannot assure that we
will continue to do so.
27
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
|
|
10.
|
Commitments
and Contingencies
|
We are involved in several legal proceedings, including the
following matters (Valeant was formerly known as ICN
Pharmaceuticals, Inc.):
Securities
Class Actions:
Section 10b-5
Litigation: Since July 25, 2002, multiple
class actions have been filed against us and some of our current
and former executive officers alleging that the defendants
violated Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934, and
Rule 10b-5
promulgated thereunder, by issuing false and misleading
financial results to the market during different class periods
ranging from May 3, 2001 to July 10, 2002, thereby
artificially inflating the price of our stock. The lawsuits
generally claim that we issued false and misleading statements
regarding our earnings prospects and sales figures (based upon
channel stuffing allegations), our operations in
Russia, the marketing of Efudex, and the earnings and sales of
our Photonics division. The plaintiffs generally seek to recover
compensatory damages, including interest.
All the actions have been consolidated to the Central District
of California. On June 24, 2004, the court dismissed the
Second Amended Complaint as to the channel stuffing claim. The
plaintiffs then stipulated to a dismissal of all the claims
against us. The plaintiffs have filed a notice of appeal to the
United States Court of Appeals for the Ninth Circuit seeking
review of the dismissal of the claims against us. Oral argument
before the Ninth Circuit in this matter has been scheduled for
June 9, 2006.
Derivative Actions: We are a nominal defendant
in a shareholder derivative lawsuit pending in state court in
Orange County, California, styled James Herrig, IRA v.
Milan Panic et al. This lawsuit, which was filed on
June 6, 2002, purports to assert derivative claims on our
behalf against certain of our current
and/or
former officers and directors. The lawsuit asserts claims for
breach of fiduciary duties, abuse of control, gross
mismanagement and waste of corporate assets. The plaintiff
seeks, among other things, damages and a constructive trust over
cash bonuses paid to the officer and director defendants in
connection with the Ribapharm offering.
On October 1, 2002, several of our former and current
directors, as individuals, as well as Valeant, as a nominal
defendant, were named as defendants in a second
shareholders derivative complaint filed in the Delaware
Court of Chancery, styled Paul Gerstley v. Norman
Barker, Jr. et al. The original complaint in the
Delaware action purported to state causes of action for
violation of Delaware General Corporation Law Section 144,
breach of fiduciary duties and waste of corporate assets in
connection with the defendants management of our company.
The allegations in the Delaware action were similar to those
contained in the derivative lawsuit filed in Orange County,
California, but included additional claims asserting that the
defendants breached their fiduciary duties by disseminating
materially misleading and inaccurate information.
We established a Special Litigation Committee to evaluate the
plaintiffs claims in both derivative actions. The Special
Litigation Committee concluded that it would not be in the best
interest of our shareholders to pursue many of the claims in
these two lawsuits, but decided to pursue, through litigation or
settlement, claims arising from the April 2002 decision of the
Board to approve the payment of approximately $50,000,000 in
bonuses to various members of the Board and management in
connection with the initial public offering of Ribapharm (the
Ribapharm Bonuses). The Court granted our motion to
stay the California proceedings in favor of the similar Delaware
proceedings. On October 27, 2003, the Delaware Court of
Chancery granted our motion to realign us as plaintiff in the
Delaware action.
We have settled the litigation with respect to ten of the
defendants, nine of whom each received Ribapharm Bonuses of
$330,500, and one who received a Ribapharm Bonus of $500,000.
Three of the settling defendants were first elected to our Board
of Directors in 2001 (the 2001 Directors), only
one of whom currently serves on the Board of Directors. Pursuant
to the settlements, the 2001 Directors forfeited their 2003
annual Board of Directors stipend and all of their
restricted stock units in exchange for a release from further
liability in the lawsuit (the 2001 Director
Settlement). The 2001 Director Settlement further
provides that, in the event we negotiate a
28
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
settlement with certain defendants on financial terms that are
materially better than those set forth in the settlement
agreements with the 2001 Directors, we agree to adjust the
2001 Directors settlement payment by a comparable
proportion. Following court-sponsored mediation in the Delaware
Court of Chancery, we entered into settlement agreements with
seven other defendants. Pursuant to these settlements, six of
these defendants (the Outside Director Defendants)
are required to pay to us $150,000 in exchange for a release
from further liability in the lawsuit. The Outside Director
Defendants will receive an offset credit of $50,000 for release
of their claimed right to payments for the automatic conversion
of our stock options that were not issued to them in 2002. As
provided in the settlement agreements, in July 2005, five of the
Outside Director Defendants have paid in cash to us $50,000 each
in settlement payments, with the remaining $50,000 to be paid on
or before May 18, 2006. The other settling former director
has paid $80,000 to us pursuant to his settlement agreement with
us in exchange for a release from further liability in the
lawsuit. On May 18, 2005, the Delaware Court of Chancery
approved all of the settlements and dismissed all claims except
those related to the Ribapharm Bonuses. Following the
mediated settlement agreements, counsel for the
2001 Directors notified us that, in the
2001 Directors opinion, the settlement agreements
with the Outside Director Defendants are on financial terms that
are materially better than those set forth in the settlements
with the 2001 Directors and have demanded that we pay to
the 2001 Directors the sum of $50,000 each. We have advised
the 2001 Directors that the settlement agreements reached
with the other defendants do not trigger this provision. If it
is deemed that the financial terms of the settlement with the
Outside Director Defendants are on financial terms that are
materially better than those set forth in the settlement with
the 2001 Directors, the 2001 Directors
settlement payment will be adjusted by a comparable proportion.
The claims with respect to defendants Milan Panic and Adam
Jerney, who received Ribapharm Bonuses of $33,000,000 and
$3,000,000, respectively, were tried in Delaware Chancery Court
in a one-week trial beginning February 27, 2006. The Court
will render its decision after the post-trial briefings and
hearing conclude in the second quarter of 2006.
Patent Oppositions: Various parties are
opposing our ribavirin patents in actions before the European
Patent Office (E.P.O.), and we are responding to these
oppositions. One patent has been revoked by the Opposition
Division of the E.P.O., and we have filed an appeal within the
E.P.O. The revoked patent benefited from patent extensions in
the major European countries that provided market protection
until 2010. A second European patent is also the subject of an
opposition proceeding in the E.P.O.
Should the opponents ultimately prevail against both of our
ribavirin patents, the ribavirin component of the combination
therapies marketed by Schering-Plough and Roche would lose
patent protection in Europe. Although data exclusivity applies
to these products until 2010, if no ribavirin patents remain in
force in Europe, we will no longer receive royalties from Roche.
Serbia & Montenegro: In March 1999,
arbitration was initiated in the following matters before the
International Chamber of Commerce International Court of
Arbitration: (a) State Health Fund of Serbia v. ICN
Pharmaceuticals, Inc., Case No. 10 373/ AMW/ BDW/ SPB/ JNK,
and (b) ICN Pharmaceuticals, Inc. v. Federal Republic
of Yugoslavia and Republic of Serbia, Case No. 10 439/ BWD/
SPB/ JNK. At issue in these matters were the parties
respective rights and obligations with respect to ICN
Yugoslavia, a joint venture known as Galenika and formed by the
parties
predecessors-in-interest
in 1990. In these proceedings, we asserted claims against the
Federal Republic of Yugoslavia (FRY) and the
Republic of Serbia, and counterclaims against the State Health
Fund of Serbia (Health Fund) for, inter alia,
unlawful seizure of our majority interest in the joint venture
and failure to pay obligations to the joint venture in excess of
$176,000,000. We sought damages in excess of $277,000,000. The
Health Fund asserted claims against us for breach of the joint
venture agreement based on our alleged failure to make our
required capital contributions, and our alleged mismanagement of
the joint venture. The Health Fund sought damages in excess of
$270,000,000. Early in the proceedings the arbitral tribunal
dismissed the FRY from these proceedings for lack of
jurisdiction. In November 2004 the arbitral tribunal issued a
final award in the case. The tribunal ruled that we had complied
with our capital contribution obligations, that the Health Fund
and Republic of Serbia had committed a de facto expropriation of
our interest in the joint venture, and that we were entitled to
a return of our capital contributions, including rights to
certain pharmaceutical compounds and $50,000,000 in cash. The
tribunal dismissed the remaining claims by us and by the Health
Fund for lack of
29
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
jurisdiction. All matters regarding Galenika were settled
pursuant to a Mutual Settlement and Release Agreement among us,
the Republic of Serbia, the Health Fund and the Galenika entity,
under which we were paid $28,000,000 on March 1, 2006 and
will be paid an additional $6,000,000 on March 1, 2007,
with respect to which we have received a bank letter of credit.
Argentina Antitrust Matter: In July 2004, we
were advised that the Argentine Antitrust Agency had issued a
notice unfavorable to us in a proceeding against our Argentine
subsidiary. The proceeding involves allegations that the
subsidiary in Argentina abused a dominant market position in
1999 by increasing its price on Mestinon in Argentina and not
supplying the market for approximately two months. The
subsidiary filed documents with the agency offering an
explanation justifying its actions, but the agency has now
rejected the explanation. The agency is collecting evidence
prior to issuing a new decision. Argentinean law permits a fine
to be levied of up to $5,000,000 plus 20% of profits realized
due to the alleged wrongful conduct. Counsel in the matter
advises that the size of the transactions alleged to have
violated the law will unlikely draw the maximum penalty.
Permax
Product Liability Cases:
Valvular Heart Disease. From time to time,
various plaintiffs have alleged that the use of Permax, a drug
for the treatment of Parkinsons disease marketed and sold
by Amarin Pharmaceuticals Inc., the shares of which were
purchased by us in February 2004, caused valvular heart disease.
We have also received from time to time and other claims
alleging that the use of Permax caused congestive heart failure
and other coronary-related damage, including a letter from an
attorney purporting to represent five persons with such claims,
but no litigation has yet been filed. All claims raised to date
related to valvular heart disease have been settled by us, for
amounts which, in the aggregate, do not represent a material
effect on us.
Compulsive Gambling. On July 18, 2005, we
were served a complaint in a case captioned Barbara E. Hermansen
and Robert B. Wilcox, Jr. v. Eli Lilly &
Company, Elan Corporation, plc, Amarin Corporation plc and
Valeant Pharmaceuticals International, Case No. 05 L 007276
in the Circuit Court of Cook County, Illinois, which case has
subsequently been removed to federal court. This case alleges
that the use of Permax caused the plaintiff to become a
compulsive gambler, and as a result, she has suffered
significant economic loss and severe emotional and mental
distress.
Eli Lilly, the former holder of the right granted by the FDA to
market and sell Permax in the United States, though such right
was licensed to Amarin, and the source of the manufactured
product, has also been named in the suits. Under an agreement
between us and Eli Lilly, Eli Lilly will bear a portion of the
liability, if any, and defense costs associated with these
claims. This case is in a preliminary stage and it is difficult
to assess whether we will have any liability and, if such
liability exists, what the extent of the liability would be.
Product liability insurance exists with respect to this claim.
There can be no assurance that the insurance will be sufficient
to cover this claim, and there can be no assurance that
defending against any future similar claims and any resulting
settlements or judgments will not, individually or in the
aggregate, have a material adverse affect on our consolidated
financial position, results of operation or liquidity.
Kali Litigation: In March 2004, Kali
Laboratories, Inc. submitted Abbreviated New Drug Application
(ANDA)
No. 76-843
with the FDA seeking approval for a generic version of
Diastat®
(a diazepam rectal gel). In July 2004, Xcel Pharmaceuticals,
Inc., which we acquired on March 1, 2005, filed a complaint
against Kali for patent infringement of U.S. Patent
No. 5,462,740 Civil Case
No. 04-3238
(JCL) pending in the United States District Court of New Jersey.
The complaint alleges that Kalis filing of ANDA
No. 76-843
is an act of infringement under 35 U.S.C. §271(e)(4)
of one or more claims of U.S. Patent No. 5,462,740.
Kali has filed an answer and counterclaims, denying all
allegations of the complaint and asserting affirmative defenses
and counterclaims for non-infringement, invalidity and
unenforceability under the doctrine of patent misuse due to
improper filing of the lawsuit. Xcel filed a reply to the
counterclaims, denying all allegations. In October 2005, Kali
filed an amended answer and counterclaims asserting affirmative
defenses and counterclaims for non-infringement, invalidity,
unenforceability due to inequitable conduct during prosecution
of the patent, and unenforceability under the
30
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
doctrine of patent misuse due to improper filing of the lawsuit.
In November 2005, we filed a reply to the amended counterclaims,
denying all allegations. We will vigorously defend ourselves
against Kalis allegations. Fact discovery has closed but
expert discovery is proceeding. The date for the pretrial
conference is June 12, 2006. No trial date has been set.
Xcel filed this suit within forty-five days of Kalis
Paragraph IV certification. As a result, The Drug Price
Competition and Patent Restoration Act of 1984 (the
Hatch-Waxman Act) provides an automatic stay on the
FDAs approval of Kalis ANDA for thirty months. If
Xcel prevails in the lawsuit, then Kalis ANDA cannot be
effective until after the expiration of U.S. Patent
No. 5,462,740 in 2013. If Kali prevails in the lawsuit at
the district court level, then the FDA may approve Kalis
ANDA at such time, even if prior to the expiration of the
thirty-month stay period.
Trademark litigation: Valent U.S.A.
Corporation and its wholly owned subsidiary Valent Biosciences
Corporation (together Valent Biosciences) have
expressed concerns regarding the possible confusion between
Valent Biosciences VALENT trademark registered in
connection with various chemical and agricultural products and
the companys VALEANT trademark. Valent Biosciences has
opposed the registration of the VALEANT trademark by us in
certain jurisdictions, including Argentina, Australia, Brazil,
Chile, Colombia, Czech Republic, European Union, France,
Germany, Indonesia, Israel, Japan, Malaysia, New Zealand,
Romania, Slovak Republic, Spain, Switzerland, Turkey, Taiwan,
Venezuela, the United Kingdom and the United States. Valent
Biosciences oppositions in Colombia, Czech Republic,
France, Romania, Spain and Turkey have been denied. Valent
Biosciences unsuccessfully appealed the French decision and has
appeals pending in Colombia, Romania, Spain and Turkey. While
some or all of Valent Biosciences oppositions in Chile and
Switzerland have been sustained, we have appealed those
decisions. We have also initiated actions to cancel trademark
registrations owned by Valent Biosciences in Germany,
Israel and South Korea and have opposed an application for the
Valent mark in Switzerland. We have responded or will respond to
the opposition proceedings that have been filed and discovery is
ongoing in the opposition proceeding in the United States.
Valent Biosciences has also filed for cancellation of the
VALEANT trademark in Austria. If the cancellation filing or any
of the opposition proceedings are successful, we would have no
trademark registration for the VALEANT mark in that particular
jurisdiction and, in addition, in those jurisdictions where
trademark rights accrue solely through the registration process,
may have no trademark rights in the VALEANT mark those
particular jurisdictions.
Breach of contract: On March 11, 2005,
Caleel + Hayden, LLC sued in the Superior Court of the State of
California for the County of Orange alleging that our
termination of their distribution agreement for Kinerase was a
breach of the contract and constituted fraud. Plaintiff is
seeking substantial damages, alleging, among other things, lost
profits. Trial is scheduled for June 6, 2006.
Other: We are a party to other pending
lawsuits and subject to a number of threatened lawsuits. While
the ultimate outcome of pending and threatened lawsuits or
pending violations cannot be predicted with certainty, and an
unfavorable outcome could have a negative impact on us, at this
time in the opinion of management, the ultimate resolution of
these matters will not have a material effect on our
consolidated financial position, results of operations or
liquidity.
We have four reportable pharmaceutical segments which are
comprised of our pharmaceutical operations in North America,
Latin America, Europe and Asia, Africa and Australia (AAA). In
addition, we have a research and development division. The
restructuring program will result in the elimination of our AAA
segment and combining the operations therein with those of other
segments. Future financial reports will reflect this
reorganization of responsibilities.
31
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
The following table sets forth the amounts of segment revenues
and operating income of the Company for the three months ended
March 31, 2006 and 2005 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
Revenues
|
|
|
|
|
|
|
|
|
Specialty pharmaceuticals
|
|
|
|
|
|
|
|
|
North America
|
|
$
|
75,856
|
|
|
$
|
48,922
|
|
Latin America
|
|
|
35,788
|
|
|
|
32,060
|
|
Europe
|
|
|
56,257
|
|
|
|
65,875
|
|
AAA
|
|
|
13,500
|
|
|
|
14,925
|
|
|
|
|
|
|
|
|
|
|
Total specialty pharmaceuticals
|
|
|
181,401
|
|
|
|
161,782
|
|
Ribavirin royalties
|
|
|
18,091
|
|
|
|
19,335
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
$
|
199,492
|
|
|
$
|
181,117
|
|
|
|
|
|
|
|
|
|
|
Operating Income
(Loss)
|
|
|
|
|
|
|
|
|
Specialty pharmaceuticals
|
|
|
|
|
|
|
|
|
North America
|
|
$
|
23,136
|
|
|
$
|
16,673
|
|
Latin America
|
|
|
8,684
|
|
|
|
9,818
|
|
Europe
|
|
|
4,550
|
|
|
|
11,734
|
|
AAA
|
|
|
154
|
|
|
|
790
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36,524
|
|
|
|
39,015
|
|
Corporate expenses(1)
|
|
|
(23,141
|
)
|
|
|
(14,699
|
)
|
|
|
|
|
|
|
|
|
|
Total specialty pharmaceuticals
|
|
|
13,383
|
|
|
|
24,316
|
|
Restructuring charges(2)
|
|
|
(26,466
|
)
|
|
|
(1,695
|
)
|
Gain on settlement of litigation
|
|
|
34,000
|
|
|
|
|
|
Research and development
|
|
|
(12,290
|
)
|
|
|
(9,336
|
)
|
Acquired IPR&D(2)
|
|
|
|
|
|
|
(126,399
|
)
|
|
|
|
|
|
|
|
|
|
Consolidated segment operating
income (loss)
|
|
|
8,627
|
|
|
|
(113,114
|
)
|
Interest income
|
|
|
2,657
|
|
|
|
3,015
|
|
Interest expense
|
|
|
(10,437
|
)
|
|
|
(9,681
|
)
|
Other, net
|
|
|
937
|
|
|
|
(1,791
|
)
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing
operations before provision for income taxes and minority
interest
|
|
$
|
1,784
|
|
|
$
|
(121,571
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
All stock based compensation expense has been considered a
corporate cost as management excludes this item in assessing the
financial performance of individual business segments and
considers it a function of valuation factors that pertain to
overall corporate stock performance. |
|
(2) |
|
Restructuring charges and IPR&D are not included in the
applicable segments as management excludes these items in
assessing the financial performance of these segments, primarily
due to their non-operational nature. |
32
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
The following table sets forth the total assets of the Company
by segment as of March 31, 2006 and December 31, 2005
(in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
|
|
|
(Restated)
|
|
|
North America
|
|
$
|
500,161
|
|
|
$
|
503,196
|
|
Latin America
|
|
|
134,882
|
|
|
|
131,070
|
|
Europe
|
|
|
379,841
|
|
|
|
373,974
|
|
AAA
|
|
|
60,403
|
|
|
|
62,886
|
|
Corporate
|
|
|
202,054
|
|
|
|
223,821
|
|
Research and development division
|
|
|
213,154
|
|
|
|
218,943
|
|
Discontinued operations
|
|
|
105
|
|
|
|
127
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,490,600
|
|
|
$
|
1,514,017
|
|
|
|
|
|
|
|
|
|
|
The following table sets forth the long-term assets of the
Company by segment as of March 31, 2006 and
December 31, 2005 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Long-Term Assets
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
|
|
|
(Restated)
|
|
|
North America
|
|
$
|
418,779
|
|
|
$
|
426,745
|
|
Latin America
|
|
|
38,970
|
|
|
|
39,287
|
|
Europe
|
|
|
130,274
|
|
|
|
129,952
|
|
AAA
|
|
|
21,072
|
|
|
|
21,762
|
|
Corporate
|
|
|
121,814
|
|
|
|
138,239
|
|
Research and development division
|
|
|
153,184
|
|
|
|
158,464
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
884,093
|
|
|
$
|
914,449
|
|
|
|
|
|
|
|
|
|
|
The following table summarizes the largest of our product lines
by therapeutic class based on sales for the three months ended
March 31, 2006 and 2005 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
%
|
|
|
|
March 31,
|
|
|
Increase/
|
|
|
|
2006
|
|
|
2005
|
|
|
(Decrease)
|
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
|
|
|
Dermatology
|
|
|
|
|
|
|
|
|
|
|
|
|
Efudix/Efudex®(T)
|
|
$
|
15,581
|
|
|
$
|
19,276
|
|
|
|
(19
|
)%
|
Kinerase®(T)
|
|
|
6,860
|
|
|
|
4,435
|
|
|
|
55
|
%
|
Oxsoralen-Ultra®(T)
|
|
|
3,508
|
|
|
|
2,968
|
|
|
|
18
|
%
|
Dermatixtm
|
|
|
1,834
|
|
|
|
1,896
|
|
|
|
(3
|
)%
|
Other Dermatology
|
|
|
8,569
|
|
|
|
8,133
|
|
|
|
5
|
%
|
Infectious
Disease
|
|
|
|
|
|
|
|
|
|
|
|
|
Infergen®(T)
|
|
|
13,705
|
|
|
|
|
|
|
|
|
|
Virazole®(T)
|
|
|
5,801
|
|
|
|
4,174
|
|
|
|
39
|
%
|
Other Infectious Disease
|
|
|
4,731
|
|
|
|
5,853
|
|
|
|
(19
|
)%
|
33
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
%
|
|
|
|
March 31,
|
|
|
Increase/
|
|
|
|
2006
|
|
|
2005
|
|
|
(Decrease)
|
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
|
|
|
Neurology
|
|
|
|
|
|
|
|
|
|
|
|
|
Diastat(T)
|
|
|
12,022
|
|
|
|
5,177
|
|
|
|
132
|
%
|
Mestinon®(T)
|
|
|
9,817
|
|
|
|
9,860
|
|
|
|
0
|
%
|
Cesamet
|
|
|
3,303
|
|
|
|
2,055
|
|
|
|
61
|
%
|
Migranal
|
|
|
3,115
|
|
|
|
774
|
|
|
|
302
|
%
|
Librax
|
|
|
2,919
|
|
|
|
4,080
|
|
|
|
(28
|
)%
|
Dalmane/Dalmadorm
|
|
|
2,466
|
|
|
|
2,642
|
|
|
|
(7
|
)%
|
Limbitrol
|
|
|
1,510
|
|
|
|
1,294
|
|
|
|
17
|
%
|
TASMAR®
|
|
|
1,185
|
|
|
|
939
|
|
|
|
26
|
%
|
Other Neurology
|
|
|
14,591
|
|
|
|
10,568
|
|
|
|
38
|
%
|
Other Therapeutic
Classes
|
|
|
|
|
|
|
|
|
|
|
|
|
Bedoyectatm(T)
|
|
|
10,580
|
|
|
|
9,244
|
|
|
|
14
|
%
|
Bisocard(T)
|
|
|
3,565
|
|
|
|
2,655
|
|
|
|
34
|
%
|
Solcoseryl(T)
|
|
|
3,377
|
|
|
|
4,194
|
|
|
|
(19
|
)%
|
Calcitonin
|
|
|
1,850
|
|
|
|
2,585
|
|
|
|
(28
|
)%
|
Nyal
|
|
|
1,754
|
|
|
|
2,474
|
|
|
|
(29
|
)%
|
Aclotin
|
|
|
1,372
|
|
|
|
1,520
|
|
|
|
(10
|
)%
|
Espaven
|
|
|
1,302
|
|
|
|
1,562
|
|
|
|
(17
|
)%
|
Other pharmaceutical products
|
|
|
46,084
|
|
|
|
53,424
|
|
|
|
(14
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total product sales
|
|
$
|
181,401
|
|
|
$
|
161,782
|
|
|
|
12
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total promoted product sales(a)
|
|
$
|
107,426
|
|
|
$
|
83,804
|
|
|
|
28
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total top 10 products based on
2006 sales
|
|
$
|
84,816
|
|
|
$
|
61,983
|
|
|
|
37
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
The products named above are all promoted products with
estimated annualized sales in excess of $5 million. |
|
(T) |
|
Represents ten products with the largest amount of sales in the
first quarter of 2006. |
During the three months ended March 31, 2006 two customers
in the United States accounted for more than 10% of consolidated
product sales. Sales to McKesson Corporation were $23,068,000
and sales to Cardinal Health were $18,112,000 in the three month
period ended March 31, 2006. In prior years no single
customer accounted for more than 10% of product sales in any
period.
|
|
12.
|
Subsequent
events relating to the restatement
|
The restatement of our financial statements caused us to delay
the filing of our quarterly report on
Form 10-Q
for the quarter ended September 30, 2006. On
December 12, 2006, we received a notice of default from The
Bank of New York, as trustee for the holders of our
3% Convertible Notes due 2010, asserting that a default
occurred under our indenture dated as of November 19, 2003,
governing the 3.0% Convertible Notes and our
4.0% Convertible Notes due 2013. The notice of default
asserts that a default occurred under the indenture when we
failed to timely file our quarterly report on
Form 10-Q
for the quarter ended September 30, 2006. The filing of our
quarterly report on
Form 10-Q
for the quarter ended September 30, 2006, within sixty days
of the notice of default, has cured the asserted default under
the indenture.
34
VALEANT
PHARMACEUTICALS INTERNATIONAL
NOTES TO
CONSOLIDATED CONDENSED FINANCIAL
STATEMENTS (Continued)
The following legal proceedings relating to the stock option
review discussed in the Explanatory Note at the beginning of
this amended quarterly report on
Form 10-Q/A
and Note 2 to the consolidated financial statements set
forth herein were initiated after March 31, 2005:
In July 2006, we were contacted by the Securities and Exchange
Commission, or SEC, with respect to an informal inquiry
regarding events and circumstances surrounding trading in the
companys commons stock and the public release of data from
its first pivotal Phase 3 trial for
Viramidine®
(taribavirin). In addition, the SEC also requested data
regarding the companys stock option grants since
January 1, 2000 and information about the companys
pursuit in the Delaware Chancery Court of the return of bonuses
paid to Milan Panic, the companys former chairman and
chief executive officer, and others, in connection with the
Ribapharm initial public offering.
In September 2006, our board of directors appointed a Special
Committee consisting solely of independent directors to conduct
a comprehensive review relating to our stock option grants and
stock option practices. The Special Committee, with the
assistance of outside legal counsel, reviewed the stock option
grants to our officers, directors and employees from 1982 to
July 2006 under our various stock option plans in effect during
this period. Our finance department has also reviewed the stock
option grants and stock option practices from November 1994 to
the present.
Derivative Actions: We are a nominal defendant
in two shareholder derivative lawsuits pending in state court in
Orange County, California, styled (i) Michael
Pronko v. Timothy C. Tyson et al., and
(ii) Kenneth Lawson v. Timothy C. Tyson et al.
These lawsuits, which were filed on October 27, 2006 and
November 16, 2006 respectively, purport to assert
derivative claims on our behalf against certain of our current
and/or
former officers and directors. The lawsuits assert claims for
breach of fiduciary duties, abuse of control, gross
mismanagement, waste of corporate assets, unjust enrichment, and
violations of the California Corporations Code related to the
purported backdating of employee stock options. The plaintiffs
seek, among other things, damages, an accounting, the rescission
of stock options, and a constructive trust over amounts acquired
by the defendants who have exercised Valeant stock options. The
defendants have not yet responded to the complaints. We expect
the actions to be consolidated before a single judge after which
the plaintiffs will file a single consolidated complaint. We
will evaluate the consolidated complaint and respond accordingly.
35
|
|
Item 2.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
We are amending our quarterly report on
Form 10-Q
for the quarter ended March 31, 2006 to restate our
condensed consolidated financial statements for the three month
periods ended March 31, 2006 and 2005 and the related
disclosures. On January 22, 2007 we filed an amended Annual
Report of
Form 10-K
for the year ended December 31, 2005.
In July 2006, we were contacted by the Securities and Exchange
Commission, or SEC, with respect to an informal inquiry
regarding events and circumstances surrounding trading in our
common stock and the public release of data from our first
pivotal Phase 3 trial for
Viramidine®
(taribavirin). In addition, on August 22, 2006, the SEC
requested data regarding our stock option grants and exercises
since January 1, 2000. The SEC has also requested
information about our pursuit in the Delaware Chancery Court of
the return of certain bonuses paid to Milan Panic, the former
chairman and chief executive officer, and others, in connection
with the Ribapharm initial public offering. We commenced an
internal review by our finance department of stock option grants
from 1982 to July 2006. In September 2006, our board of
directors appointed a special committee of the board composed
solely of independent directors (the Special
Committee) to conduct a review of our historic stock
option practices and related accounting. The Special Committee,
with the assistance of outside legal counsel, undertook a
comprehensive review of the stock option grants to our officers,
directors and employees from 1982 to July 2006 under our various
stock option plans in effect during this period. The Special
Committee has concluded its investigation and has reported its
findings to our board of directors.
On October 20, 2006, our board of directors concluded that
certain of our consolidated financial statements should be
restated to record the additional non-cash stock-based
compensation expense items and certain other items that had been
incorrectly accounted for under accounting principles generally
accepted in the United States, or GAAP.
Continuing the work done in September, the Special Committee
analyzed in detail stock option grants awarded between November
1994 and July 2006 and analyzed supporting documentation for
awards granted between 1982 and 1994. For the period between
November 1994 and July 2006, the Special Committees
analysis included an extensive review of paper and electronic
documents supporting or related to our stock option grants, the
accounting for those grants, compensation-related financial and
securities disclosures and
e-mail
communications as well as interviews with numerous current and
former employees and current and former members of our board of
directors. While the Special Committee concluded that there were
some errors as late as January 2006, the majority of errors in
accounting for options pertain to those options granted prior to
the change in our board of directors and management in mid-2002
(the Change in Control). None of the errors
occurring in periods after the Change in Control related to
options granted to the chief executive officer, chief financial
officer or members of our board of directors.
The Special Committee made a determination, based on the
available evidence, of measurement dates for each affected
grant. If the grants were approved at a meeting of the
compensation committee of the board of directors and there was
no actual evidence of a change in the approved list of
individual awards, the measurement date selected was the date of
the compensation committee meeting. If there was actual evidence
of a change in the list of individual awards and evidence of
when the list became final, the measurement date selected was
the date when the list became final. If there was actual
evidence of a change in the list but evidence of when the list
became final was not definitive, the measurement date was
reconstructed using the best available evidence to ensure that
an adequate amount of compensation expense was recorded in the
restatement
In total we recorded $31,049,000 of additional pre-tax,
non-cash, stock-based compensation expense in the restatement to
correct errors for awards granted from 1982 to date. Of this,
$28,651,000 related to awards granted prior to the Change in
Control and $2,398,000 to awards granted after the Change in
Control. None of these changes affected our previously reported
revenues, cash, or cash equivalents. As explained below,
however, we also reported corrections for certain other items
which impact our reported revenues and cash flow presentations.
36
Options
Granted Prior to the Change in Control
The Special Committee found that the recorded grant dates for
the majority of stock options awarded prior to the Change in
Control differed from the actual grant dates for those
transactions. In connection with that finding, the Special
Committee concluded that, with respect to many broad-based
grants of stock options prior to the Change in Control, prior
management used a methodology of selecting a recorded grant date
based on the lowest closing price during some time period (e.g.,
quarter, ten trading days) preceding the actual grant date.
While the Special Committee did not reach a conclusion as to how
prior management selected other recorded grant dates for
broad-based or individual grants that did not use the lowest
closing price methodology, there is some evidence that dates
were selected based on the occurrence of an event or when the
former chief executive officer, Milan Panic, agreed in principle
to the grant. While these and similar practices resulted in the
grant of
in-the-money
options, and the Special Committee identified evidence that two
pre-Change in Control directors may have been aware of these
backdating practices, it does not appear that prior management
pre-Change in Control attempted to conceal that the stock option
grants were discounted using the backdating methodology.
Between November 1994 and the June 2002 Change in Control, eight
broad-based grants were made. All of the 908 individual awards
of options to purchase 6.9 million shares comprising those
grants had recorded grant dates that differed from the actual
grant dates for those transactions and each resulted in
additional compensation charges that are reflected in our
restated financial statements. Of those eight broad-based
grants, six appear to have been annual grants that used the
lowest closing price methodology and two appear to have been
event-related (in those instances, there are lower prices
between the recorded grant date and actual grant date). These
eight broad-based option grants accounted for $11,488,000 of the
$31,049,000 in pre-tax compensation charges.
During this period, options to directors to purchase a total of
334,000 shares were also found to have recorded grant dates
earlier than the dates when the board of directors acted to
approve the grants. The grants were dated in accordance with the
1994 Stock Option Plan which provided expressly that the grants
were to be dated as of November 11, 1994. The board of
directors, however, did not approve that stock option plan until
January 1995. Accordingly, we are taking additional non-cash
compensation charges equal to the difference between the closing
stock price on the date of approval and November 11, 1994.
These option grants to directors accounted for $148,000 of the
$31,049,000 in pre-tax compensation charges.
Also during this period, there were 114 other individual grants
of options to purchase a total of 2.0 million shares with
stipulated grant dates earlier than the dates the compensation
committee acted to approve these awards. The Special Committee
could not determine whether the date of those grants were based
on an event or when the former chief executive officer, Milan
Panic, agreed in principle to the award. These individual option
grants accounted for $4,538,000 of the $31,049,000 in additional
compensation charges.
The restatement also includes a pre-tax charge of $997,000
related to a stock option grant to a former chief financial
officer, who left in 2002. This grant of options to purchase
100,000 shares was granted to him with a recorded grant
date a few days before he joined us in May 1998. The Special
Committee concluded that this award of options was effectively
amended in December 1998 to lower its exercise price. There is
evidence which suggests that certain members of former
management knew or should have known that this transaction and
one other transaction (resulting in a pre-tax charge of
$450,000) had accounting, tax, and disclosure consequences and
that they failed to take appropriate action. These options have
been accounted for as variable awards in accordance with FASB
Interpretation No. 44, Accounting for Certain
Transactions involving Stock Compensation
(FIN 44) in the restated financial
statements. Variable accounting ceased in 2002 when these
options were surrendered.
We also recorded $1,375,000 of additional pre-tax, non-cash,
stock-based compensation expense in the restatement for awards
granted between 1982 and 1994.
In total 1,038 individual awards of options to purchase a total
of 9.2 million shares granted before the Change in Control
were found to have been granted
in-the-money,
representing 71% of total awards granted in the period November
1994 through June 11, 2002. This included 87 awards of
options to purchase 4.5 million shares awarded to ten
executive officers, including the former chief executive
officer, Milan Panic. These
in-the-money
awards to executive officers accounted for $10,507,000, 34% of
the total pre-tax accounting charge of additional stock-based
compensation expense in the restatement.
37
Cash
Surrender of Options at Change in Control in 2002
The election of certain persons as directors at the annual
meeting of our stockholders on May 29, 2002 caused a Change
in Control under our stock option plans. Our 1998 Stock Option
Plan (the 1998 Plan) provided that all outstanding
options vested immediately upon the Change in Control and that
an option holder had 60 days following the Change in
Control to surrender his or her non-incentive stock options for
a cash payment equal to the excess of the highest closing price
of the stock during the 90 days preceding the Change in
Control, which was $32.50 per share, or the closing price
on the day preceding the date of surrender, whichever was
higher, over the exercise price for the surrendered options.
During the year ended December 31, 2002, we recorded a
pre-tax charge of $61,400,000 related to our cash payment
obligation under the 1998 Plan. The findings of the Special
Committee relating to
in-the-money
options that were affected by the Change in Control require that
we recognize the remaining grant date intrinsic value resulting
from the acceleration of vesting for a number of these options
and the value that certain other options could have been
surrendered for cash under APB 25 and FIN 44. As a
result, an additional compensation charge of $10,105,000 has
been recorded in fiscal year 2002.
Options
Granted After the Change in Control
The Special Committee also found that, due to flaws in the
processes relied on to make our annual broad-based grants after
the Change in Control, we did not correctly apply the
requirements of APB 25 through December 2005. These option
accounting errors, however, differ significantly from those made
prior to the Change in Control. Unlike the broad-based grants
made prior to the Change in Control, for which the recorded
grant dates were selected from a period prior to the approval
dates, the broad-based grants after the Change in Control were
approved at either regularly scheduled meetings of the
compensation committee or at meetings of the board of directors,
and the exercise price for each of these grants was the closing
price on the date of such meetings.
The stock option accounting errors after the Change in Control
resulted from allocation adjustments to the list of grants to
individual non-executives after the compensation committee or
the board of directors had approved the allocation of an
aggregate number of shares to be available to non-executive
employees. In no event did the adjustments result in shares
being granted in excess of the aggregate number of shares
approved by the compensation committee or the board of
directors. Further, none of those adjustments related to the
chief executive officer, chief financial officer, or any member
of the board of directors. The Special Committee concluded that
there was no evidence that management operating since the Change
in Control were aware that the processes used to grant and
account for broad-based grants were flawed or that the process
employed was for the purpose of granting
in-the-money
stock options. In reaching this conclusion, the Special
Committee took note that that process had been consistently
employed even for the November 2005 grants in which the process
resulted in stock option grants at higher exercise prices than
the closing price of our common stock on the date of
finalization of the allocation list for non-executives. The
Special Committee also concluded that there was no evidence that
current management was aware of any financial statement impact,
tax consequences or disclosure implications of its flawed
processes.
Between May 2003 and November 2005, we made four broad-based
grants (May 2003, November 2003, November 2004 and November
2005). The May 2003 grants were made to non-executive employees.
The November 2003, 2004 and 2005 grants were made to a broad
base of employees, including senior executives (the
November Grants). With respect to each of the
November Grants, the granting authority (either the compensation
committee or the board of directors) made specific grants to
specific members of executive management, including, among
others, the chief executive officer, the chief operating
officer, and the chief financial officer. Additionally, the
broad-based grants made after the Change in Control were
approved either at regularly scheduled meetings of the
Compensation Committee or at meetings of the board of directors.
The stock option accounting errors that affected 164 individual
grants of options to purchase 1.5 million shares resulted
from slight adjustments to the non-executive grant lists after
the relevant compensation committee or board meetings. In no
event did the adjustments result in shares being granted in
excess of the number of options approved by the compensation
committee or the board of directors. As a result of its work,
the Special Committee made a determination of new measurement
dates for each affected grant. With respect to three of the four
broad-based grants (May 2003, November 2003 and November 2005),
the measurement date selected was the date on which the
38
rank and file list became final. With respect to the remaining
broad-based grant (November 2004), there was actual evidence of
a change in the rank and file list but inconclusive evidence
when the list became final. The measurement date for that grant
was reconstructed using the best available evidence to ensure
that an adequate amount of compensation expense was recorded in
the restatement. A total of 14 other individual awards
(0.1 million shares) made to
rank-and-file
employees since the change of control were also found to contain
administrative stock option accounting errors.
To correct these errors, we recorded $2,398,000 of additional
pre-tax, non-cash, stock-based compensation expense in the
restatement for the period July 1, 2002 through
March 31, 2006. These non-cash charges have no impact on
previously reported revenues, cash or cash equivalents. As
explained below, however, we also reported corrections for
certain other items which do have an impact on reported revenues
and cash flow presentations.
New
Hire Grant Practices
The Special Committee investigated our new hire stock option
grant practices and concluded that the new hire grants were
appropriately accounted for under the applicable accounting
principles. Until January 2004, our practice was to set forth,
in a prospective employees offer letter a specific number
of options, specifying that the strike price would be equal to
the closing price on the new employees first date of
employment pending approval of the compensation committee.
Beginning in January 2004, the offer letters set the strike
price equal to the closing price of our stock on the later of
compensation committee approval or the employees start
date.
With respect to our new hire grant practices prior to January
2004, the Special Committee reviewed each offer letter and
related grant during the period June 2002 to January 2004 and a
sample of offer letters and related grants prior to June 2002.
The Special Committee also questioned relevant individuals about
the option-related new hire practices and procedures. This
intensive review confirmed that in each instance reviewed, the
number of options approved was equal to the number of options
set forth in the applicable offer letter, and that no material
terms of the options were changed by the compensation committee
in its approval process. Accordingly, the Special Committee
concluded that, with respect to new hire grants prior to January
2004, compensation committee approval was a mere formality and
that there had been finality with respect to the new hire grants
upon the first day of employment, which had been used as the
measurement date. Based upon the investigation, the Special
Committee concluded that new hire grants were accounted for
appropriately.
Income
Tax Effects
Incremental, stock-based, pre-tax compensation charges resulted
in tax benefits of $7,920,000. These tax benefits through 2000
were $1,940,000, recorded as an increase in the deferred tax
assets with a corresponding increase in retained earnings. For
2001 through 2003, deferred tax assets increased by $5,980,000
and income tax expense decreased by the same amount. In 2004,
the deferred tax asset was fully reserved with a valuation
allowance.
As a result of the review of our stock option granting
practices, management determined that the limitation of tax
benefits for executive compensation imposed by
Section 162(m) of the Internal Revenue Code (the
IRC) was not considered in the income tax returns or
financial statements prior to the Change in Control. The amount
of this limitation has been impacted by the determination that
many of the stock options were granted at prices below fair
market value on the date of grant. As a result of correctly
applying the Section 162(m) limitations, retained earnings
have been decreased by $1,896,000 as of December 31, 2000
and income tax expense has been increased by $702,000, $518,000
and $748,000 in 2001, 2002 and 2003, respectively. Adjustments
of ($205,000) and $122,000 for 2004 and 2005 respectively, did
not affect tax expense due to the valuation allowance. Also, the
cumulative impact on income tax of $3,864,000 was reversed in
2004. This occurred because the valuation allowance for the
deferred tax assets decreased with the Section 162(m)
reductions to the net operating loss.
As a result of our determination that the exercise prices of
certain option grants were below the closing price of our common
stock on the actual grant date, we evaluated whether the
affected employees would have any adverse tax consequences under
Section 409A of the IRC. It was determined that certain of
these options were unvested as of December 31, 2004, and
may be subject to Section 409A unless further action is
taken. None of these options belong to persons who, as of the
date of grant, were subject to the disclosure requirements of
Section 16(a) of the Securities
39
Exchange Act of 1934. Therefore, transition relief is available
with respect to these options through December 31, 2007.
Additional guidance may be available before that time that will
allow us to determine whether Section 409A will apply to
the circumstances under which these options were granted.
Depending upon the determination about the correct treatment of
these options for Section 409A purposes, the recipients of
these options may make an election to exercise the options in a
way that excludes them from Section 409A treatment. This
election is available through December 31, 2007.
Summary
and Other Items
In addition, we have restated the aforementioned financial
statements to correct certain accounting errors which were
previously identified but not considered to be material through
December 31, 2005. These corrections related to accounting
for employee tax withholding on certain compensation
transactions, elimination of an intercompany difference,
accounting for product exchanges (resulting in a revenue
adjustment), and certain income tax adjustments. The income tax
adjustments include reducing the charge taken to increase the
valuation allowance in 2004 by $11,566,000 as a result of
recording less U.S. deferred tax assets in prior periods,
which had originated from administrative errors in the
preparation of tax returns in earlier periods and were
immaterial to each of those prior periods. The cumulative effect
of these errors on retained earnings as of December 31,
2005 was $4,714,000. The restatement impact through
March 31, 2006 of these other corrections and of the
non-cash charges for stock-based compensation that have resulted
from the review of the Special Committee are summarized in the
table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
Three Months
|
|
|
|
|
|
|
|
|
|
|
|
Cumulative
|
|
|
Additional
|
|
|
|
Ended March 31,
|
|
|
Year Ended December 31,
|
|
|
Effect
|
|
|
Expense
|
|
|
|
2006
|
|
|
2005
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
1982 -2002
|
|
|
(Income)
|
|
|
|
(In thousands)
|
|
|
Stock option grants prior to 2002
Change in Control:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Broad-based option grants with
improper measurement dates
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
11,488
|
|
|
$
|
11,488
|
|
Option grants to directors with
improper measurement dates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
148
|
|
|
|
148
|
|
Other option grants with improper
measurement dates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,538
|
|
|
|
4,538
|
|
Re-priced option grant
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
997
|
|
|
|
997
|
|
Improper measurement dates for
option grants
1982-1994
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,375
|
|
|
|
1,375
|
|
Incremental charge in connection
with Change in Control
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,105
|
|
|
|
10,105
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sub total pre Change in Control
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28,651
|
|
|
|
28,651
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock option grants after 2002
Change in Control:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company-wide option grants with
improper measurement dates
|
|
|
(64
|
)
|
|
|
312
|
|
|
|
1,171
|
|
|
|
1,085
|
|
|
|
172
|
|
|
|
|
|
|
|
2,364
|
|
Other stock option matters after
June 2002
|
|
|
|
|
|
|
6
|
|
|
|
21
|
|
|
|
(7
|
)
|
|
|
20
|
|
|
|
|
|
|
|
34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sub total post Change in Control
|
|
|
(64
|
)
|
|
|
318
|
|
|
|
1,192
|
|
|
|
1,078
|
|
|
|
192
|
|
|
|
|
|
|
|
2,398
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total impact of additional stock
compensation on operating income
|
|
|
(64
|
)
|
|
|
318
|
|
|
|
1,192
|
|
|
|
1,078
|
|
|
|
192
|
|
|
|
28,651
|
|
|
|
31,049
|
|
Other items corrected in
connection with restatement
|
|
|
(629
|
)
|
|
|
35
|
|
|
|
(2,273
|
)
|
|
|
(1,265
|
)
|
|
|
(90
|
)
|
|
|
7,766
|
|
|
|
3,509
|
|
Tax effects of above and other tax
items
|
|
|
300
|
|
|
|
147
|
|
|
|
964
|
|
|
|
(14,957
|
)
|
|
|
1,785
|
|
|
|
3,357
|
|
|
|
(8,551
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income decrease (increase)
resulting from all restatement items
|
|
$
|
(393
|
)
|
|
$
|
500
|
|
|
$
|
(117
|
)
|
|
$
|
(15,144
|
)
|
|
$
|
1,887
|
|
|
$
|
39,774
|
|
|
$
|
26,007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The cumulative effect of the errors in 2002 and prior years of
$39,774,000 was recorded as a reduction of retained earnings at
December 31, 2002.
The pre-tax effect of the correction for stock-based
compensation was $157,000, $206,000, $792,000, $2,503,000,
$2,690,000, $3,491,000, $4,492,000 and $12,945,000 for 1995,
1996, 1997, 1998, 1999, 2000,
40
2001 and 2002, respectively. The cumulative pre-tax effect of
the correction for stock-based compensation between 1982 and
1994 was $1,375,000.
The following table summarized the effect of the restatement on
our consolidated statements of operations for the three months
ended March 31, 2006 and 2005 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
|
March 31, 2006
|
|
|
March 31, 2005
|
|
|
|
As Previously
|
|
|
|
|
|
|
|
|
As Previously
|
|
|
|
|
|
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
As Restated
|
|
|
Reported
|
|
|
Adjustments
|
|
|
As Restated
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product sales
|
|
$
|
180,757
|
|
|
$
|
644
|
|
|
$
|
181,401
|
|
|
$
|
161,803
|
|
|
$
|
(21
|
)
|
|
$
|
161,782
|
|
Ribavirin royalties
|
|
|
18,091
|
|
|
|
|
|
|
|
18,091
|
|
|
|
19,335
|
|
|
|
|
|
|
|
19,335
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
198,848
|
|
|
|
644
|
|
|
|
199,492
|
|
|
|
181,138
|
|
|
|
(21
|
)
|
|
|
181,117
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold (excluding
amortization)
|
|
|
58,580
|
|
|
|
21
|
|
|
|
58,601
|
|
|
|
48,721
|
|
|
|
62
|
|
|
|
48,783
|
|
Selling expenses
|
|
|
64,270
|
|
|
|
6
|
|
|
|
64,276
|
|
|
|
52,815
|
|
|
|
35
|
|
|
|
52,850
|
|
General and administrative expenses
|
|
|
28,540
|
|
|
|
(94
|
)
|
|
|
28,446
|
|
|
|
24,577
|
|
|
|
128
|
|
|
|
24,705
|
|
Research and development costs
|
|
|
29,535
|
|
|
|
18
|
|
|
|
29,553
|
|
|
|
25,724
|
|
|
|
107
|
|
|
|
25,831
|
|
Acquired in -process research and
development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
126,399
|
|
|
|
|
|
|
|
126,399
|
|
Gain on settlement of litigation
|
|
|
(34,000
|
)
|
|
|
|
|
|
|
(34,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring charges
|
|
|
26,466
|
|
|
|
|
|
|
|
26,466
|
|
|
|
1,695
|
|
|
|
|
|
|
|
1,695
|
|
Amortization expense
|
|
|
17,523
|
|
|
|
|
|
|
|
17,523
|
|
|
|
13,968
|
|
|
|
|
|
|
|
13,968
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
190,914
|
|
|
|
(49
|
)
|
|
|
190,865
|
|
|
|
293,899
|
|
|
|
332
|
|
|
|
294,231
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss ) from operations
|
|
|
7,934
|
|
|
|
693
|
|
|
|
8,627
|
|
|
|
(112,761
|
)
|
|
|
(353
|
)
|
|
|
(113,114
|
)
|
Other income (loss), net,
including translation and exchange
|
|
|
937
|
|
|
|
|
|
|
|
937
|
|
|
|
(1,791
|
)
|
|
|
|
|
|
|
(1,791
|
)
|
Interest income
|
|
|
2,657
|
|
|
|
|
|
|
|
2,657
|
|
|
|
3,015
|
|
|
|
|
|
|
|
3,015
|
|
Interest expense
|
|
|
(10,437
|
)
|
|
|
|
|
|
|
(10,437
|
)
|
|
|
(9,681
|
)
|
|
|
|
|
|
|
(9,681
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing
operations before income taxes and minority interest
|
|
|
1,091
|
|
|
|
693
|
|
|
|
1,784
|
|
|
|
(121,218
|
)
|
|
|
(353
|
)
|
|
|
(121,571
|
)
|
Provision for income taxes
|
|
|
7,242
|
|
|
|
300
|
|
|
|
7,542
|
|
|
|
16,367
|
|
|
|
147
|
|
|
|
16,514
|
|
Minority interest, net
|
|
|
1
|
|
|
|
|
|
|
|
1
|
|
|
|
171
|
|
|
|
|
|
|
|
171
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(6,152
|
)
|
|
|
393
|
|
|
|
(5,759
|
)
|
|
|
(137,756
|
)
|
|
|
(500
|
)
|
|
|
(138,256
|
)
|
Loss from discontinued operations
|
|
|
(212
|
)
|
|
|
|
|
|
|
(212
|
)
|
|
|
(1,503
|
)
|
|
|
|
|
|
|
(1,503
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(6,364
|
)
|
|
$
|
393
|
|
|
$
|
(5,971
|
)
|
|
$
|
(139,259
|
)
|
|
$
|
(500
|
)
|
|
$
|
(139,759
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(0.07
|
)
|
|
$
|
0.01
|
|
|
$
|
(0.06
|
)
|
|
$
|
(1.55
|
)
|
|
$
|
|
|
|
$
|
(1.55
|
)
|
Loss from discontinued operations
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(0.02
|
)
|
|
|
|
|
|
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per
share
|
|
$
|
(0.07
|
)
|
|
$
|
|
|
|
$
|
(0.06
|
)
|
|
$
|
(1.57
|
)
|
|
$
|
|
|
|
$
|
(1.57
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted shares used in
per share computation
|
|
|
92,770
|
|
|
|
|
|
|
|
92,770
|
|
|
|
88,836
|
|
|
|
|
|
|
|
88,836
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41
The following table sets forth the impact of the restatement on
our consolidated statements of cash flows from operating
activities three months ended March 31, 2006 and 2005 (in
thousands).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
|
March 31, 2006
|
|
|
March 31, 2005
|
|
|
|
As Previously
|
|
|
|
|
|
|
|
|
As Previously
|
|
|
|
|
|
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
As Restated
|
|
|
Reported
|
|
|
Adjustments
|
|
|
As Restated
|
|
|
Cash flows from operating
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$
|
(6,364
|
)
|
|
$
|
393
|
|
|
$
|
(5,971
|
)
|
|
$
|
(139,259
|
)
|
|
$
|
(500
|
)
|
|
$
|
(139,759
|
)
|
Loss from discontinued operations
|
|
|
(212
|
)
|
|
|
|
|
|
|
(212
|
)
|
|
|
(1,503
|
)
|
|
|
|
|
|
|
(1,503
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(6,152
|
)
|
|
|
393
|
|
|
|
(5,759
|
)
|
|
|
(137,756
|
)
|
|
|
(500
|
)
|
|
|
(138,256
|
)
|
Adjustments to reconcile net loss
to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
23,482
|
|
|
|
|
|
|
|
23,482
|
|
|
|
21,038
|
|
|
|
|
|
|
|
21,038
|
|
Provision for losses on accounts
receivable and inventory
|
|
|
3,597
|
|
|
|
|
|
|
|
3,597
|
|
|
|
1,594
|
|
|
|
|
|
|
|
1,594
|
|
Stock compensation expense
|
|
|
5,682
|
|
|
|
(64
|
)
|
|
|
5,618
|
|
|
|
544
|
|
|
|
319
|
|
|
|
863
|
|
Translation and exchange (gains)
losses, net
|
|
|
(937
|
)
|
|
|
|
|
|
|
(937
|
)
|
|
|
1,791
|
|
|
|
|
|
|
|
1,791
|
|
Impairment charges and other
non-cash items
|
|
|
20,426
|
|
|
|
|
|
|
|
20,426
|
|
|
|
1,461
|
|
|
|
|
|
|
|
1,461
|
|
Acquired in-process research and
development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
126,399
|
|
|
|
|
|
|
|
126,399
|
|
Deferred income taxes
|
|
|
1,910
|
|
|
|
|
|
|
|
1,910
|
|
|
|
(14,026
|
)
|
|
|
147
|
|
|
|
(13,879
|
)
|
Change in assets and liabilities,
net of effects of acquisitions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts Receivable
|
|
|
13,779
|
|
|
|
|
|
|
|
13,779
|
|
|
|
6,482
|
|
|
|
|
|
|
|
6,482
|
|
Inventories
|
|
|
(3,736
|
)
|
|
|
|
|
|
|
(3,736
|
)
|
|
|
(10,951
|
)
|
|
|
|
|
|
|
(10,951
|
)
|
Prepaid expenses and other assets
|
|
|
1,216
|
|
|
|
3,702
|
|
|
|
4,918
|
|
|
|
(129
|
)
|
|
|
|
|
|
|
(129
|
)
|
Trade payables and accrued
liabilities
|
|
|
(9,886
|
)
|
|
|
|
|
|
|
(9,886
|
)
|
|
|
(7,740
|
)
|
|
|
34
|
|
|
|
(7,706
|
)
|
Income taxes
|
|
|
(9,085
|
)
|
|
|
(4,031
|
)
|
|
|
(13,116
|
)
|
|
|
15,960
|
|
|
|
|
|
|
|
15,960
|
|
Other liabilities
|
|
|
842
|
|
|
|
|
|
|
|
842
|
|
|
|
3,995
|
|
|
|
|
|
|
|
3,995
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow from operating
activities in continuing operations
|
|
|
41,138
|
|
|
|
|
|
|
|
41,138
|
|
|
|
8,662
|
|
|
|
|
|
|
|
8,662
|
|
Cash flow from operating
activities in discontinued operations
|
|
|
(281
|
)
|
|
|
|
|
|
|
(281
|
)
|
|
|
(471
|
)
|
|
|
|
|
|
|
(471
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating
activities
|
|
$
|
40,857
|
|
|
$
|
|
|
|
$
|
40,857
|
|
|
$
|
8,191
|
|
|
$
|
|
|
|
$
|
8,191
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42
The following table sets for the impact of the restatement on
our consolidated balance sheet as of March 31, 2006 and
December 31, 2005 (in thousands).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2006
|
|
|
December 31, 2005
|
|
|
|
As Previously
|
|
|
|
|
|
|
|
|
As Previously
|
|
|
|
|
|
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
As Restated
|
|
|
reported
|
|
|
Adjustments
|
|
|
As Restated
|
|
|
ASSETS
|
Current Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
244,362
|
|
|
$
|
|
|
|
$
|
244,362
|
|
|
$
|
224,856
|
|
|
$
|
|
|
|
$
|
224,856
|
|
Marketable securities
|
|
|
11,121
|
|
|
|
|
|
|
|
11,121
|
|
|
|
10,210
|
|
|
|
|
|
|
|
10,210
|
|
Accounts receivable, net
|
|
|
174,433
|
|
|
|
|
|
|
|
174,433
|
|
|
|
187,987
|
|
|
|
|
|
|
|
187,987
|
|
Inventories, net
|
|
|
137,729
|
|
|
|
|
|
|
|
137,729
|
|
|
|
136,034
|
|
|
|
|
|
|
|
136,034
|
|
Prepaid expenses and other current
assets
|
|
|
38,862
|
|
|
|
|
|
|
|
38,862
|
|
|
|
36,652
|
|
|
|
3,702
|
|
|
|
40,354
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
606,507
|
|
|
|
|
|
|
|
606,507
|
|
|
|
595,739
|
|
|
|
3,702
|
|
|
|
599,441
|
|
Property, plant and equipment, net
|
|
|
217,813
|
|
|
|
|
|
|
|
217,813
|
|
|
|
230,126
|
|
|
|
|
|
|
|
230,126
|
|
Deferred tax assets, net
|
|
|
21,510
|
|
|
|
|
|
|
|
21,510
|
|
|
|
45,904
|
|
|
|
(20,562
|
)
|
|
|
25,342
|
|
Goodwill
|
|
|
79,767
|
|
|
|
|
|
|
|
79,767
|
|
|
|
79,486
|
|
|
|
|
|
|
|
79,486
|
|
Intangible assets, net
|
|
|
519,614
|
|
|
|
|
|
|
|
519,614
|
|
|
|
536,319
|
|
|
|
|
|
|
|
536,319
|
|
Other assets
|
|
|
45,284
|
|
|
|
|
|
|
|
45,284
|
|
|
|
43,176
|
|
|
|
|
|
|
|
43,176
|
|
Assets of discontinued operations
|
|
|
105
|
|
|
|
|
|
|
|
105
|
|
|
|
127
|
|
|
|
|
|
|
|
127
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total non-current assets
|
|
|
884,093
|
|
|
|
|
|
|
|
884,093
|
|
|
|
935,138
|
|
|
|
(20,562
|
)
|
|
|
914,576
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,490,600
|
|
|
$
|
|
|
|
$
|
1,490,600
|
|
|
$
|
1,530,877
|
|
|
$
|
(16,860
|
)
|
|
$
|
1,514,017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS EQUITY
|
Current Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade payables
|
|
$
|
48,708
|
|
|
$
|
|
|
|
$
|
48,708
|
|
|
$
|
55,279
|
|
|
$
|
|
|
|
$
|
55,279
|
|
Accrued liabilities
|
|
|
135,043
|
|
|
|
3,508
|
|
|
|
138,551
|
|
|
|
136,701
|
|
|
|
4,137
|
|
|
|
140,838
|
|
Notes payable and current portion
of long-term
|
|
|
346
|
|
|
|
|
|
|
|
346
|
|
|
|
495
|
|
|
|
|
|
|
|
495
|
|
Income taxes
|
|
|
37,995
|
|
|
|
1,470
|
|
|
|
39,465
|
|
|
|
42,452
|
|
|
|
4,872
|
|
|
|
47,324
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
222,092
|
|
|
|
4,978
|
|
|
|
227,069
|
|
|
|
234,927
|
|
|
|
9,009
|
|
|
|
243,936
|
|
Long-term debt, less current
portion
|
|
|
785,850
|
|
|
|
|
|
|
|
785,850
|
|
|
|
788,439
|
|
|
|
|
|
|
|
788,439
|
|
Deferred tax liabilities, net
|
|
|
5,126
|
|
|
|
|
|
|
|
5,126
|
|
|
|
28,770
|
|
|
|
(20,562
|
)
|
|
|
8,208
|
|
Other liabilities
|
|
|
19,918
|
|
|
|
|
|
|
|
19,918
|
|
|
|
16,372
|
|
|
|
|
|
|
|
16,372
|
|
Liabilities of discontinued
operations
|
|
|
23,024
|
|
|
|
|
|
|
|
23,024
|
|
|
|
23,118
|
|
|
|
|
|
|
|
23,118
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total non-current liabilities
|
|
|
833,918
|
|
|
|
|
|
|
|
833,918
|
|
|
|
856,699
|
|
|
|
(20,562
|
)
|
|
|
836,137
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock
|
|
|
928
|
|
|
|
|
|
|
|
928
|
|
|
|
928
|
|
|
|
|
|
|
|
928
|
|
Additional capital
|
|
|
1,209,926
|
|
|
|
21,029
|
|
|
|
1,230,955
|
|
|
|
1,203,814
|
|
|
|
21,093
|
|
|
|
1,224,907
|
|
Accumulated deficit
|
|
|
(757,480
|
)
|
|
|
(26,007
|
)
|
|
|
(783,487
|
)
|
|
|
(743,950
|
)
|
|
|
(26,400
|
)
|
|
|
(770,350
|
)
|
Accumulated other comprehensive
income (loss)
|
|
|
(18,784
|
)
|
|
|
|
|
|
|
(18,784
|
)
|
|
|
(21,541
|
)
|
|
|
|
|
|
|
(21,541
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
434,590
|
|
|
|
(4,978
|
)
|
|
|
429,612
|
|
|
|
439,251
|
|
|
|
(5,307
|
)
|
|
|
433,944
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,490,600
|
|
|
$
|
|
|
|
$
|
1,490,601
|
|
|
$
|
1,530,877
|
|
|
$
|
(16,860
|
)
|
|
$
|
1,514,017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43
The following table summarizes the specific income statement
accounts as reported and as affected by the restatement for the
three month periods ended March 31, 2006 and 2005.
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(In thousands)
|
|
|
Revenues
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
198,848
|
|
|
$
|
181,138
|
|
Adjustment
|
|
|
644
|
|
|
|
(21
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
199,492
|
|
|
$
|
181,117
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
58,580
|
|
|
$
|
48,721
|
|
Adjustment
|
|
|
21
|
|
|
|
62
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
58,601
|
|
|
$
|
48,783
|
|
|
|
|
|
|
|
|
|
|
Selling expenses
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
64,270
|
|
|
$
|
52,815
|
|
Adjustment
|
|
|
6
|
|
|
|
35
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
64,276
|
|
|
$
|
52,850
|
|
|
|
|
|
|
|
|
|
|
Research and development costs
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
29,535
|
|
|
$
|
25,724
|
|
Adjustment
|
|
|
18
|
|
|
|
107
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
29,553
|
|
|
$
|
25,831
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
28,540
|
|
|
$
|
24,577
|
|
Adjustment
|
|
|
(94
|
)
|
|
|
128
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
28,446
|
|
|
$
|
24,705
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations,
before interest, taxes and other items
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
7,934
|
|
|
$
|
(112,761
|
)
|
Adjustment
|
|
|
693
|
|
|
|
(353
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
8,627
|
|
|
$
|
(113,114
|
)
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing
operations before income taxes income taxes and minority interest
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
1,091
|
|
|
$
|
(121,218
|
)
|
Adjustment
|
|
|
693
|
|
|
|
(353
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
1,784
|
|
|
$
|
(121,571
|
)
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
7,242
|
|
|
$
|
16,367
|
|
Adjustment
|
|
|
300
|
|
|
|
147
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
7,542
|
|
|
$
|
16,514
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing
operations
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
(6,152
|
)
|
|
$
|
(137,756
|
)
|
Adjustment
|
|
|
393
|
|
|
|
(500
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
(5,759
|
)
|
|
$
|
(138,256
|
)
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
(6,364
|
)
|
|
$
|
(139,259
|
)
|
Adjustment
|
|
|
393
|
|
|
|
(500
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
(5,971
|
)
|
|
$
|
(139,759
|
)
|
|
|
|
|
|
|
|
|
|
Basic and diluted earnings per
share from continuing operations
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
(0.07
|
)
|
|
$
|
(1.55
|
)
|
Adjustment
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
(0.06
|
)
|
|
$
|
(1.55
|
)
|
|
|
|
|
|
|
|
|
|
Basic and diluted earnings per share
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
(0.07
|
)
|
|
$
|
(1.57
|
)
|
Adjustment
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
(0.06
|
)
|
|
$
|
(1.57
|
)
|
|
|
|
|
|
|
|
|
|
44
The following table summarizes the specific balance sheet
accounts as reported and as affected by the restatement as of
March 31, 2006 and December 31, 2005.
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
December 31,
|
|
|
|
2006
|
|
|
2005
|
|
|
|
(In thousands)
|
|
|
Other current assets (deferred
taxes)
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
38,862
|
|
|
$
|
36,652
|
|
Adjustment
|
|
|
|
|
|
|
3,702
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
38,862
|
|
|
$
|
40,354
|
|
|
|
|
|
|
|
|
|
|
Deferred tax assets, Net
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
21,510
|
|
|
$
|
45,904
|
|
Adjustment
|
|
|
|
|
|
|
(20,562
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
21,510
|
|
|
$
|
25,342
|
|
|
|
|
|
|
|
|
|
|
Accrued liabilities (reserve for
product returns)
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
135,043
|
|
|
$
|
136,701
|
|
Adjustment
|
|
|
3,508
|
|
|
|
4,137
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
138,551
|
|
|
$
|
140,838
|
|
|
|
|
|
|
|
|
|
|
Income taxes current
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
37,995
|
|
|
$
|
42,452
|
|
Adjustment
|
|
|
1,470
|
|
|
|
4,872
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
39,465
|
|
|
$
|
47,324
|
|
|
|
|
|
|
|
|
|
|
Deferred taxes
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
5,126
|
|
|
$
|
28,770
|
|
Adjustment
|
|
|
|
|
|
|
(20,562
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
5,126
|
|
|
$
|
8,208
|
|
|
|
|
|
|
|
|
|
|
Additional capital
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
1,209,926
|
|
|
$
|
1,203,814
|
|
Adjustment
|
|
|
21,029
|
|
|
|
21,093
|
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
1,230,955
|
|
|
$
|
1,224,907
|
|
|
|
|
|
|
|
|
|
|
Accumulated deficit
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
(757,480
|
)
|
|
$
|
(743,950
|
)
|
Adjustment
|
|
|
(26,007
|
)
|
|
|
(26,400
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
(783,487
|
)
|
|
$
|
(770,350
|
)
|
|
|
|
|
|
|
|
|
|
Stockholders equity
|
|
|
|
|
|
|
|
|
As previously reported
|
|
$
|
434,590
|
|
|
$
|
439,251
|
|
Adjustment
|
|
|
(4,978
|
)
|
|
|
(5,307
|
)
|
|
|
|
|
|
|
|
|
|
As restated
|
|
$
|
429,612
|
|
|
$
|
433,944
|
|
|
|
|
|
|
|
|
|
|
Overview
We are a global, science-based, specialty pharmaceutical company
that develops, manufactures and markets a broad range of
pharmaceutical products. We focus our greatest resources and
attention principally in the therapeutic areas of neurology,
infectious disease and dermatology. Our marketing and promotion
efforts focus on our promoted
45
products, which include products marketed globally, regionally
and locally with annual sales in excess of $5 million. Our
products are currently sold in more than 100 markets around the
world, with our primary focus on the United States, Canada,
Mexico, the United Kingdom, France, Italy, Poland, Germany, and
Spain.
Our two primary value drivers are: a specialty pharmaceutical
business with a global platform, and strong clinical development
and regulatory capabilities. We believe that our global reach
and focused clinical development capability make us unique among
specialty pharmaceutical companies, and provide us with the
ability to take compounds through the clinical stage and
commercialize them in major markets around the world. In
addition, we receive royalties from the sale of ribavirin by
Schering-Plough and Roche, although such royalties currently
represent a much smaller contribution to our revenues than they
have in the past.
Specialty
Pharmaceuticals
Specialty pharmaceutical sales accounted for 91% and 89% of our
total revenues from continuing operations for the three months
ended March 31, 2006 and 2005, respectively, and increased
$19,619,000 (12%) in the three months ended March 31, 2006
compared to the similar period in 2005. The increase in
specialty pharmaceutical sales was due to an approximate 8%
increase in volume, a 5% increase due to changes in selling
prices, and a 1% negative impact from foreign exchange rate
fluctuations. New products acquired in the Xcel and Infergen
transactions contributed $24,747,000 to the increase in sales,
which was offset in part by decreases in sales of other product
lines.
Our specialty pharmaceutical business focuses its efforts in
three therapeutic areas and a portfolio of promoted products
which we have identified as offering the best opportunities for
returns on investment. Promoted products constituted 59% and 52%
of our specialty pharmaceutical sales for the three months ended
March 31, 2006 and 2005, respectively. Sales of promoted
products increased $23,622,000 (28%) in the three months ended
March 31, 2006 compared to the similar period in 2005.
Newly acquired promoted products contributed $22,891,000 of this
increase. We also experience generic challenges to some products
and pricing challenges, primarily in Europe, through government
imposed price controls and reductions. We expect these
challenges to continue.
Clinical
Development
We seek to develop and commercialize innovative products for the
treatment of significant unmet medical needs, principally in the
areas of infectious diseases and neurology. Research and
development expenses for the three months ended March 31,
2006 and 2005 were $29,553,000 and $25,831,000, respectively,
and increased $3,722,000 (14%) in the three months ended
March 31, 2006 compared to the same period in 2005.
Research and development costs have increased sharply in 2005
and 2006 over prior years as a result of clinical trials
conducted for late stage drug candidates.
In April 2006 we announced a major restructuring program which
will result in a reduction of the size and scope of our research
and development activities. See Company Strategy and
Restructuring below.
Ribavirin
Royalties
Ribavirin royalty revenues decreased $1,244,000 (6%) and
accounted for 9% of our total revenues from continuing
operations for the three months ended March 31, 2006 as
compared to 11% in 2005. The decline in ribavirin royalty
revenues for the three months ended March 31, 2006 as
compared to the same period in the prior year was primarily due
to reductions in reserves against the royalty revenues recorded
in the three month period ended March 31, 2005.
Company
Strategy and Restructuring
The key elements of our strategy, as refined by the
restructuring program announced on April 3, 2006, include
the following:
Targeted Growth of Existing Products. We focus
our business on key markets, across three core therapeutic
areas. We believe that our core therapeutic areas are positioned
for further growth and that it is
46
possible for a mid-sized company to attain a leadership position
within these categories. We intend to continue to pursue life
cycle management strategies for our products.
Efficient Manufacturing and Supply Chain
Organization. The objective of the restructuring
program as it relates to manufacturing is to further rationalize
our manufacturing operations and further reduce our excess
capacity after considering the likely delay in the launch of
Viramidine. Under our global manufacturing strategy, we also
seek to minimize our costs of goods sold by increasing capacity
utilization in our manufacturing facilities or by outsourcing or
by other actions to improve efficiencies. We have undertaken
major process improvement initiatives and the deployment of lean
six sigma process improvements, affecting all phases of our
operations, from raw material and supply logistics, to
manufacturing, warehousing and distribution.
Clinical Development Activities. We are
focusing efforts and expenditures on three late stage projects
(Viramidine and Infergen, both of which are potential treatments
of patients with hepatitis C, and retigabine, a potential
treatment for partial onset seizures of patients with epilepsy)
currently in development. The restructuring program is designed
to rationalize our investments in research and development
efforts in line with our financial resources. We intend to sell
rights to, out-license or secure partners to share the costs of
other major clinical projects and discovery programs that the
research and development division has underway.
Product Acquisitions. We plan to selectively
license or acquire product candidates, technologies and
businesses from third parties which complement our existing
business and provide for effective life cycle management of key
products. We believe that our drug development and
commercialization expertise will allow us to recognize licensing
opportunities and to capitalize on research initially conducted
and funded by others.
The restructuring program will also result in reduced selling,
general and administrative expenses primarily through
consolidation of the management functions in fewer
administrative groups to achieve greater economies of scale.
Management and administrative responsibilities for our regional
operations in Asia, Africa and Australia, (AAA)
which have been managed as a separate business unit, will be
combined with those of other regions.
We anticipate that the total restructuring program will result
in charges that will range between $90,000,000 and $115,000,000.
Although no impairments currently exist for any of our
long-lived asset groups under the assets held and used model of
FAS 144, Accounting for the Impairment or Disposal of
Long-Lived Assets these anticipated charges include
potential future losses that may occur upon the disposition of
specific assets related to our manufacturing operations in
Switzerland and Puerto Rico, as well as assets of other
operations that may be sold or abandoned. The anticipated
charges also include employee severance costs resulting from a
reduction of approximately 750 employees, the majority of whom
work in the manufacturing facilities anticipated to be disposed.
We recorded a provision of $26,466,000 in the three months ended
March 31, 2006 in connection with our decision to implement
the restructuring program. This charge consists of the write off
of the costs of assets to be abandoned in the restructuring
process of $19,822,000 and an accrual for a portion of the
severance costs of employees who will be terminated in the
program of $6,644,000. The severance charges recorded in the
three months ended March 31, 2006 relate to 103 employees
in administrative and research positions whose positions were
eliminated in the restructuring. The amount of the accrual for
severance in the three months ended March 31, 2006 was
determined in accordance with Financial Accounting Standard
No. 112 Employers Accounting for Postemployment
Benefits.
In compliance with Financial Accounting Standard No. 146
Accounting for Costs Associated with Exit or Disposal
Activities certain costs relating to the termination of
employees in the restructuring program were not recorded in the
three months ended March 31, 2006 but will be recorded when
communicated to the affected employees (in the second quarter of
2006). Other costs associated with the restructuring and the
associated termination of employees in connection therewith will
be expensed as incurred. Additionally, losses from assets
expected to be sold will be recorded upon disposal, or earlier
if an impairment of the carrying value of the assets is
identified under FAS 144.
47
Results
of Operations
For the first quarter of 2006, our four reportable
pharmaceutical segments were comprised of pharmaceuticals
operations in North America, Latin America, Europe and AAA. In
addition, we have a research and development division. Certain
financial information for our business segments is set forth
below. This discussion of our results of operations should be
read in conjunction with our consolidated condensed financial
statements included elsewhere in this quarterly report. For
additional financial information by business segment, see
Note 10 of notes to consolidated condensed financial
statements included elsewhere in this quarterly report.
Our restructuring will result in our four pharmaceutical
segments being consolidated into three. Future financial reports
will include the new segment organization.
The following table compares 2006 and 2005 revenues by
reportable segments and operating expenses for the three months
ended March 31, 2006 and 2005 (in thousands, except
percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
Increase/
|
|
|
Percent
|
|
|
|
2006
|
|
|
2005
|
|
|
(Decrease)
|
|
|
Change
|
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Specialty pharmaceuticals
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America
|
|
$
|
75,856
|
|
|
$
|
48,922
|
|
|
$
|
26,934
|
|
|
|
55
|
%
|
Latin America
|
|
|
35,788
|
|
|
|
32,060
|
|
|
|
3,728
|
|
|
|
12
|
%
|
Europe
|
|
|
56,257
|
|
|
|
65,875
|
|
|
|
(9,618
|
)
|
|
|
(15
|
)%
|
AAA
|
|
|
13,500
|
|
|
|
14,925
|
|
|
|
(1,425
|
)
|
|
|
(10
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total specialty pharmaceuticals
|
|
|
181,401
|
|
|
|
161,782
|
|
|
|
19,619
|
|
|
|
12
|
%
|
Ribavirin royalties
|
|
|
18,091
|
|
|
|
19,335
|
|
|
|
(1,244
|
)
|
|
|
(6
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
199,492
|
|
|
|
181,117
|
|
|
|
18,375
|
|
|
|
10
|
%
|
Costs and
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold (excluding
amortization)
|
|
|
58,601
|
|
|
|
48,783
|
|
|
|
9,818
|
|
|
|
20
|
%
|
Selling expenses
|
|
|
64,276
|
|
|
|
52,850
|
|
|
|
11,426
|
|
|
|
22
|
%
|
General and administrative expenses
|
|
|
28,446
|
|
|
|
24,705
|
|
|
|
3,741
|
|
|
|
15
|
%
|
Research and development costs
|
|
|
29,553
|
|
|
|
25,831
|
|
|
|
3,722
|
|
|
|
14
|
%
|
Gain on settlement of litigation
|
|
|
(34,000
|
)
|
|
|
|
|
|
|
(34,000
|
)
|
|
|
NM
|
|
Acquired IPR&D
|
|
|
|
|
|
|
126,399
|
|
|
|
(126,399
|
)
|
|
|
NM
|
|
Restructuring charges
|
|
|
26,466
|
|
|
|
1,695
|
|
|
|
24,771
|
|
|
|
NM
|
|
Amortization expense
|
|
|
17,523
|
|
|
|
13,968
|
|
|
|
3,555
|
|
|
|
25
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
$
|
8,627
|
|
|
$
|
(113,114
|
)
|
|
$
|
121,741
|
|
|
|
NM
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit on product sales
(excluding amortization)
|
|
$
|
122,800
|
|
|
$
|
112,999
|
|
|
$
|
9,801
|
|
|
|
9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit margin on product
sales
|
|
|
68
|
%
|
|
|
70
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NM Percentage not meaningful
Specialty Pharmaceutical Revenues: Specialty
pharmaceutical sales increased $19,619,000 (12%) for the three
months ended March 31, 2006 over the same period in 2005.
The increase in pharmaceutical sales was led by our promoted
products which increased $23,622,000 (28%). In addition, sales
of products acquired from Xcel and Infergen contributed
$32,046,000 and $7,298,000 to pharmaceutical sales in the three
months ended March 31, 2006 and 2005, respectively.
In the North America pharmaceuticals segment, revenues for the
three months ended March 31, 2006 were $75,856,000 compared
to $48,922,000 for the same period in 2005, an increase of
$26,934,000 (55%). The increase
48
was primarily driven by sales of products acquired from Xcel
(which were acquired on March 1, 2005) and Infergen
(which was acquired on December 30, 2005). Sales of
products acquired from Xcel totaled $18,341,000 in the three
months ended March 31, 2006 and $7,299,000 in the three
months ended March 31, 2005 (representing only one
months sales in 2005). Sales of Infergen were $13,705,000
in the three months ended March 31, 2006; we did not record
any sales of Infergen in 2005.
In the Latin America pharmaceuticals segment, revenues for the
three months ended March 31, 2006 were $35,788,000 compared
to $32,060,000 for the same period in 2005, an increase of
$3,728,000 (12%). The increase is primarily due to favorable
foreign exchange effects ($2.1 million), sales of a newly
acquired product, Melleril, in Brazil ($1,408,000) and increased
sales of Bedoyecta ($1,336,000) resulting from a continuing
successful
direct-to-consumer
campaign. These increases were partially offset by declines in
sales of non-promoted products.
In the Europe pharmaceuticals segment, revenues for the three
months ended March 31, 2006 were $56,257,000 compared to
$65,875,000 for the same period in 2005, a decrease of
$9,618,000 (15%). Approximately $3,769,000 of the decrease in
European sales is attributable to currency exchange rate
movements and approximately $6,200,000 is due to lower sales
volumes. The lower sales volumes were experienced across all
European markets with the exceptions of Poland and the United
Kingdom. Sales in Germany decreased approximately $5,922,000
partially as a result of changes in purchase patterns in the
wholesale market.
In the AAA pharmaceuticals segment, revenues for the three
months ended March 31, 2006 were $13,500,000 compared to
$14,925,000 for the same period in 2005, a decrease of
$1,425,000 (10%). The decrease was primarily due to lower sales
in China and Australia.
Ribavirin Royalties: Ribavirin royalties
represent amounts earned under the license and supply agreements
with Schering-Plough and Roche. Under a license and supply
agreement, Schering-Plough licensed all oral forms of ribavirin
for the treatment of chronic hepatitis C. We receive
royalty fees from Roche under a license agreement on sale of
Roches version of ribavirin, Copegus, for use in
combination with interferon alfa or pegylated interferon alfa.
Ribavirin royalties from Schering-Plough and Roche for the three
months ended March 31, 2006 were $18,091,000 compared to
$19,335,000 for the same period in 2005, a decrease of
$1,244,000 (6%). The relative decline in ribavirin royalty
revenues for the three months ended March 31, 2006 as
compared to the same period in the prior year primarily reflects
reductions in reserves against the royalty revenues recorded in
the three month period ended March 31, 2005.
Gross Profit Margin (excluding
amortization): Gross profit margin on
pharmaceutical sales for the three months ended March 31,
2006 was 68% compared to 70% the same period in 2005. The
decrease in gross profit margin is attributable to a temporary
maintenance shutdown in our Mexico plant that lasted longer than
anticipated and to adjustments made for products that were not
manufactured to specifications and to other inventory
write-offs. Cost of goods sold in 2006 includes a provision of
$434,000 related to employee stock option and purchase programs
following the implementation of SFAS 123(R) in 2005 Stock
compensation expense included in cost of sales was $62,000.
Selling Expenses: Selling expenses were
$64,276,000 for the three months ended March 31, 2006
compared to $52,850,000 for the same period in 2005, an increase
of $11,426,000 (22%). As a percent of pharmaceutical sales,
selling expenses were 35% for the three months ended
March 31, 2006 compared to 33% for 2005. The increase in
selling expenses reflects our increased promotional efforts
primarily in North America and includes costs related to the
launch of line extensions and new products. Selling expenses in
2006 include a provision of $854,000 for expenses associated
with stock option and stock purchase programs following the
implementation of SFAS 123(R), in 2005 selling expenses
included $35,000 of stock-based compensation.
General and Administrative Expenses: General
and administrative expenses were $28,446,000 for the three
months ended March 31, 2006 compared to $24,705,000 for the
same period in 2005, an increase of $3,741,000 (15%). As a
percent of pharmaceutical sales, general and administrative
expenses were 16% for the three months ended March 31, 2006
compared to 15% for the same period in 2005. Stock compensation
expense included in general and administrative expense increased
to $3,532,000 in the three months ended March 31, 2006 from
$525,000 in the same period in 2005 as a result of implementing
SFAS 123(R). Excluding stock compensation costs,
49
general and administrative expenses declined as a percentage of
pharmaceutical revenues in 2006 as compared to 2005.
Research and Development: Research and
development expenses were $29,553,000 for the three months ended
March 31, 2006 compared to $25,831,000 for the same period
in 2005, an increase of $3,722,000 (14%). The increase in
research and development expenses reflects the costs of clinical
trials for Viramidine and pradefovir. Research and development
expenses include $798,000 of stock compensation expense in the
three months ended March 31, 2006 and $240,000 in the same
period in 2005 following the implementation of SFAS 123(R).
Gain on litigation settlement: In March 2006
we settled a long standing dispute with the Republic of Serbia
relating to the ownership and operations of a joint venture we
formerly participated in known as Galenika. We received a
payment of $28,000,000 in March 2006 and will receive an
additional $6,000,000 in 2007, with respect to which we have
received a bank letter of credit.
Acquired In-Process Research and
Development: In the three months ended
March 31, 2005, we incurred an expense of $126,399,000
associated with IPR&D related to the acquisition of Xcel
Pharmaceuticals, Inc. The amount expensed as acquired IPR&D
represents our estimate of fair value of purchased in-process
technology for projects that, as of the acquisition date, had
not yet reached technological feasibility and had no alternative
future use.
Restructuring Charges: On April 3, 2006
Valeant announced a restructuring program to reduce costs and
accelerate earnings growth. This program is discussed in more
detail in the Company Strategy and Restructuring above.
We recorded a provision of $26,466,000 in the three months ended
March 31, 2006 in connection with our decision to implement
the restructuring program. This charge consists of the write off
of costs related to assets to be abandoned ($19,822,000) and a
portion of the severance costs of employees who will be
terminated in the program ($6,644,000).
Restructuring charges of $1,695,000 in the three months period
ended March 31, 2005 relate to the decision to dispose of
the Companys manufacturing facility in China ($2,220,000)
offset in part by the gain ($525,000) on the sale of a
manufacturing plant in Argentina.
Amortization: Amortization expense was
$17,523,000 for the three months ended March 31, 2006
compared to $13,968,000 for the same period in 2005, an increase
of $3,555,000 (5%). The increase was due to amortization of
intangibles acquired with the acquisition of Xcel and Infergen.
Other Income, Net, Including Translation and
Exchange: Other income, net, including
translation and exchange was $937,000 for the three months ended
March 31, 2006 compared to a loss of $1,791,000 for the
same period in 2005. These amounts consist primarily of foreign
currency exchange gains and losses. The variation between years
reflects foreign exchange movements during the period.
Interest Expense and Income: Interest expense
increased $756,000 during the three months ended March 31,
2006 compared to the same period in 2005 primarily as result of
higher interest rates on variable rate debt. Interest income
decreased $358,000 during the year ended March 31, 2006
compared to the same period in 2005 as a result of lower cash
and investment securities balances.
Income Taxes: The tax provisions in the first
quarters of both 2006 and 2005 relate to the profits of our
foreign operations and state and local taxes in the
U.S. The decrease in 2006 is a result of the reduced
profitability of our operations, withholding taxes, in Europe
and the AAA regions. Our U.S. operations, which include our
research and development activities, have substantial net
operating loss carryforwards for US income tax reporting
purposes. Since, at this time, there is insufficient objective
evidence that we will generate sufficient U.S. taxable
income to utilize these net operating loss benefits, the tax
benefits associated with U.S. operating losses have been
fully reserved. Additionally, in 2005 a significant portion of
the loss relates to a charge for IPR&D associated with the
Xcel acquisition that will not be deductible for tax purposes
since that acquisition was structured as a stock purchase.
50
Loss from Discontinued Operations, Net of
Taxes: Loss from discontinued operations was
$212,000 for the three months ended March 31, 2006 compared
to $1,503,000 in the same period in 2005. The losses in 2006
relate to closure and wind up of our remaining administrative
activities associated with the discontinued manufacturing
operations in Central Europe, the last of which was disposed of
in 2005.
Liquidity
and Capital Resources
Cash and marketable securities totaled $255,483,000 at
March 31, 2006 compared to $235,066,000 at
December 31, 2005. Working capital was $379,437,000 at
March 31, 2006 compared to $355,505,000 at
December 31, 2005. The increase in working capital of
$23,932,000 was primarily attributable to gain on litigation
settlement of $34,000,000, partially offset by cash used in
operations, including research and development activities.
Cash provided by operating activities and working capital is
expected to be our primary source of funds in 2006. During the
three months ended March 31, 2006, cash provided by
operating activities totaled $41,138,000 compared to $8,662,000
in same period in 2005, an increase of $32,476,000. The increase
in cash provided by operating activities is primarily due to a
gain on the settlement of litigation of $34,000,000 (of which
$28,000,000 was received in the first quarter) offset in part by
a reduction in royalty revenues and reduction in the profit
contribution of foreign pharmaceutical operations and increased
spending on research and development activities.
Cash used in investing activities was $15,156,000 for the three
months ended March 31, 2006 compared to $83,477,000 for
2005. In 2006 cash used in investing activities consisted
primarily of capital expenditures on corporate programs and
existing facilities. In 2005, net cash used in investing
activities consisted of payments for the acquisition of Xcel and
various other product rights of $281,778,000 and capital
expenditures of $4,848,000, partially offset by net proceeds
from investments of $202,387,000 and proceeds from the sale of
assets of $762,000.
Cash used in financing activities was $6,900,000 in the three
months ended March 31, 2006 and principally consisted of
dividends paid on common stock ($7,173,000) offset in part by
cash proceeds for employee stock option exercises. Cash
generated from financing activities for the three months ended
March 31, 2005 was $182,938,000, which includes proceeds
from our stock offering in connection with the Xcel acquisition
of $189,393,000, partially offset by cash dividends paid on
common stock of $6,502,000.
In January 2005, the Company entered into an interest rate swap
agreement with respect to $150,000,000 principal amount of its
7.0% Senior Notes due 2011. The interest rate on the swap
is variable at LIBOR plus 2.41%. The effect of this transaction
was to initially lower our effective interest rate by exchanging
fixed rate payments for floating rate payments. On a prospective
basis, the effective interest rate will float and correlate to
the variable interest earned on our cash held.
We have collateral requirements on the interest rate swap
agreement. The amount of collateral varies monthly depending on
the fair value of the underlying swap contract. As of
March 31, 2006, we have collateral of $10,200,000 comprised
of marketable securities and included in other assets in the
accompanying balance sheet.
Management believes that its existing cash and cash equivalents
and funds generated from operations will be sufficient to meet
its operating requirements at least through March 31, 2007,
and to provide cash needed to fund capital expenditures and its
clinical development program. While we have no current intent to
issue additional debt or equity securities, we may seek
additional debt financing or issue additional equity securities
to finance future acquisitions or for other purposes. We fund
our cash requirements primarily from cash provided by operating
activities. Our sources of liquidity are cash and cash
equivalent balances and cash flow from operations.
While we have historically paid quarterly cash dividends, there
can be no assurance that we will continue to do so in the future.
The restatement of our financial statements caused us to delay
the filing of our quarterly report on
Form 10-Q
for the quarter ended September 30, 2006. On
December 12, 2006, we received a notice of default from The
Bank of New York, as trustee for the holders of our 3%
Convertible Notes due 2010, asserting that a default occurred
under our indenture dated as of November 19, 2003,
governing the 3.0% Convertible Notes and our 4.0% Convertible
Notes due 2013. The notice of default asserts that a default
occurred under the indenture when we failed to timely
51
file our quarterly report on
Form 10-Q
for the quarter ended September 30, 2006. The filing of our
quarterly report on
Form 10-Q
for the quarter ended September 30, 2006, within sixty days
of the notice of default, has cured the asserted default under
the indenture.
Products
in Development
Viramidine (taribavirin): Viramidine
(taribavirin) is a nucleoside (guanisine) analog that is
converted into ribavirin by adenosine deaminase in the liver and
intestine. We are developing Viramidine, in oral form, for
administration in combination with pegylated interferon for the
treatment of chronic hepatitis C in treatment-naïve
patients.
On March 21, 2006, we reported the results of the first of
two pivotal Phase 3 trials for Viramidine. The VISER1
(VISER stands for VIramidine Safety and Efficacy Versus
Ribavirin) trial included two co-primary endpoints: one for
safety (superiority to ribavirin in incidence of anemia) and one
for efficacy (non-inferiority to ribavirin in sustained viral
response, SVR). The results of VISER1 met the safety criteria
but did not meet the efficacy criteria.
The results of the study were significantly impacted by the
VISER1 dosing methodology which was a fixed dose of Viramidine
for all patients and a variable dose of ribavirin based on a
patients weight. The results of the study indicate that
the dosage of Viramidine, like ribavirin, likely needs to be
based on a patients weight to achieve efficacy equal or
superior to that of ribavirin. VISER2, our second Phase 3
trial, is expected to conclude in June 2006. VISER2 is
similar in design to VISER1 (a fixed dose of Viramidine and a
weight based, variable dose of ribavirin).
We intend to consult with external experts and meet with the FDA
to discuss the Phase 3 study results and potential
development plans for Viramidine.
While we intend to pursue development of Viramidine, the
timeline and path to regulatory approval is uncertain at this
time. Further development of Viramidine may require the
completion of another Phase 3 trial, which could add
significantly to the drugs development cost and the time
it takes to complete development, thereby delaying the
commercial launch of Viramidine and possibly weakening its
position in relation to competing treatments. We will evaluate
the economics of the Viramidine development program and decide
on its course of action by the end of the year.
Retigabine: We acquired the rights to
retigabine, an adjunctive treatment for partial-onset seizures
in patients with epilepsy, in the Xcel acquisition on
March 1, 2005. Retigabine is believed to have a unique,
dual- acting mechanism and has undergone several Phase 2
clinical trials. The Phase 2 trials included more than
600 patients in several dose-ranging studies compared to
placebo. We, successfully completed an
End-of-Phase 2
meeting concerning retigabine with the FDA in November 2005. The
results of the key Phase 2 study indicate that the compound
is potentially efficacious with a demonstrated reduction in
monthly seizure rates of 23% to 35% as adjunctive therapy in
patients with partial seizures. Response rates in the two higher
doses were statistically significant compared to placebo
(p>0.001).
Following a Special Protocol Assessment by the FDA two
Phase 3 trials of retigabine were initiated in 2005. One
Phase 3 trial (RESTORE1) was conducted at approximately 45
sites, mainly in the Americas (U.S.,
Central/South
America); the second Phase 3 trial (RESTORE2) will be
performed at 55 sites, mainly in Europe. On September 2,
2005, the first patient in the RESTORE1 trial was enrolled.
Enrollment of the first patient in the RESTORE2 trial occurred
in December 2005. The enrollment period in epilepsy studies can
be lengthy, frequently requiring a year to a
year-and-a-half
to enroll.
A Phase 1 cardiology trial in healthy volunteers, a hepatic
impairment study and a renal impairment study are being planned
to start in mid-2006.
Assuming successful completion of the Phase 3 trials,
availability of the trials results in the second half of
2007, and approval by the FDA, we expect to launch retigabine in
late 2008 or early 2009.
Infergen: On December 30, 2005, we
completed the acquisition of the United States and Canadian
rights to the hepatitis C drug Infergen (interferon
alfacon-1) from InterMune. Infergen, or consensus interferon, is
a bio-
52
optimized, selective and highly potent type 1 interferon alpha
originally developed by Amgen and launched in the United States
in 1997. It is currently indicated as monotherapy for the
treatment of adult patients suffering from chronic
hepatitis C viral infections with compensated liver disease
who have not responded to other treatments or have relapsed
after such treatment. Infergen is the only interferon with data
in the label regarding use in patients following relapse or
non-response to certain previous treatments.
In connection with this transaction, we acquired patent rights
and rights to a clinical trial underway to expand the
applications of Infergen. In the DIRECT trial (001) that
started in the second quarter of 2004, 514 patients were
enrolled and treatment was completed in the first quarter of
2006. An Extension to the DIRECT trial (002) is underway
for some of the patients who participated in the first trial.
Post-treatment
follow-up
for DIRECT and Extension trials are expected to be completed
(i.e., last patient visit) in the first and third quarters,
respectively, of 2007. We expect to report and publish the
results from these studies sometime in late 2007. We plan to use
the results from the study for expansion of the products
label.
Zelapar: We acquired the rights to Zelapar, a
late-stage candidate for the treatment of Parkinsons
disease, in the Amarin acquisition in February 2004. Zelapar is
a late-stage candidate under review by the FDA as an oral tablet
using the patented
Zydis®
fast-dissolving technology and is being developed as an adjunct
treatment in the management of patients with Parkinsons
disease being treated with levodopa/carbidopa. Prior to the
acquisition, Amarin had received an approvable letter from the
FDA for Zelapar, subject to the completion of two safety
studies. In late 2004, following our completion of two safety
studies, we submitted a response to the approvable letter. We
received a response to this submission from the FDA that
required us to provide the FDA with additional information. A
revised submission for Zelapar was sent to the FDA in March
2005. On September 30, 2005, an additional approvable
letter was received from the FDA with a request for additional
data. We filed the requested information with the FDA in the
fourth quarter of 2005, and this filing was accepted as
complete. We received a new PDUFA date in mid-2006.
Additionally, we are conducting preclinical and clinical studies
that were originally part of Amarins
agreed-upon
Phase 4 commitment with the FDA, which include a renal
impairment study that started in November 2005 and a hepatic
impairment study that started in January 2006. Both of the
Phase 4 studies will conclude in 2006. Assuming successful
completion of the Phase 4 studies and approval by the FDA,
we expect to launch Zelapar in later this year.
Pradefovir (formerly called
remofovir): Pradefovir is a compound that we
licensed from Metabasis Therapeutics, Inc., or Metabasis, in
October 2001. We are developing this compound into an oral
once-a-day
monotherapy for patients with chronic hepatitis B infection. The
active molecule in this compound exhibits anti-hepatitis B
activity against both the wild type and lamivudine
drug-resistant hepatitis B. Based on biologic and molecular
modeling data, this compound binds to the active site of the
hepatitis B replication enzyme so that the virus is prevented
from utilizing the natural substrate from the host to replicate.
A prodrug modification developed by Metabasis significantly
improved the compounds physiochemical properties and
ability to target the liver. In preliminary experiments in
rodents, the active molecule was delivered in significantly
greater proportion to the targeted organ, the liver, as compared
to the non-targeted organ, the kidney. The kidney is the organ
responsible for the dose-limiting toxicity. In these
experiments, the amount of the active species, adefovir,
selectively delivered to the liver versus kidney was
approximately 10 times greater than the amount of compound
delivered by another well established process. We have completed
Phase 1 and Phase 2 clinical trials of Pradefvoir, and
the compound is now prepared for a Phase 3 project. As
announced in our restructuring program, we intend to out-license
pradefovir.
VRX-840773: In January 2006, we submitted an
IND for VRX-840773, an internally developed compound which we
plan to develop in clinical trials for the treatment of HIV. The
benefits of this compound have been demonstrated in-vitro, and,
if similar benefits can be proven in the clinic, VRX-840773
could become a valuable new HIV therapy. All preclinical studies
to support the first human study have been completed. As
announced in our restructuring program, we intend to out-license
VRX-840773.
Foreign
Operations
Approximately 66% and 75% of our revenues from continuing
operations, which includes royalties, for the three months ended
March 31, 2006 and 2005, respectively, were generated from
operations outside the United States. All of our foreign
operations are subject to risks inherent in conducting business
abroad, including
53
possible nationalization or expropriation, price and currency
exchange controls, fluctuations in the relative values of
currencies, political instability and restrictive governmental
actions. Changes in the relative values of currencies occur from
time to time and may, in some instances, materially affect our
results of operations. The effect of these risks remains
difficult to predict.
In January 2006, the parent company of one of our toll
manufacturers in Europe filed for bankruptcy. Sales of products
obtained from this manufacturer are estimated to be
approximately $60 million in 2006. The supplier has
developed a business plan to continue to successfully operate
and we have developed plans to respond to a disruption should it
occur. The supplier has submitted a proposal to emerge from
bankruptcy to the bankruptcy court and is seeking the requisite
approval of its credits. To date, this bankruptcy filing has had
no significant effect on our operations or the suppliers
ability to operate and meet its commitments to supply us with
products.
Critical
Accounting Estimates
The consolidated condensed financial statements appearing
elsewhere in this quarterly report have been prepared in
conformity with accounting principles generally accepted in the
United States. The preparation of these statements requires us
to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent
assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the
reporting periods. On an on-going basis, we evaluate our
estimates, including those related to product returns,
collectibility of receivables, inventories, intangible assets,
income taxes and contingencies and litigation. The actual
results could differ materially from those estimates.
We believe the following critical accounting policies affect our
more significant judgments and estimates used in the preparation
of our consolidated condensed financial statements.
Revenue
Recognition
We recognize revenues from product sales when title and risk of
ownership transfers to the customer. Revenues are recorded net
of provisions for rebates, discounts and returns, which are
estimated and recorded at the time of sale. Allowances for
future returns of products sold to our direct and indirect
customers, who include wholesalers, retail pharmacies and
hospitals, are calculated as a percent of sales based on
historical return percentages taking into account additional
available information on competitive products and contract
changes.
Our product sales are subject to a variety of deductions,
primarily representing rebates and discounts to government
agencies, wholesalers and managed care organizations. These
deductions represent estimates of the related obligations and,
as such, judgment is required when estimating the impact of
these sales deductions on revenues for a reporting period.
In the United States we record provisions for Medicaid and
contract rebates based upon our actual experience ratio of
rebates paid and actual prescriptions written during prior
quarters. We apply the experience ratio to the respective
periods sales to determine the rebate accrual and related
expense. This experience ratio is evaluated regularly and
adjusted if necessary to ensure that the historical trends are
as current as practicable. We adjust the ratio to better match
our current experience or our expected future experience, as
appropriate. In developing this ratio, we consider current
contract terms, such as changes in formulary status and discount
rates. Because our revenues in the United States include newly
acquired products and have increased significantly in the last
few years, ratios based on our historical experience may not be
indicative of future experience. If our ratio is not indicative
of future experience, our results could be materially affected.
Outside of the United States, the majority of our rebates are
contractual or legislatively mandated and our estimates are
based on actual invoiced sales within each period; both of these
elements help to reduce the risk of variations in the estimation
process. Some European countries base their rebates on the
governments unbudgeted pharmaceutical spending and we use
an estimated allocation factor against our actual invoiced sales
to project the expected level of reimbursement. We obtain third
party information that helps us to monitor the adequacy of these
accruals. If our estimates are not indicative of actual
unbudgeted spending, our results could be materially affected.
Historically, our adjustments to actual have not been material;
on a quarterly basis, they generally have been less than 2% of
product sales. The sensitivity of our estimates can vary by
program, type of customer and geographic
54
location. However, estimates associated with U.S. Medicaid,
Medicare and contract rebates are most at-risk for material
adjustment because of the extensive time delay between the
recording of the accrual and its ultimate settlement. This
interval can range up to one year. Because of this time lag, in
any given quarter, our adjustments to actual can incorporate
revisions of several prior quarters.
We record sales incentives as a reduction of revenues at the
time the related revenues are recorded or when the incentive is
offered, whichever is later. We estimate the cost of our sales
incentives based on our historical experience with similar
incentives programs.
In some markets customers have the rights to return products to
us under certain conditions. Historically and in the three month
periods ended March 31, 2006 and 2005, the provision for
sales returns was less than 2% of product sales. We conduct a
review of the current methodology and assess the adequacy of the
allowance for returns on a quarterly basis, adjusting for
changes in assumptions, historical results and business
practices, as necessary. We use third-party data, when
available, to estimate the level of product inventories,
expiration dating, and product demand at our major wholesalers.
Actual results could be materially different from our estimates,
resulting in future adjustments to revenue.
We earn ribavirin royalties as a result of sales of products by
third-party licensees, Schering-Plough and Roche. Ribavirin
royalties are earned at the time the products subject to the
royalty are sold by the third party and are reduced by an
estimate for discounts and rebates that will be paid in
subsequent periods for those products sold during the current
period. We rely on a limited amount of financial information
provided by Schering-Plough and Roche to estimate the amounts
due to us under the royalty agreements.
In the U.S. market, our current practice is to offer sales
incentives primarily in connection with launches of new products
or changes of existing products where demand has not yet been
established. We monitor and restrict sales in the
U.S. market in order to limit wholesaler purchases in
excess of their
ordinary-course-of-business
inventory levels. We operate Inventory Management Agreements
(IMAs) with major wholesalers in the United States. However,
specific events such as the case of sales incentives described
above or seasonal demand (e.g. antivirals during an outbreak)
may justify larger purchases by wholesalers. We may offer sales
incentives primarily in international markets, where typically
no right of return exists except for goods damaged in transit,
product recalls or replacement of existing products due to
packaging or labeling changes. Our revenue recognition policy on
these types of purchases and on incentives in international
markets is consistent with the policies described above.
Income
Taxes
Our income tax returns are subject to audit in various
jurisdictions. Existing and future audits by, or other disputes
with, tax authorities may not be resolved favorably for us and
could have a material adverse effect on our reported effective
tax rate and after-tax cash flows. We record liabilities for
potential tax assessments based on our estimate of the potential
exposure. New laws and new interpretations of laws and rulings
by tax authorities may affect the liability for potential tax
assessments. Due to the subjectivity and complex nature of the
underlying issues, actual payments or assessments may differ
from our estimates. To the extent that our estimates differ from
amounts eventually assessed and paid our income and cash flows
can be materially and adversely affected.
We assess whether it is more likely than not that we will
realize the tax benefits associated with our deferred tax assets
and establish a valuation allowance for assets that are not
expected to result in a realized tax benefit. A significant
amount of judgment is used in this process, including
preparation of forecasts of future taxable income and evaluation
of tax planning initiatives. If we revise these forecasts or
determine that certain planning events will not occur, an
adjustment to the valuation allowance will be made to tax
expense in the period such determination is made. We have
increased the valuation allowance significantly since 2004 to
recognize the uncertainty of realizing the benefits of the
U.S. net operating losses and research credits.
Impairment
of Property, Plant and Equipment
We evaluate the carrying value of property, plant and equipment
when conditions indicate a potential impairment. We determine
whether there has been impairment by comparing the anticipated
undiscounted future cash flows expected to be generated by the
property, plant and equipment with its carrying value. If the
55
undiscounted cash flows are less than the carrying value, the
amount of the impairment, if any, is then determined by
comparing the carrying value of the property, plant and
equipment with its fair value. Fair value is generally based on
a discounted cash flows analysis, independent appraisals or
preliminary offers from prospective buyers.
Valuation
of Intangible Assets
We periodically review intangible assets for impairment using an
undiscounted net cash flows approach. We determine whether there
has been impairment by comparing the anticipated undiscounted
future operating cash flows of the products associated with the
intangible asset with its carrying value. If the undiscounted
operating income is less than the carrying value, the amount of
the impairment, if any, will be determined by comparing the
value of each intangible asset with its fair value. Fair value
is generally based on a discounted cash flows analysis.
We use a discounted cash flow model to value acquired intangible
assets and for the assessment of impairment. The discounted cash
flow model requires assumptions about the timing and amount of
future cash inflows and outflows, risk, the cost of capital, and
terminal values. Each of these factors can significantly affect
the value of the intangible asset.
The estimates of future cash flows, based on reasonable and
supportable assumptions and projections, require
managements judgment. Any changes in key assumptions about
our businesses and their prospects, or changes in market
conditions, could result in an impairment charge. Some of the
more significant estimates and assumptions inherent in the
intangible asset impairment estimation process include: the
timing and amount of projected future cash flows; the discount
rate selected to measure the risks inherent in the future cash
flows; and the assessment of the assets life cycle and the
competitive trends impacting the asset, including consideration
of any technical, legal or regulatory trends.
Purchase
Price Allocation Including Acquired In-Process Research and
Development
The purchase price for the acquisitions were allocated to the
tangible and identifiable intangible assets acquired and
liabilities assumed based on their estimated fair values at the
acquisition date. Such a valuation requires significant
estimates and assumptions, including but not limited to:
determining the timing and expected costs to complete the
in-process projects; projecting regulatory approvals; estimating
future cash flows from product sales resulting from completed
products and in-process projects; and developing appropriate
discount rates and probability rates by project. We believe the
fair values assigned to the assets acquired and liabilities
assumed are based on reasonable assumptions. However, these
assumptions may be incomplete or inaccurate, and unanticipated
events and circumstances may occur. Additionally, estimates for
the purchase price allocations may change as subsequent
information becomes available.
We value IPR&D acquired in a business combination based on
an approach consistent with the AICPA Practice Aid, Assets
Acquired in Business Combinations to be Used in Research and
Development Activities: A Focus in Software, Electronic Devices
and Pharmaceutical Industries. The amounts expensed as
acquired IPR&D represents an estimate of the fair value of
purchased in-process technology for projects that, as of the
acquisition date, had not yet reached technological feasibility
and had no alternative future use. The data used to determine
fair value requires significant judgment. The estimated fair
values were based on our use of a discounted cash flow model.
For each project, the estimated after-tax cash flows were
probability weighted to take account of the stage of completion
and the risks surrounding the successful development and
commercialization. The assumed tax rates are our estimate of the
effective tax rates that will apply to the expected cash flows.
These cash flows were then discounted to a present value using
discount rates between 15% and 20%.
The major risks and uncertainties associated with the timely and
successful completion of these projects include the uncertainty
of our ability to confirm the safety and efficacy of product
candidates based on the data from clinical trials and of
obtaining necessary regulatory approvals. In addition, no
assurance can be given that the underlying assumptions we used
to forecast the cash flows or the timely and successful
completion of these projects will materialize as estimated. For
these reasons, among others, actual results may vary
significantly from the estimated results.
56
We operate in numerous countries where our income tax returns
are subject to audit. Internal and external tax professional are
employed to minimize tax audit adjustments where possible. We
consider the expected outcome of these audits in the calculation
of our tax provision.
We assesses whether it is more likely than not that we will
realize the tax benefit associated with our deferred tax assets
and establish a valuation allowance for assets that are not
expected to result in a realized tax benefit. A significant
amount of judgment is used in this process, including
preparation of forecasts of future taxable income and evaluation
of tax planning initiatives. If we revise these forecasts or
determine that certain planning events will not occur, an
adjustment to the valuation allowance will be made to tax
expense in the period such determination is made.
Stock-based
Compensation Expense
On January 1, 2006, we adopted Statement of Financial
Accounting Standards No. 123 (revised 2004),
Share-Based Payment, (SFAS 123(R))
which requires the measurement and recognition of compensation
expense for all share-based payment awards made to our employees
and directors, including employee stock options and employee
stock purchases related to the Employee Stock Purchase Plan,
based on estimated fair values. Stock-based compensation expense
recognized under SFAS 123(R) for the three months ended
March 31, 2006 was $5,618,000, which consisted of
stock-based compensation expense related to employee stock
options and the Employee Stock Purchase Plan of $4,981,000, and
stock-based compensation expense related to restricted stock
awards and acquisitions of $637,000. We adopted SFAS 123(R)
on a prospective basis and have not restated financial
statements for prior years for this new pronouncement.
Stock-based compensation expense of $862,000 for the three ended
March 31, 2005 included $318,000 for stock options and
$544,000 related to restricted stock awards and acquisitions
which the Company had been recognizing under previous accounting
standards (see Notes 1 and 2 to Consolidated Condensed
Financial Statements). The following table shows the pro forma
effects had we applied SFAS 123R in 2005:
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 31, 2005
|
|
|
|
(In thousands, except
|
|
|
|
per share amounts)
|
|
|
|
(Restated)
|
|
|
Net loss as reported
|
|
$
|
(139,759
|
)
|
Stock compensation expense
recorded at intrinsic value for stock incentive plans
|
|
|
862
|
|
Stock compensation expense
determined under fair value method for stock incentive plans
|
|
|
(5,560
|
)
|
|
|
|
|
|
Pro forma net loss
|
|
$
|
(144,457
|
)
|
|
|
|
|
|
Net loss per share:
|
|
|
|
|
Basic and diluted as
reported
|
|
$
|
(1.57
|
)
|
|
|
|
|
|
Basic and diluted pro
forma
|
|
$
|
(1.63
|
)
|
|
|
|
|
|
We estimate the value of employee stock options on the date of
grant using the Black-Scholes model. The determination of fair
value of share-based payment awards on the date of grant using
an option-pricing model is affected by our stock price as well
as assumptions regarding a number of highly complex and
subjective variables. These variables include, but are not
limited to the expected stock price volatility over the term of
the awards, and actual and projected employee stock option
exercise behaviors. The weighted-average estimated value of
employee
57
stock options granted during the three months ended
March 31, 2006 was $5.48 determined using the Black-Scholes
model and the following weighted-average assumptions:
|
|
|
|
|
|
|
2006
|
|
|
Weighted-average life (years)
|
|
|
4.1
|
|
Volatility
|
|
|
39
|
%
|
Expected dividend per share
|
|
$
|
0.31
|
|
Risk-free interest rate
|
|
|
4.80
|
%
|
Weighted-average fair value of
options
|
|
$
|
5.48
|
|
As stock-based compensation expense recognized in the
consolidated statement of operations in 2006 is based on awards
ultimately expected to vest, it has been reduced for estimated
forfeitures. SFAS 123(R) requires forfeitures to be
estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those
estimates. Forfeitures were estimated based on historical
experience.
The total future compensation costs associated with employee
stock options and restricted stock awards that were outstanding
at March 31, 2006 is as follows:
|
|
|
|
|
|
|
(In Thousands)
|
|
|
Remainder of 2006
|
|
$
|
13,580
|
|
2007
|
|
|
8,255
|
|
2008
|
|
|
3,108
|
|
2009 and thereafter
|
|
|
767
|
|
|
|
|
|
|
|
|
$
|
25,710
|
|
|
|
|
|
|
If factors change and we employ different assumptions in the
application of SFAS 123(R) in future periods, the
compensation expense that we record under SFAS 123(R) may
differ significantly from what we have recorded in the current
period.
Contingencies
We are exposed to contingencies in the ordinary course of
business, such as legal proceedings and business-related claims,
which range from product and environmental liabilities to tax
matters. In accordance, with SFAS No. 5, Accounting
for Contingencies, we record accruals for such contingencies
when it is probable that a liability will be incurred and the
amount of loss can be reasonably estimated. The estimates are
refined each accounting period, as additional information is
known. See Notes 10 and 12 of notes to consolidated
condensed financial statements for a discussion of contingencies.
Other
Financial Information
With respect to the unaudited condensed consolidated financial
information of Valeant Pharmaceutical International for the
three months ended March 31, 2006 and 2005,
PricewaterhouseCoopers LLP reported that they have applied
limited procedures in accordance with professional standards for
a review of such information. However, their report dated
May 8, 2006 except for Note 2, which is as of
January 22, 2007, appearing herein, states that they did
not audit and they do not express an opinion on that unaudited
condensed consolidated financial information. Accordingly, the
degree of reliance on their report on such information should be
restricted in light of the limited nature of the review
procedures applied. PricewaterhouseCoopers is not subject to the
liability provisions of Section 11 of the Securities Act of
1933 (the Act) for their report on the unaudited
condensed consolidated financial information because that report
is not a report or a part of a
registration statement prepared or certified by
PricewaterhouseCoopers within the meaning of Sections 7 and
11 of the Act.
Forward-Looking
Statements
Except for the historical information contained herein, the
matters addressed in Managements Discussion and
Analysis of Financial Condition and Results of Operations
and elsewhere in this quarterly report on
Form 10-Q
58
constitute forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking statements may be identified
by the use of the words anticipates,
expects, intends, plans, and
variations or similar expressions. These forward-looking
statements are subject to a variety of risks and uncertainties,
including those discussed below and elsewhere in this quarterly
report on
Form 10-Q/A,
which could cause actual results to differ materially from those
anticipated by our management. In addition, the information set
forth in our annual report on
Form 10-K
for the fiscal year ended December 31, 2005, describes
certain additional risks and uncertainties that could cause
actual results to vary materially from the future results
covered in such forward-looking statements. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements, which speak only as of the date of
this report. We undertake no obligation to update any of these
forward-looking statements to reflect events or circumstances
after the date of this report or to reflect actual outcomes.
RISK
FACTORS
Our short and long-term success is subject to a variety of risks
and uncertainties, many of which are beyond our control. Our
stockholders and prospective stockholders should consider
carefully the following risk factors, in addition to other
information contained in this report and our annual report on
Form 10-K
for the fiscal year ended December 31, 2005. Our actual
results could differ materially from these anticipated in this
report as a result of various factors, including those set forth
below.
|
|
|
|
|
The future growth of our business depends on the development and
approval of new products, including Viramidine, pradefovir and
retigabine. The process of developing new drugs has an inherent
risk of failure. For example, product candidates may turn out to
be ineffective or unsafe in clinical testing; their patent
protection may become compromised; other therapies may prove
safer or more effective; or the prevalence of the disease for
which they are being developed may decrease. Our inability to
successfully develop our products due to these or other factors
could have a material adverse effect on future revenues.
|
|
|
|
We can protect our products from generic substitution by third
parties only to the extent that our technologies are covered by
valid and enforceable patents, are effectively maintained as
trade secrets or are protected by data exclusivity. However, our
pending or future patent applications may not issue as patents.
Any patent issued may be challenged, invalidated, held
unenforceable or circumvented. Furthermore, our patents may not
be sufficiently broad to prevent third parties competing
products. The expiration of patent protection for ribavirin has
resulted in significant competition from generic substitutes and
declining royalty revenues and may negatively impact future
financial results.
|
|
|
|
Trade secret protection is less effective than patent protection
because competitors may discover the technology or develop
parallel technology.
|
|
|
|
The scope of protection afforded by a patent can be highly
uncertain. A pending claim or a result unfavorable to us in a
patent dispute may preclude development or commercialization of
products or impact sales of existing products, result in
cessation of royalty payments to us
and/or
result in payment of monetary damages.
|
|
|
|
Obtaining drug approval in the United States and other countries
is costly and time consuming. Uncertainties and delays inherent
in the process can preclude or delay development and
commercialization of our products.
|
|
|
|
Our current business plan includes targeted expansion through
acquisitions of compatible businesses and product lines and the
formation of strategic alliances, joint ventures and other
business combinations, in addition to the development of new
products. If we are unable to successfully execute on our
expansion plans to find attractive acquisition candidates at
appropriate prices, and to integrate successfully any acquired
companies or products, the expected growth of our business may
be negatively affected.
|
|
|
|
We and our competitors are always striving to develop products
that are more effective, safer, more easily tolerated or less
costly. If our competitors succeed in developing better
alternatives to our current products
|
59
|
|
|
|
|
before we do, we will lose sales and revenues to their
alternative products. If vaccines are introduced to prevent the
diseases treated by our products, our potential sales and
revenues will decrease.
|
|
|
|
|
|
The pharmaceutical industry is subject to substantial government
regulation, including the approval of new pharmaceutical
products, labeling, advertising and, in most countries, pricing,
as well as inspection and approval of manufacturing facilities.
The costs of complying with these regulations are high, and
failure to comply could result in fines or interruption in our
business.
|
|
|
|
We collect and pay a substantial portion of our sales and
expenditures in currencies other than the U.S. dollar. As a
result, fluctuations in foreign currency exchange rates affect
our operating results. Additionally, future exchange rate
movements, inflation or other related factors may have a
material adverse effect on our sales, gross profit or operating
expenses. At March 31, 2006 we have in place foreign
currency hedge transactions to reduce our exposure to
variability in the Polish Zloty. We continue to evaluate the
possibility of entering into additional hedge arrangements.
|
|
|
|
A significant part of our revenue is derived from products
manufactured by third parties. We rely on their quality level,
compliance with the FDA regulations or similar regulatory
requirements enforced by regulatory agencies in other countries
and continuity of supply. Any failure by them in these areas
could disrupt our product supply and negatively impact our
revenues.
|
|
|
|
Our flexibility in maximizing commercialization opportunities
for our compounds may be limited by our obligations to
Schering-Plough. In November 2000, we entered into an agreement
that provides Schering-Plough with an option to acquire the
rights to up to three of our products intended to treat
hepatitis C that Schering-Plough designates prior to our
entering Phase 2 clinical trials and a right for first/last
refusal to license various compounds we may develop and elect to
license to others. Viramidine was not subject to the option of
Schering-Plough, but it would be subject to their right of
first/last refusal if we elected to license it to a third party.
The interest of potential collaborators in obtaining rights to
our compounds or the terms of any agreement we ultimately enter
into for these rights may be hindered by our agreement with
Schering-Plough.
|
|
|
|
To purchase our products, many patients rely on reimbursement by
third party payors such as insurance companies, HMOs and
government agencies. These third party payors are increasingly
attempting to contain costs by limiting both coverage and the
level of reimbursement of new drug products. The reimbursement
levels established by third party payors in the future may not
be sufficient for us to realize an appropriate return on our
investment in product development and our continued manufacture
and sale of existing drugs.
|
|
|
|
Some of our development programs are based on the library of
nucleoside compounds we have developed. It is not practicable to
create backups for our nucleoside library, and accordingly it is
at risk of loss in earthquakes, fire and other natural disasters
and catastrophes. Any insurance we maintain may not be adequate
to cover our losses.
|
|
|
|
All drugs have potential harmful side effects and can expose
drug manufacturers and distributors to liability. In the event
one or more of our products is found to have harmed an
individual or individuals, we may be responsible for paying all
or substantially all damages awarded. A successful product
liability claim against us could have a material negative impact
on our financial position and results of operations.
|
|
|
|
Our debt agreements permit us to incur additional debt, subject
to certain restrictions, but there is no guaranty that we will
actually be able to borrow any money should the need for it
arise.
|
|
|
|
We are involved in several legal proceedings, including those
described in Notes 10 and 12 to notes to consolidated
condensed financial statements, any of which could result in
substantial cost and divert managements attention and
resources.
|
|
|
|
Dependence on key personnel leaves us vulnerable to a negative
impact if they leave. Our continued success will depend, to a
significant extent, upon the efforts and abilities of the key
members of management. The loss of their services could have a
negative impact on us.
|
|
|
|
Our research and development activities involve the controlled
use of potentially harmful biological materials as wells as
hazardous materials, chemicals and various radioactive
compounds. We cannot
|
60
|
|
|
|
|
completely eliminate the risk of accidental contamination or
injury from the use, storage, handling or disposal of these
materials. In the event of contamination or injury, we could be
held liable for damages that result. Any liability could exceed
our resources.
|
|
|
|
|
|
Our stockholder rights plan, provisions of our certificate of
incorporation and provisions of the Delaware General Corporation
Law could provide our Board of Directors with the ability to
deter hostile takeovers or delay, deter or prevent a change in
control of our company, including transactions in which
stockholders might otherwise receive a premium for their shares
over then current market prices.
|
|
|
|
We are authorized to issue, without stockholder approval,
approximately 10,000,000 shares of preferred stock,
200,000,000 shares of common stock and securities
convertible into either shares of common stock or preferred
stock. If we issue additional equity securities, the price of
our securities may be materially and adversely affected. The
Board of Directors can also use issuances of preferred or common
stock to deter a hostile takeover or change in control of our
company.
|
|
|
|
We are subject to a consent order with the Securities and
Exchange Commission, which permanently enjoins us from violating
securities laws and regulations. The consent order also
precludes protection for forward-looking statements under the
safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 with respect to forward-looking statements we
made prior to November 28, 2005. The existence of the
permanent injunction under the consent order, and the lack of
protection under the safe harbor with respect to forward-looking
statements made prior to November 28, 2005 may limit our
ability to defend against future allegations.
|
61
|
|
Item 3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
Our business and financial results are affected by fluctuations
in world financial markets. We evaluate our exposure to such
risks on an ongoing basis, and seek ways to manage these risks
to an acceptable level, based on managements judgment of
the appropriate trade-off between risk, opportunity and cost. We
do not hold any significant amount of market risk sensitive
instruments whose value is subject to market price risk. Our
significant foreign currency exposure relates to the Euro, the
Mexican Peso, the Polish Zloty, the Swiss Franc and the Canadian
Dollar. We seek to manage our foreign currency exposure through
operational means by managing local currency revenues in
relation to local currency costs. We take steps to mitigate the
impact of foreign currency on the income statement, which
include hedging our foreign currency exposure.
In the normal course of business, we also face risks that are
either non-financial or non-quantifiable. Such risks principally
include country risk, credit risk and legal risk and are not
discussed or quantified in the following analysis. At
March 31, 2006, the fair values of the Companys
financial instruments were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notional/
|
|
|
Assets (Liabilities)
|
|
|
|
Contract
|
|
|
Carrying
|
|
|
Fair
|
|
Description
|
|
Amount
|
|
|
Value
|
|
|
Value
|
|
|
Forward contracts
|
|
$
|
45,000
|
|
|
$
|
(2,345
|
)
|
|
$
|
(2,345
|
)
|
Interest rate swaps
|
|
|
150,000
|
|
|
|
(6,982
|
)
|
|
|
(6,982
|
)
|
Outstanding debt
|
|
|
780,000
|
|
|
|
(780,000
|
)
|
|
|
(720,000
|
)
|
We currently do not hold financial instruments for trading or
speculative purposes. Our financial assets are not subject to
significant interest rate risk due to their short duration. At
March 31, 2006, we had $12,150,000 of foreign denominated
variable rate debt that would subject it to both interest rate
and currency risks. A 100 basis-point increase in interest rates
affecting our financial instruments would not have had a
material effect on our first quarter 2006 pretax earnings. In
addition, we have $780,000,000 of fixed rate debt as of
March 31, 2006, that requires U.S. dollar repayment.
To the extent that we require, as a source of debt repayment,
earnings and cash flow from some of our subsidiary units located
in foreign countries, we are subject to risk of changes in the
value of certain currencies relative to the U.S. dollar.
However, the increase of 100 basis-points in interest rates
would have reduced the fair value of our remaining fixed-rate
debt instruments by approximately $32,900,000 as of
March 31, 2006.
We estimated the sensitivity of the fair value of our derivative
foreign exchange contracts to a hypothetical 10% strengthening
and 10% weakening of the spot exchange rates for the
U.S. dollar against the Zloty at March 31, 2006. The
analysis showed that a 10% strengthening of the U.S. dollar
would have resulted in a gain from a fair value change of
$4,306,000 and a 10% weakening of the U.S. dollar would
have resulted in a loss from a fair value change of $5,263,000
in these instruments. Losses and gains on the underlying
transactions being hedged would have largely offset any gains
and losses on the fair value of derivative contracts. These
offsetting gains and losses are not reflected in the above
analysis.
62
|
|
Item 4.
|
Controls
and Procedures
|
As disclosed in the Note 2 to the consolidated condensed
financial statements contained in this
Form 10-Q/A,
we announced on September 11, 2006 that a Special Committee
consisting solely of independent members of the board of
directors had been formed to conduct an internal review of our
historic stock option practices and related accounting.
The Special Committee, with the assistance of outside legal
counsel, undertook a comprehensive review of the stock option
grants to our officers, directors and employees from 1982 to
July 2006 under our various stock option plans in effect during
this period. The Special Committee has concluded its
investigation and has reported its findings to our board of
directors. On October 20, 2006, our board of directors
concluded that our consolidated financial statements should be
restated to record the additional non-cash stock-based
compensation expense items and certain other items that had been
incorrectly accounted for under GAAP.
The Special Committee analyzed in detail stock option grants
awarded between November 1994 and July 2006 and analyzed
supporting documentation for awards granted between 1982 and
1994. For the period between November 1994 and July 2006, the
Special Committees analysis included an extensive review
of paper and electronic documents supporting or related to our
stock option grants, the accounting for or impacted by those
grants, compensation-related financial and securities
disclosures and
e-mail
communications as well as interviews with numerous current and
former employees and current and former members of our board of
directors. While the Special Committee concluded that there were
some errors as late as January 2006, the majority of errors in
accounting for options pertain to those options granted prior to
the change in our board of directors and management in mid-2002
(Change in Control). None of the errors occurring in
periods after the Change in Control related to options granted
to the chief executive officer (CEO), chief
financial officer (CFO), or members of our board of
directors.
Disclosure
Controls and Procedures
We maintain disclosure controls and procedures that are designed
to ensure that information required to be disclosed in our
Exchange Act reports is recorded, processed, summarized and
reported within the time periods specified in the SECs
rules and forms, and that such information is accumulated and
communicated to our management, including our CEO and CFO, as
appropriate, to allow timely decisions regarding required
disclosure. In designing and evaluating the disclosure controls
and procedures, management recognizes that any controls and
procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired
control objectives, and management necessarily is required to
apply its judgment in evaluating the cost-benefit relationship
of possible controls and procedures.
At the time that our annual report on
Form 10-K
for the year ended December 31, 2005 was filed on
March 15, 2006, our CEO and CFO concluded that our
disclosure controls and procedures were effective as of
December 31, 2005. Subsequent to that evaluation, our CEO
and CFO concluded that our disclosure controls and procedures
were not effective at a reasonable level of assurance as of
December 31, 2005 because of the material weakness in our
internal control over financial reporting discussed below.
Notwithstanding the material weakness described below, our
management has concluded that our consolidated condensed
financial statements included in this quarterly report have been
properly prepared pursuant to the rules and regulations of the
SEC.
A material weakness is a control deficiency, or combination of
control deficiencies, that results in more than a remote
likelihood that a material misstatement of the annual or interim
financial statements will not be prevented or detected.
As of December 31, 2005, we did not maintain effective
controls over the accounting for and disclosure of stock-based
compensation expense. Specifically, effective controls,
including monitoring, were not maintained to ensure the accuracy
and valuation of our stock-based compensation transactions
related to the granting of our stock options. This control
deficiency resulted in the misstatement of stock-based
compensation expense and additional paid-in capital accounts and
related financial disclosures, and in the restatement of our
consolidated financial statements for the years 2005, 2004, and
2003, each of the quarters of 2005 and 2004, and the first two
quarters of 2006. Additionally, this control deficiency could
result in misstatements of the aforementioned accounts and
63
disclosures that would result in a material misstatement of the
annual or interim consolidated financial statements that would
not be prevented or detected. Accordingly, our management has
determined that this control deficiency constitutes a material
weakness in our internal control over financial reporting.
Remediation
Plan
Subsequent to the initiation of our investigation into our stock
option granting practices in September 2006, we considered the
effectiveness of both the design and operation of our internal
control over financial reporting as they relate to the granting
of stock-based compensation. We implemented several improvements
during the fourth quarter of 2006. In particular, we developed
and implemented specific procedures and controls to ensure
compensation committee approval of the final specific awards to
all individual recipients at the time of the compensation
committee meeting. As of December 31, 2006, management has
implemented these additional procedures and controls.
Additionally, we have evaluated the design of these new
controls, which have been placed into operation for a sufficient
period of time. We will test their operating effectiveness in
connection with our assessment of internal control over
financial reporting as of December 31, 2006. We believe
that the controls that have been implemented have improved the
effectiveness of our internal control over financial reporting.
Changes
in Internal Control over Financial Reporting
There were changes in our internal control over financial
reporting during the most recently completed fiscal quarter as
discussed in the Remediation Plan section above that have
materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.
64
PART II
OTHER INFORMATION
|
|
Item 1.
|
Legal
Proceedings
|
See Note 10 of notes to consolidated condensed financial
statements in Item 1 of Part I of this quarterly
report, which is incorporated herein by reference.
Our annual report on
Form 10-K/A
for the year ended December 31, 2005 includes a detailed
discussion of our risk factors. Pursuant to the instructions to
Form 10-Q,
we have provided below only those risk factors that are new or
that have been materially amended since the time that we filed
our most recent annual report on
Form 10-K/A.
Accordingly, the information presented below should be read in
conjunction with the risk factors and information disclosed in
our most recent
Form 10-K/A
and the other risks described in this
Form 10-Q/A.
If we
do not realize the expected benefits from the restructuring plan
we announced in April 2006, our operating results and financial
conditions would be negatively impacted.
In April 2006, we announced a strategic restructuring of our
company designed to focus our resources on programs and products
that have the greatest opportunity for success. Accordingly, we
elected to rationalize certain of our assets, including our
discovery program and certain manufacturing facilities. We have
sold and out licensed pradefovir and certain discovery programs,
and any future compensation relating thereto is contingent upon
the transferees successful development of the applicable
product
and/or
program. Such success is subject to the risks inherent in
developing and obtaining approval for pharmaceutical products.
Accordingly, it is possible that we may not receive any
financial benefit from the sale or out license of these assets.
In addition, if we are unable to realize the expected
operational efficiencies from our restructuring plan, our
operating results and financial condition would be adversely
affected.
If we
or our third-party manufacturers are unable to manufacture our
products or the manufacturing process is interrupted due to
failure to comply with regulations or for other reasons, the
manufacture of our products could be interrupted.
We manufacture and have contracted with third parties to
manufacture some of our drug products, including products under
the rights acquired from other pharmaceutical companies.
Manufacturers are required to adhere to current good
manufacturing (cGMP) regulations enforced by the FDA
or similar regulations required by regulatory agencies in other
countries. Compliance with the FDAs cGMP requirements
applies to both drug products seeking regulatory approval and to
approved drug products. Our manufacturing facilities and those
of our contract manufacturers must be inspected and found to be
in full compliance with cGMP standards before approval for
marketing. We and contract manufacturers of our approved
products are subject to ongoing regulation by the FDA, including
compliance with cGMP requirements, and to similar regulatory
requirements enforced by regulatory agencies in other countries.
Our dependence upon others to manufacture our products may
adversely affect our profit margins and our ability to develop
and obtain approval for our products on a timely and competitive
basis, if at all. Our failure or that of our contract
manufacturers to comply with cGMP regulations or similar
regulations outside of the United States can result in
enforcement action by the FDA or its foreign counterparts,
including, among other things, warning letters, fines,
injunctions, civil penalties, recall or seizure of products,
total or partial suspension of production, refusal of the
government to renew marketing applications and criminal
prosecution. In addition, delays or difficulties with our
contract manufacturers in producing, packaging, or distributing
our products could adversely affect the sales of our current
products or introduction of other products.
Schering-Plough manufactures and sells ribavirin under license
from us. In May 2002, Schering-Plough signed a consent decree of
permanent injunction with the FDA, agreeing to measures to
assure that the drug products manufactured at their Puerto Rico
plant are made in compliance with FDAs current good
manufacturing practice regulations. While Schering-Plough has
advised us that the deficiencies were not specifically
applicable to the production of ribavirin, the consent decree
covers the facility producing ribavirin. Schering-Ploughs
ability to
65
manufacture and ship ribavirin could be affected by temporary
interruption of some production lines to install system upgrades
and further enhance compliance, and other technical production
and equipment qualification issues. If the FDA is not satisfied
with Schering-Ploughs compliance under the consent decree,
the FDA could take further regulatory actions against
Schering-Plough, including the seizure of products, an
injunction against further manufacture, a product recall or
other actions that could interrupt production of ribavirin.
Interruption of ribavirin production for a sustained period of
time could materially reduce our royalty revenue.
In addition to regulatory compliance risks, our contract
manufacturers in the United States and in other countries are
subject to a wide range of business risks, such as seizure of
assets by governmental authorities, natural disasters, and
domestic and international economic conditions. Were any of our
contract manufacturers not able to manufacture our products
because of regulatory, business or any other reasons, the
manufacture of our products would be interrupted. This could
have a negative impact on our sales, financial condition and
competitive position. In January 2006, the parent company of one
of our toll manufacturers in Europe filed for bankruptcy. Sales
of products obtained from this manufacturer are estimated to be
approximately $60 million in 2006. Although the
manufacturer has received court approval to emerge from
bankruptcy and we have developed plans to respond to a
disruption in supply by this manufacturer, there can be no
assurance that, should a disruption in supply occur, we will be
able to respond in time with alternative sources of supply or
have sufficient levels of inventory to prevent a material
negative impact on revenues. In addition, we cannot assure you
that the supplier will be able to meet our supply needs after it
emerges from bankruptcy.
The
matters relating to the Special Committees review of our
historical stock option granting practices and the restatement
of our consolidated financial statements have resulted in
increased litigation and regulatory proceedings against us and
could have a material adverse effect on us.
In September 2006, our board of directors appointed a Special
Committee, which consists solely of independent directors, to
conduct a review of our historical stock option granting
practices and related accounting during the period from 1982
through July 2006. As described in Item 7,
Managements Discussion and Analysis of Financial
Condition and Results of Operations Restatement of
Consolidated Financial Statements, Special Committee and Company
Findings, the Special Committee has identified a number of
occasions on which the exercise prices for stock options granted
to certain of our directors, officers, and employees were set
using closing prices for our common stock with dates different
than the actual grant approval dates, resulting in additional
compensation charges. To correct these and other accounting
errors, we have amended the 2005
10-K and our
quarterly reports on
Form 10-Q
for the quarters ended March 31, 2006 and June 30,
2006 to restate the consolidated financial statements contained
in those reports. The review of our historical stock option
granting practices and the related accounting, as well as the
resulting restatements, have required us to incur substantial
expenses for legal, accounting, tax and other professional
services and have diverted our managements attention from
our business and could adversely affect our business, financial
condition, results of operations and cash flows.
Our historical stock option granting practices and the
restatement of our prior financial statements have exposed us to
greater risks associated with litigation and regulatory
proceedings. We are a named defendant in two shareholder
derivative lawsuits pending in the state court in Orange County,
California, which assert claims related to our historic stock
option practices. In addition, the SEC has opened an informal
inquiry into our historical stock option grant practices. We
cannot assure you that this current litigation, the SEC inquiry
or any future litigation or regulatory action will result in the
same conclusions reached by the Special Committee. The conduct
and resolution of these matters will be time consuming,
expensive and distracting from the conduct of our business.
Furthermore, if we are subject to adverse findings in any of
these matters, we could be required to pay damages or penalties
or have other remedies imposed upon us which could have a
material adverse effect on our business, financial condition,
results of operations and cash flows.
The
delay in filing the quarterly report on
Form 10-Q
may increase the resources to file registration
statements.
As a result of our delayed filing of our quarterly report on
Form 10-Q
for the quarter ended September 30, 2006, we will be
ineligible to register our securities on
Form S-3
for sale by us or resale by others until we have timely filed
all material required to be filed pursuant to
Section 13, 14, or 15(d) of the Securities Exchange
Act of
66
1934 for a period of least 12 calendar months. We may use other
registration statement forms to raise capital or complete
acquisitions, but such use would increase our transaction costs
and may adversely impact our ability to raise capital or
complete acquisitions of other companies in a timely manner.
The
pending SEC inquiry could adversely affect our business and the
trading price of our securities.
In July 2006, we were contacted by the SEC, with respect to an
informal inquiry regarding events and circumstances surrounding
trading in our common stock and the public release of data from
our first pivotal Phase 3 trial for
Viramidine®
(taribavirin). In addition, the SEC later requested data
regarding our stock option grants since January 1, 2000 and
information about our pursuit in the Delaware Chancery Court of
the return of certain bonuses paid to Milan Panic, the former
chairman and chief executive officer, and others. In September
2006, our board of directors established the Special Committee
to review our historical stock option practices and related
accounting, and informed the SEC of these efforts. We have
cooperated fully and will continue to cooperate with the SEC on
its informal inquiry. We cannot predict the outcome of the
inquiry. In the event that the inquiry leads to SEC action
against any current or former officer or director, our business
(including our ability to complete financing transactions) and
the trading price of our securities may be adversely impacted.
In addition, if the SEC inquiry continues for a prolonged period
of time, it may have an adverse impact on our business or the
trading price of our securities regardless of the ultimate
outcome of the investigation. In addition, the SEC inquiry has
resulted in the incurrence of significant legal expenses and the
diversion of managements attention from our business, and
this may continue, or increase, until the inquiry is concluded.
|
|
|
|
|
Exhibit
|
|
|
|
|
10
|
.1
|
|
Description of Registrants
Executive Incentive Plan, previously filed as Item 1.01 in
the Registrants Current Report on
Form 8-K,
dated April 19, 2006, which is incorporated herein by
reference.
|
|
15
|
.1
|
|
Review Report of Independent
Registered Public Accounting Firm.
|
|
31
|
.1
|
|
Certification of Chief Executive
Officer pursuant to
Rule 13a-14(a)
under the Exchange Act and Section 302 of the
Sarbanes-Oxley Act of 2002.
|
|
31
|
.2
|
|
Certification of Chief Financial
Officer pursuant to
Rule 13a-14(a)
under the Exchange Act and Section 302 of the
Sarbanes-Oxley Act of 2002.
|
|
32
|
.1
|
|
Certification of Chief Executive
Officer and Chief Financial Officer of Periodic Financial
Reports pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, 18 U.S.C. § 1350.
|
67
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this quarterly report on
Form 10-Q
to be signed on its behalf by the undersigned thereunto duly
authorized.
Valeant Pharmaceuticals
International
Registrant
Timothy C. Tyson
President and Chief Executive Officer
Date: January 30, 2007
Bary G. Bailey
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
Date: January 30, 2007
68
EXHIBIT INDEX
|
|
|
|
|
Exhibit
|
|
|
|
|
10
|
.1
|
|
Description of Registrants
Executive Incentive Plan, previously filed as Item 1.01 in
the Registrants Current Report on
Form 8-K,
dated April 19, 2006, which is incorporated herein by
reference.
|
|
15
|
.1
|
|
Review Report of Independent
Registered Public Accounting Firm.
|
|
31
|
.1
|
|
Certification of Chief Executive
Officer pursuant to
Rule 13a-14(a)
under the Exchange Act and Section 302 of the
Sarbanes-Oxley Act of 2002.
|
|
31
|
.2
|
|
Certification of Chief Financial
Officer pursuant to
Rule 13a-14(a)
under the Exchange Act and Section 302 of the
Sarbanes-Oxley Act of 2002.
|
|
32
|
.1
|
|
Certification of Chief Executive
Officer and Chief Financial Officer of Periodic Financial
Reports pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, 18 U.S.C. § 1350.
|
69